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Abstract	  
	  
The	  natural	  selection	  imposed	  by	  host	  immunity	  and	  antimalarial	  drugs	  has	  driven	  extensive	  
adaptive	   evolution	   in	   Plasmodium	   falciparum,	   leading	   to	   an	   ever-­‐changing	   landscape	   of	  
genetic	   variation.	   We	   have	   carried	   out	   whole-­‐genome	   sequencing	   of	   93	   P.	   falciparum	  
clinical	   isolates	   from	   Malawi	   and	   used	   population	   genetic	   methods	   to	   investigate	   the	  
genetic	  diversity	  and	  regions	  under	  selection.	  In	  addition,	  by	  computing	  XP-­‐EHH,	  PCA	  and	  FST	  
we	  have	  compared	  the	  Malawi	  isolates	  to	  five	  dispersed	  others	  (Kenya,	  Mali,	  Burkina	  Faso,	  
Cambodia	   and	   Thailand),	   and	   identified	   genes	   potentially	   under	   positive	   directional	  
selection.	   Geographic	   stratification	   of	   genetic	   diversity	   in	   the	   populations	   followed	  
continental	   lines	   and	   small	   population	   differences	   were	   observed	   within	   Africa.	   Positive	  
directional	   selection	   signals	   were	   identified	   at	   or	   near	   pfdhps,	   pfcrt,	   pfmdr1	   and	   pfgch1	  
(known	   drug	   targets)	   and	   in	   several	   merozoite	   invasion	   ligands	   (e.g.,	  msp3.8,	   trap	   and	  
ama1).	   We	   discuss	   the	   role	   of	   drug	   selection	   in	   promoting	   fixation	   of	   alleles	   between	  
populations	   with	   differing	   adaptation	   to	   local	   drug	   pressure.	   Analysis	   of	   copy	   number	  
variation	   in	   Malawi	   provides	   a	   detailed	   catalogue	   of	   new	   and	   previously	   identified	   gene	  
deletions	  and	  duplications	  with	  critical	  roles	  in	  cytoadherence,	  gametocytogenesis,	  invasion	  
and	  drug	  response.	  This	  work	  provides	  the	  first	  genome-­‐wide	  scan	  of	  selection	  and	  CNV	  in	  
Malawi	   to	   guide	   future	   studies	   in	   investigating	   parasite	   evolution,	   changing	   malaria	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Chapter	  1	  
Introduction	  to	  malaria	  and	  malaria	  genetics	  
	  
1.1 Global	  malaria	  burden	  
	  
Malaria	  is	  caused	  by	  eukaryotic	  parasites	  of	  the	  genus	  Plasmodium	  (P.	  falciparum,	  P.	  
vivax,	  P.	  ovale,	  P.	  malariae	  and	  P.	  knowlesi).	  Human	  P.	  falciparum	  malaria	  is	  the	  deadliest,	  
and	   predominates	   in	   Africa	   while	   P.	   vivax	   is	   the	   most	   widespread.	   P.	   falciparum	   is	  
transmitted	  to	  humans	  by	  the	  bite	  of	  an	  infected	  female	  Anopheles	  mosquito	  (Mendis	  et	  al.	  
2001;	  Genton	  et	  al.	  2008).	  An	  estimated	  3.3	  billion	  people	  are	  at	  risk	  of	  malaria	  worldwide,	  
with	  populations	  living	  in	  sub-­‐Sahara	  Africa	  at	  the	  highest	  risk	  of	  malaria	  (Figure	  1.1).	  There	  
were	  an	  estimated	  219	  million	  cases	  of	  malaria	  (range	  154–289	  million)	  and	  660	  000	  deaths	  
(range	  610	  000–971	  000)	  in	  2010.	  (WHO.	  World	  Malaria	  Report	  2012).	  	  
	  
	   	  2	  
Figure	   1.1:	   Global	   distribution	   of	   P.	   falciparum	   transmission	   risk,	   2010.	   Medium	   grey	  
regions	  indicate	  low	  rates	  of	  P.	  falciparum	  infections	  (unstable	  risk,	  P.	  falciparum	  annual	  
parasite	   incidence,	  PfAPI	  <0.1	  per	  1000	  people	  per	  annum)	  while	   light	  grey	  indicate	  no	  
risk.	   Shadings	   of	   red	   indicate	   levels	   of	   infections:	   low	   risk,	  P.	   falciparum	   parasite	   rate	  
age-­‐standardized	   to	   2–10	   year	   for	   endemic	   mapping	   (PfPR2-­‐10	   ≤5%),	   in	   light	   red;	  
intermediate	  risk,	  PfPR2-­‐10	  >	  5%	  <	  40%,	   in	  medium	  red;	  high	  risk,	  PfPR2-­‐10	  ≥40%,	   in	  dark	  
red.	  Adapted	  from	  (Gething	  et	  al.	  2011).	  
	  
1.2 P.	  falciparum	  and	  life	  cycle	  	  
	  
P.	  falciparum	  is	  a	  eukaryotic	  pathogen	  with	  a	  complex	  life	  cycle,	  spending	  part	  of	  its	  
lifespan	   in	   the	  Anopheles	  mosquito	   (definitive	   host),	   as	  mostly	   diploid,	   and	   in	   the	   human	  
host	  as	  a	  haploid	  organism,	  where	  it	  gives	  rise	  to	  numerous	  clinical	  manifestations	  ranging	  
from	  mild	  to	  life-­‐	  threatening	  illness	  (Figure	  1.2).	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Within	   its	  hosts,	   the	  parasite	  must	  adapt	  to	  varying	  environmental	  conditions	  such	  
as	  cellular	  metabolism,	   temperature,	  drugs	  and	   immune	  response	  and	  as	  such,	   it	   requires	  
specific	  capabilities	  to	  proliferate	  and	  transmit.	  	  
During	  a	  blood	  meal,	  female	  Anopheles	  mosquito	  injects	  sporozoites	  into	  the	  human	  
host	   (A).	  Within	   thirty	   seconds,	   the	   sporozoites	   enter	   the	   liver	   into	   hepatocytes	   and	   are	  
hardly	   detected	   in	   the	   blood	   stream	   after	   thirty	   minutes	   (Essential	   Malariology.	   Fourth	  
Edition.	   David	   A.	   Warrell	   and	   Herbert	   M.	   Gilles).	   The	   sporozoites	   develop	   into	   exo-­‐
erythrocytic	   schizonts	  undergoing	  asexual	   reproduction	  until	   the	  hepatocyte	  bursts	   (B),	   to	  
release	  up	   to	  40,000	  merozoites	   into	   the	  human	  bloodstream,	  and	   infect	  erythrocytes.	  At	  
this	   stage,	   a	   few	  differences	   are	  observed	  between	  different	  Plasmodium	   species	   -­‐	   in	   the	  
case	   of	  P.	   vivax	   and	  P.	   ovale,	   some	   sporozoites	   enter	   hepatocytes	   and	   form	   hypnozoites	  
(dormant	  stage)	   instead	  of	  directly	  developing	  exo-­‐erythrocytic	  schizonts.	  The	  hypnozoites	  
(4-­‐5	  μm	  in	  diameter)	  can	  remain	  dormant	  in	  the	  liver	  for	  years	  and	  at	  some	  point,	  through	  a	  
triggering	   signal	   that	   is	   still	   not	   fully	   described,	   the	   hypnozoites	   develop	   into	   exo-­‐
erythrocytic	  schizonts,	  producing	  thousands	  of	  merozoites	  that	  cause	  relapse	  of	  the	  disease.	  
Merozoites	   do	   not	   usually	   remain	   in	   the	   blood	   stream	   for	   long	   periods	   (helping	   to	   avoid	  
direct	   contact	   to	   the	   host	   immune	   system),	   infecting	   erythrocytes	   as	   soon	   as	   they	   are	  
released,	  and	  undergo	  an	  asexual	  reproduction	  cycle	  called	  the	  erythrocytic	  schizogony.	  At	  
this	  stage,	  the	  nucleus	  is	  divided	  3	  to	  5	  times,	  followed	  by	  division	  of	  the	  cytoplasm.	  The	  ring	  
stage	   is	   formed,	   followed	   by	   a	   more	  metabolically	   active	   trophozoite	   stage	   and	   finally	   a	  
schizont.	   Schizonts	   are	   fully	   developed	   parasite	   forms,	   containing	   a	   variable	   number	   of	  
merozoites,	   usually	   8	   to	   24,	   again	   depending	   on	   species	   and	   strain.	   Once	   the	   schizonts	  
rupture,	   the	  meroziotes	   are	   released	   into	   the	   blood	   stream	   and	   directly	   invade	   new	   red	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blood	   cells,	   thereby	   starting	   a	   new	   cycle	   of	   schizogony	   (C).	   The	   length	   of	   the	   intra-­‐
erythrocytic	   cycle	   also	  differs	  between	  different	  Plasmodium	   species	   and	   strains,	   typically	  
48	  hours	  (in	  P.	  falciparum,	  P.	  vivax	  and	  P.	  ovale)	  or	  72	  hours	  (in	  P.	  malariae),	  which	  explains	  
the	   periodicity	   of	   the	   fever	   paroxysms	   experienced	   by	   the	   patient.	   Some	   merozoites	  
invading	  new	  red	  blood	  cells	  do	  not	  develop	  into	  schizonts	  but	   into	  sexually	  differentiated	  
forms	  called	  gametocytes	  (D).	  	  
	  
When	  a	  female	  Anopheles	  mosquito	  feeds	  on	  a	  blood	  meal	  from	  a	  malaria	  positive	  
person,	   it	   ingests	   infected	  erythrocytes	   (IE),	  male	  and	   female	  gametocytes	  and	  uninfected	  
erythrocytes.	  In	  the	  male	  gametocytes,	  the	  nucleus	  divides	  into	  four	  to	  eight	  nuclei,	  which	  
ex-­‐flagellate	  to	  form	  microgametes,	  each	  being	  able	  to	  fertilize	  a	  macrogamete	  -­‐	  the	  mature	  
form	   of	   the	   female	   gametocyte.	   Fertilization	   of	   the	   microgamete	   and	   macrogamete	  
produces	  a	  zygote,	  which	  develops	   into	  an	  ookinete	  that	  crosses	  the	  mosquito	  gut	  wall	   to	  
form	  an	  oocyst	  between	  the	  epithelial	  lining	  and	  the	  basal	  lamina.	  As	  the	  oocyst	  grows,	  the	  
nucleus	   divides,	   forming	   elongated	   sporozoites,	   approximately	   1000	   per	   oocyst	   (E).	   The	  
sporozoites	  actively	  break	  through	  the	  wall	  of	  the	  oocyst,	  and	  reach	  the	  salivary	  glands	  via	  
the	   haemolymph.	   An	   infected	   mosquito	   will	   inject	   sporozoites	   into	   the	   human	   host,	   to	  
complete	   the	   life	   cycle	   (F)	   (Essential	   Malariology.	   Fourth	   Edition.	   David	   A.	   Warrell	   and	  
Herbert	  M.	  Gilles).	  	  
The	   Plasmodium	   lifecycle	   differs	   at	   some	   stages	   depending	   on	   the	   species	   and	  
strains.	  For	  example	  only	  P.	  vivax	  and	  P.	  ovale	   form	  hypnozoites	   in	   the	   liver,	  which	  cause	  
relapse	  of	  the	  disease.	  P.	  ovale	  and	  P.	  vivax	  merozoites	  invade	  reticulocytes	  only,	  whereas	  P.	  
falciparum	   and	   P.	   malariae	   infect	   erythrocytes	   of	   different	   ages.	   The	   length	   of	   the	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erythrocytic	  schizogony	  cycle	  also	  varies,	  which	  results	  in	  different	  periodicity	  of	  the	  febrile	  
paroxysms.	   The	   amount	   of	   released	   merozoites	   from	   the	   hepatocyte	   schizonts	   or	   the	  
erythrocytic	   schizonts	   can	  also	  determine	   the	   severity	  of	   the	  disease.	   For	  example,	  whilst	  
the	  mortality	  level	  for	  P.	  falciparum	  is	  high,	  accounting	  for	  most	  malaria	  deaths	  in	  the	  world,	  
P.	  vivax	  malaria	  is	  generally	  considered	  only	  rarely	  fatal	  but	  there	  is	  now	  growing	  concern	  of	  
serious	   and	   fatal	   illnesses	   associated	   with	   Vivax	  malaria	   (Price	   et	   al.	   2009;	  Mendis	   et	   al.	  
2001;	  Nurleila	  et	  al.	  2012).	  
1.3 Malaria	  control	  and	  impact	  on	  the	  P.	  falciparum	  genome	  
	  
Malaria	  transmission	  can	  be	  controlled	  in	  many	  ways.	  Preventing	  mosquito	  bites	  and	  
killing	   mosquitoes	   with	   insecticide-­‐impregnated	   bed-­‐nets	   (ITNs),	   insect	   repellents,	   indoor	  
residual	   spraying	   (IRS)	   or	   draining	   standing	   water	   where	   mosquitoes	   lay	   their	   eggs	   have	  
become	  common.	  	  Also	  available	  are	  antimalarial	  drugs	  (e.g.,	  artemisinin-­‐based	  combination	  
therapies	  (ACT)),	  and	  under	  development	  are	  vaccines	  whose	  success	  would	  provide	  a	  high	  
level	  of	  protection	   for	  a	   sustained	  period	   (Kilama	  and	  Ntoumi	  2009;	  Agnandji	   et	   al.	   2011;	  
Bejon	  et	  al.	  2013).	  	  
The	   WHO	   malaria	   2012	   report	   indicated	   that	   international	   funding	   for	   malaria	  
control	  has	  continued	  to	  rise,	  to	  a	  peak	  of	  US$	  2	  billion	  in	  2011.	  However,	  they	  also	  noted	  
that	  this	  funding	  still	  fell	  short	  of	  the	  projected	  resources	  required	  (US$5	  billion	  per	  year	  for	  
the	  years	  2010	  -­‐	  2015)	  to	  achieve	  malaria	  control	  targets.	  This	  funding	  was	  also	  projected	  to	  
remain	  at	  these	  levels	  or	  decrease	  before	  2015	  unless	  new	  sources	  of	  funds	  were	  identified.	  
This,	   it’s	  noted,	  will	  pose	  great	  challenges	  on	  the	  effective	  and	  efficient	  control	  of	  malaria.	  
Nevertheless,	  efforts	  have	  been	  put	  in	  place	  to	  allow	  expansion	  of	  access	  to	  valuable	  public	  
health	  tools	  such	  as	  long-­‐lasting	  ITNs	  and	  IRS,	  as	  well	  as	  early	  access	  to	  rapid	  diagnosis	  and	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effective	  antimalarial	  drugs,	  to	  reduce	  death	  toll	  in	  a	  number	  of	  countries.	  For	  example,	  the	  
percentage	   of	   households	   owning	   at	   least	   one	   ITN	   in	   sub-­‐Saharan	  Africa	   stood	   at	   50%	   in	  
2010	  from	  3%	  in	  2000,	  while	  the	  percentage	  protected	  by	  IRS	  increased	  to	  11%	  in	  2010	  from	  
less	  than	  5%	  in	  2005	  (WHO.	  World	  Malaria	  Report	  2012)	  Household	  surveys	  also	  indicated	  
that	  96%	  of	  persons	  with	  access	  to	  an	  ITN	  within	  the	  household	  actually	  used	  it.	  The	  number	  
of	   rapid	  diagnostic	   tests	   (RDTs)	   and	  ACTs	  procured	  has	   increased,	   so	   is	   the	  percentage	  of	  
reported	  suspected	  cases	  receiving	  a	  parasitological	  test,	  from	  67%	  globally	  in	  2005	  to	  76%	  
in	  2010,	  with	  the	  largest	  increase	  in	  sub-­‐Saharan	  Africa	  (WHO.	  World	  Malaria	  Report	  2012).	  
Despite	  this	  significant	  progress,	  more	  work	  is	  needed	  before	  the	  target	  of	  universal	  access	  
is	  attained.	  More	  than	  50%	  reduction	  in	  malaria	  cases	  was	  reported	  between	  2000-­‐2010	  in	  
43	  of	  the	  99	  countries	  with	  on-­‐going	  transmission	  (WHO.	  World	  Malaria	  Report	  2012).	  
Nonetheless,	   behind	   these	   successes	   to	  malaria	   control	   lie	   a	  worrying	   reality,	   that	  
the	   P.	   falciparum	   is	   adapting	   in	   response	   to	   selection	   pressures	   from	   the	   host	   immune	  
system,	   drug	   treatment	   and	   changes	   in	   transmission	   intensity	   owing	   to	   specific	   malaria	  
interventions	  (Anderson	  et	  al.	  2011;	  Weedall	  and	  Conway	  2010).	  The	  major	  consequence	  of	  
this	  adaptation	  has	  been	  emergence	  and	  spread	  of	  drug	  resistant	  parasites	  and	  difficulties	  in	  
developing	  a	  vaccine.	  In	  addition,	  mosquito	  resistance	  to	  commonly	  used	  components	  in	  IRS	  
and	   ITN	   (pyrimethrin	   and	   DDT)	   is	   spreading	   (Kilama	   and	   Ntoumi	   2009).	   However,	   these	  
changes	   to	   P.	   falciparum	   population	   structure	   can	   potentially	   be	   used	   to	   identify	   and	  
circumvent	   survival	   strategies	   used	  by	   the	  parasite	  with	   an	   eye	   towards	   reducing	  malaria	  
burden.	  
It	  has	  widely	  been	  suggested	  that	  a	  vaccine	  against	  P.	  falciparum	  would	  probably	  be	  
the	  best	  way	  to	  curb	  malaria	  and	  reduce	  much	  of	  the	  burden	  associated	  with	  it.	  The	  RTS,S	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vaccine	   from	   GlaxoSmithKline	   Biologicals	   has	   so	   far	   been	   the	   most	   promising.	   This	  
recombinant	   malaria	   protein	   (consisting	   of	   components	   of	   the	   P.	   falciparum	  
circumsporozoite	   protein	   (CSP)	   joined	   to	   hepatitis	   surface	   antigen)	   has	   been	   shown	   to	  
reduce	  number	  of	   severe	   cases	  of	  malaria	   and	  delay	   the	   time	   to	   the	   first	   clinical	   episode	  
(Agnandji	  et	  al.	  2011;	  Aponte	  et	  al.	  2007).	  A	  pooled	  survey	  of	  all	  phase	  two	  trials	  reported	  
that	  RTS,S	  efficacy	  against	  all	  episodes	  of	  clinical	  malaria	  varied	  by	  transmission,	  with	  high	  
efficacy	  (60%)	  in	  low	  transmission	  areas,	  falling	  to	  4%	  in	  high	  transmission	  areas	  (Bejon	  et	  al.	  
2013).	  	  
1.4 P.	  falciparum	  genome	  
	  
Despite	  challenges	  such	  as	  high	  A+T	  content,	  the	  P.	  falciparum	  genome	  was	  one	  of	  
the	  first	  eukaryotic	  genomes	  sequenced.	  The	  full	  genome	  sequence	  was	  published	  in	  2002	  
and	  was	   followed	   by	   the	   publication	   of	   other	  Plasmodium	   genome	   sequences	   such	   as	  P.	  
vivax	   (Carlton	   et	   al.	   2008).	   These	   data	   have	   allowed	   elucidation	   of	   basic	   genome	  
architecture	   and	   identification	   of	   key	   structural	   elements,	   common	   metabolic	   and	  
biosynthesis	   pathways	   and	   unique	   aspects	   that	   are	   shared	   among	   several	   Plasmodium	  
parasites	   (Gardner	   et	   al.	   2002;	   Carlton	   et	   al.	   2008;	   Hall	   et	   al.	   2005).	   For	   example,	   it	   was	  
observed	   that	   a	   large	   proportion	   of	   P.	   falciparum	   proteins	   lack	   similarity	   with	   known	  
proteins	  from	  other	  organisms,	  suggesting	  a	  Plasmodium-­‐specific	  role.	  	  
The	   P.	   falciparum	   life	   cycle	   has	   a	   mostly	   haploid	   genome	   containing	   ~23.3	   Mb	  
nucleotides	  encoding	  ~	  5500	  genes	  and	  ~145	  pseudogenes	  (www.genedb.org,	  Hertz-­‐Fowler	  
et	  al.	  2004)	  organised	  into	  14	  chromosomes,	  ranging	  in	  size	  from	  ~640-­‐kb	  to	  3.3-­‐Mb	  in	  the	  
nuclear	  genome,	  along	  with	  two	  extra	  chromosomal	  DNA	  elements	  (35-­‐kb	  circular	  plasmid	  
and	   6-­‐kb	   mitochondrial	   genomes)	   (Gardner	   et	   al.	   2002,	   1993).	   The	   nucleotide	   content	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(percentage	   of	   the	   G/A/T/C)	   is	   80.6%	   AT	   rich	   (80.6%	   in	   coding	   regions	   and	   ~90%	   in	  
noncoding	  regions),	  greater	   than	  the	  67.7%	   in	  P.	  vivax	   (Gardner	  et	  al.	  2002).	  The	  A+T	  rich	  
regions	  are	  thought	  to	  be	  more	  recombinogenic	  thus	  helping	  to	  produce	  antigenic	  variation	  
(Winzeler	   2008).	   Almost	   one-­‐half	   of	   the	   predicted	   genes	   encode	   conserved	   hypothetical	  
proteins	  with	  unknown	  functions	  (Carlton	  et	  al.	  2008),	  although	  recent	  re-­‐annotation	  of	  the	  
genome	  has	  assigned	  putative	  functions	  to	  many	  additional	  genes.	  	  
There	  is	  a	  high	  incidence	  of	  tandem	  repeats	  and	  low	  complexity	  regions	  (LCRs)	  in	  P.	  
falciparum	  antigens.	  These	  tandem	  repeats	  are	  thought	  to	  be	   involved	   in	   immune	  evasion	  
mechanisms,	   for	  example	   through	  antigen	  diversification	   (Hughes	  2004),	   they	  may	   reduce	  
the	  host’s	  antibody	  response	  to	  critical	  epitopes	  through	  multiple	  cross-­‐reactivity	  amongst	  
them	   (Anders	  1986).	   LCR	  expansion	  also	  partly	   contributes	   to	   the	   slightly	   larger	   size	  of	  P.	  
falciparum	  proteins	  (Carlton	  et	  al.	  2008).	  	  
1.5 The	  P.	  falciparum	  genetic	  diversity	  map	  and	  function	  
	  
Genetic	  variation	   is	  key	   to	   the	  survival	  of	  P.	   falciparum,	  as	   it	  provides	  a	  means	   for	  
overcoming	  environmental	   challenges	   such	   as	   immune	  and	  drug	  pressure.	   Several	   factors	  
have	  contributed	  to	  this	  variation	  and	  are	  described	  below.	  
	  	   The	   large	  numbers	  of	  asexual	  blood	  stage	  parasites	   in	  a	  single	   infection	  provides	  a	  
reservoir	   within	   which	   biological	   selection	   can	   act.	   Chromosomal	   polymorphisms	   (e.g.,	  
genetic	   recombination,	   single	   nucleotide	   polymorphism	   (SNPs),	   insertions	   and	   deletions	  
(INDELs),	   copy	   number	   variation	   (CNV),	   inversions,	   translocations	   and	   tandem	   repeats	   in	  
surface	   antigens)	   occurring	   primarily	   during	   the	   sexual	   cycle	   largely	   contribute	   to	   this	  
variation.	   In	   the	   sexual	   phase,	   meiosis	   (an	   act	   of	   genetic	   recombination	   through	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independent	   assortment	   of	   chromosomes	   and	   crossing	   over	   between	   chromosomes)	  
generates	  new	  parasite	  variants	  with	  phenotypic	  traits	  such	  as	  drug	  resistance.	  Outcrossing	  
(characterized	  by	  high	  frequency	  of	  multiple	  and	  distinct	  genotype	  infections)	  produces	  an	  
effective	   recombination	   rate	   that	   breaks	   down	   linkage	   disequilibrium	   (LD,	   non	   random	  
association	  of	   alleles),	  whereas	   selfing/inbreeding	  preserves	   LD,	   a	   principle	   that	   has	   been	  
used	   to	  map	  drug	   resistant	  markers	   and	   virulence	   in	  P.	   falciparum.	   Also	   occurring	   at	   this	  
sexual	  phase	  is	  subtelomeric	  hypervariability,	  as	  a	  result	  of	  unstable	  AT	  repeat	  rich	  regions	  
producing	  recombination	  hotspots	  (Mu	  et	  al.	  2005;	  Volkman	  et	  al.	  2002;	  Kidgell	  et	  al.	  2006;	  
Corcoran	   et	   al.	   1988;	   Vernick	   et	   al.	   1988).	   Another	   form	  of	   variation	   is	   achieved	   through	  
presence	  of	   repetitive	   sequences	   in	   certain	   genes	   such	   as	   circumsporozoite	   protein	   (csp),	  
where	   the	   size	   of	   the	   repeat	   sequences	   vary	   significantly	   between	   clones	   thus	   providing	  
antigenic	  diversity	  needed	  to	  escape	  immune	  system.	  For	  example,	  adults	  have	  specifically	  
acquired	   strain	   specific	   immunity	   to	   the	   csp	   repeat	   length	   variants	   (Bowman	   et	   al.	   2013;	  
Zeeshan	  et	  al.	  2012).	  	  
However,	   to	   date,	   point	   mutations	   or	   SNPs	   are	   the	   widely	   characterized	   form	   of	  
variation	  and	  the	  markers	  of	  choice.	  SNPs	  involve	  a	  single	  base	  pair	  variation,	  are	  relatively	  
abundant	  in	  P.	  falciparum	  and	  their	  frequency	  vary	  across	  the	  14	  chromosomes	  and	  genes.	  
A	  high	  frequency	  of	  SNPs	  has	  been	  observed	  in	  surface	  molecules	  and	  putative	  transporters,	  
that	   are	   likely	   to	   be	   under	   drug	   or	   immune	   selection,	   whilst	   house-­‐keeping	   genes	   show	  
lesser	  SNP	  frequencies	  (Jeffares	  et	  al.	  2006;	  Volkman	  et	  al.	  2007a;	  Mu	  et	  al.	  2007).	  Studies	  of	  
P.	   falciparum	   genetic	   diversity	   have	   revealed	   their	   population	   structure	   and	   involvement	  
with	   drug	   response.	   For	   example,	   reduction	   in	   SNP	   diversity	   accompanied	   by	   selective	  
sweeps	   has	   been	   associated	   with	   positive	   selection	   (e.g.,	   in	   pfcrt,	   pfdhps,	   pfdhfr)	   largely	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driven	  by	  drug	  pressure	  (Nair	  et	  al.	  2003;	  Wootton	  et	  al.	  2002),	  while	  diversifying	  selection	  
produced	  highly	  polymorphic	  regions	  at	  candidate	  vaccine	  targets	  such	  as	  ama1,	  msp1	  and	  
2,	  csp	  and	  eba175	  genes	  (Polley	  et	  al.	  2003;	  Baum	  et	  al.	  2003;	  Ferreira	  et	  al.	  2003).	  A	  rich	  
SNP	  density	  has	  been	  observed	  in	  P.	  falciparum:	  Volkman	  et	  al.	  sequenced	  14	  parasite	  lines	  
and	  identified	  46,937	  SNPs	  (1/446-­‐bp)	  and	  37,039	  indels	  (1/548-­‐bp)	  (Volkman	  et	  al.	  2007);	  
Jeffares	   et	   al.	   compared	   the	   genomes	   of	   P.	   falciparum	   and	   P.	   reichenowi	   and	   identified	  
27,169	   SNPs	   (1/762-­‐bp)	   and	   27,478	   indels	   (1/631-­‐bp)	   (Jeffares	   et	   al.	   2006)	   and	  Mu	   et	   al.	  
identified	   3,918	   SNPs	   (1/5.9-­‐kb)	   and	   2,548	   microsatellites	   (MS,	   1/1.7-­‐kb)	   by	   sequencing	  
3,539	  genomic	  regions	  (Mu	  et	  al.	  2010).	  This	  SNP	  discovery	  has	  been	  revolutionized	  by	  the	  
recent	  advent	  of	  next	  generation	  sequencing	  (NGS)	  which	  enables	  the	  rapid	  sequencing	  of	  
whole	   genomes,	   making	   SNP	   discovery	   and	   genotyping	   less	   laborious.	   A	   recent	   study	  
detected	  86,158	  exonic	  SNPs	  (1/266-­‐bp)	  in	  227	  worldwide	  isolates	  using	  NGS	  (Manske	  et	  al.	  
2012).	   Taken	   together,	   a	   SNP	  density	  of	   1/266-­‐bp	  within	  23	  Mb	  genome	  of	  P.	   falciparum	  
(Manske	  et	  al.	  2012),	  a	  population	  pairwise	  diversity	  (π)	  of	  1.29	  x	  10-­‐3	  (Volkman	  et	  al.	  2007),	  
physical	  versus	  genetic	  distance	  of	  17-­‐kb	  per	  cM	  (Su	  et	  al.	  1999)	  and	  LD	  range	  of	  1.5	  to	  16-­‐
kb	  (Volkman	  et	  al.	  2007)	  demonstrate	  a	  very	  rich	  map	  of	  diversity	  in	  this	  eukaryotic	  parasite.	  
CNV	  also	  act	  as	  a	  major	  source	  of	  genome	  variation,	  are	  prevalent	  in	  P.	  falciparum,	  
and	   are	   increasingly	   being	   studied.	   Some	   CNV	   even	   encompass	   entire	   genes,	   and	   so	   can	  
influence	   gene	   expression	   levels	   as	   well	   as	   phenotypic	   variation,	   thereby	   revealing	  
important	  functions	  both	  in	  disease	  and	  drug	  response	  such	  as	  pfmdr1	  (on	  chromosome	  5)	  
and	  msp3.8	  (on	  chromosome	  10)	  in	  drug	  resistance	  (Carret	  et	  al.	  2005;	  Ribacke	  et	  al.	  2007;	  
Van	  Tyne	  et	  al.	  2011).	  In	  addition,	  amplifications	  on	  chromosome	  12	  of	  GTP	  cyclohydrolase	  
1,	  the	  first	  enzyme	  in	  the	  folate	  biosynthesis	  pathway	  is	  likely	  due	  to	  compensation	  for	  the	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decreased	  efficiency	  of	  the	  folate	  pathway	  caused	  by	  mutations	  in	  pfdhps	  and	  pfdhfr	  (Kidgell	  
et	   al.	   2006;	   Nair	   et	   al.	   2008).	   Subtelomeric	   deletions	   on	   chromosome	   2	   of	   the	   knob-­‐
associated	   histidine	   rich	   protein	   gene	   (kahrp)	   and	   chromosome	   9	   of	   the	   cytoadherence	  
linked	   asexual	   gene	   9	   (clag9)	   are	   associated	   with	   the	   loss	   of	   cytoadherence	   (Biggs	   et	   al.	  
1989;	  Trenholme	  et	  al.	   2000).	  Also	  detected	   is	   a	  gain	   in	   copy	  number	  of	   the	   reticulocyte-­‐
binding	  protein	  1	  gene	   (pfRh1),	   involved	   in	  human	  erythrocyte	   invasion	  and	   linked	   to	   fast	  
growth,	  that	  may	  have	  arisen	  during	  culture	  adaptation	  of	  certain	  parasite	  lines	  (Nair	  et	  al.	  
2011).	  CNV	  also	  play	  a	  role	  in	  altering	  gene	  expression	  throughout	  the	  P.	  falciparum	  genome	  
as	  demonstrated	  by	  Gonzales	  et	  al.	   In	  this	  study,	  a	   large	  regulatory	   locus	   (269	  transcripts)	  
occurred	  within	   the	   pfmdr1	   amplification	   and	   13	   other	   unlinked	   genes.	   In	   addition,	   drug	  
selection	   in	   the	  Dd2	  parental	   clone	  not	  only	   led	   to	  amplicons	   in	  pfmdr1	   but	  also	   in	  other	  
putative	  neighbouring	  regulatory	   factors	   that	   influence	  the	  overall	   transcriptional	  network	  
in	   the	  P.	   falciparum	   genome	   (Gonzales	   et	   al.	   2008).	   CNV	   have	   also	   been	   used	   to	   explain	  
gene	  expression	  differences	  between	  field	  and	  lab	  isolates	  (Mackinnon	  et	  al.	  2009).	  
1.6 Immunity	  and	  antigenic	  variation	  
	  
In	   highly	   endemic	   areas,	   acquisition	   of	   protective	   immunity	   to	   clinical	   disease	   is	   a	  
slow	  process	  involving	  years	  of	  multiple	  infections	  by	  the	  parasite.	  A	  person	  with	  protective	  
immunity	  will	  usually	  develop	  mild	  malaria	  even	  with	  high	  parasitemia	  (Doolan	  et	  al.	  2009;	  
Day	   and	   Marsh	   1991),	   however,	   young	   children	   aged	   less	   than	   5	   years	   and	   pregnant	  
mothers	   are	   at	   greater	   risk	   of	   developing	   severe	   malarial	   disease.	   In	   regions	   of	  
unstable/patchy	   malaria	   transmission	   and	   no	   significant	   protective	   immunity,	   the	   whole	  
population	  is	  generally	  susceptible	  to	  clinical	  malaria	  (Carter	  and	  Mendis	  2002).	  Because	  of	  
immune	   responses	   killing	   the	   parasite,	   P.	   falciparum	   has	   had	   to	   exploit	   tricks	   to	   evade	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death,	   mostly	   through	   antigenic	   variation.	   Antigenic	   variation	   derails	   acquisition	   of	  
protective	   immunity,	   partly	   attributed	   to	   the	   parasites	   highly	   polymorphic	   antigens	   that	  
require	  a	  constant	  production	  of	  new	  antibodies	  by	  the	  host	  immune	  system	  (Rogers	  et	  al.	  
1992;	  Newbold	  et	  al.	  1992).	  Given	  the	  fact	  that	  in	  nature	  no	  sterile	  immunity	  develops,	  it	  is	  
challenging	  to	  develop	  a	  vaccine,	   	  
1.6.1 Multi-­‐gene	  families	  
	  
The	   success	  of	  P.	   falciparum	   also	  depends	  on	   its	   ability	   to	   invade	  host	   tissues	  and	  
counter	   host	   defence	  mechanisms.	   To	   ensure	   long-­‐term	   survival	   they	  must	   also	  maintain	  
infectivity	   through	   transmission.	   Antigenic	   variation	   defined	   as	   expression	   of	   functionally	  
and	   antigenic	   distinct	   proteins,	   is	   a	   strategy	   employed	   by	   P.	   falciparum	   to	   evade	   host	  
immune	  responses	  (Craig	  and	  Scherf	  2001).	  As	   it	   invades	  a	  host	  cell	  such	  as	  red	  blood	  cell	  
(RBC),	  it	  expresses	  antigenic	  variant	  surface	  proteins	  (VSA)	  on	  the	  surface	  of	  infected	  RBC	  to	  
help	  avoid	  specific	  recognition	  from	  immune	  system	  (Craig	  and	  Scherf	  2001;	  Dzikowski	  et	  al.	  
2006a,	   2006b).	   	   Most	   of	   these	   proteins	   are	   encoded	   by	   various	   multi-­‐gene	   families	  
(accounting	  for	  approximately	  7%	  of	  genes	   in	  the	  genome)	   located	  mostly	   in	  subtelomeric	  
end	   of	   the	   chromosomes,	   are	   highly	   polymorphic,	   and	   some	   expressed	   in	   a	   mutually	  
exclusive	   way.	   Widely	   studied	   VSA	   include	   PfEMP1	   (encoded	   by	   var	   genes),	   STEVOR	  
(encoded	  by	   stevor	  genes)	   and	  RIFINS	   (encoded	  by	   rif	  genes).	  P.	   falciparum	   is	   particularly	  
known	   to	   use	   PfEMP1	   to	   adhere	   to	   receptors	   of	   the	   host	   microvasculature	   leading	   to	  
sequestration	  of	  the	  parasites	  in	  the	  deep	  vascular	  bed,	  for	  example	  in	  the	  brain	  leading	  to	  
cerebral	  malaria.	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1.7 Antimalarial	  drug	  resistance	  in	  P.	  falciparum	  
	  
Emergence	   and	   spread	   of	   drug	   resistant	  malaria	   parasites	   have	   greatly	   influenced	  
epidemiology	  of	  malaria	  and	  options	  for	  its	  treatment.	  	  For	  many	  decades,	  chloroquine	  (CQ)	  
was	  used	  as	  first	  line	  drug	  treatment	  for	  malaria	  due	  to	  its	  low	  cost,	  safety	  and	  efficacy.	  CQ	  
binds	  to	  heme	  molecules	  in	  the	  parasite	  food	  vacuole,	  interfering	  with	  heme	  detoxification	  
and	   leading	  to	  toxic	   levels	  of	  heme	   in	  the	  parasite	   (Egan	  et	  al.	  1999).	  CQ	  resistance	  (CQR)	  
was	   first	   reported	   in	   two	   foci	   in	   southeast	  Asia	   (Thai-­‐Cambodia	  border	   in	   late	  1950s)	   and	  
South	  America	  (Columbia	  in	  early	  1960s)	  and	  spread	  to	  all	  malaria	  endemic	  regions,	  mainly	  
in	  sub-­‐Sahara	  Africa	  and	  parts	  of	  south	  America	  (Wootton	  et	  al.	  2002;	  Hayton	  and	  Su	  2008;	  
Chen	   et	   al.	   2003;	   Vieira	   2001).	   CQR	   was	   established	   through	   the	   use	   of	   a	   genetic	   cross	  
between	  a	  CQ	  sensitive	  and	  CQ	  resistant	  parasite	  that	  led	  to	  the	  discovery	  of	  a	  mutation	  in	  a	  
putative	  transporter,	  P.	  falciparum	  chloroquine	  resistant	  transporter	  (pfcrt)	  on	  chromosome	  
7,	  and	  in	  particular	  a	  substitution	  of	  lysine	  by	  threonine	  at	  codon	  position	  76	  (K76T)	  (Fidock	  
et	  al.	  2000;	  Sidhu	  et	  al.	  2002).	  To	   some	  extent	   its	  also	  modulated	  by	  mutations	  and	  copy	  
number	  variation	  (CNV)	  in	  P.	  falciparum	  multidrug	  resistant	  (pfmdr1)	  gene	  on	  chromosome	  
5	   (Mu	   et	   al.	   2003).	   However,	   the	   contribution	   of	   pfmdr1	   in	   CQR	   remains	   unclear	   and	   is	  
thought	   to	   be	   a	   compensation	   for	   fitness	   costs	   (Patel	   et	   al.	   2010).	  Mutations	   in	  pfcrt	   are	  
thought	   to	   confer	   resistance	   by	   preventing	   CQ	   accumulation	   in	   the	   digestive	   vacuole	   to	  
levels	  required	  for	  inhibition	  of	  endogenous	  heme	  detoxification	  (Egan	  et	  al.	  1999).	  
After	  emergence	  and	  spread	  of	  CQR	  in	  most	  countries,	  the	  next	  primary	  drug	  to	  be	  
adopted	   was	   the	   co-­‐formulated	   synergistic	   combination	   of	   sulfadoxine	   (SDX)	   and	  
pyrimethamine	  (PYR),	  known	  as	  sulfadoxine-­‐pyrimethamine	  (SP)	  which	  targeted	  and	  inhibits	  
two	   enzymes	   -­‐	   the	   dihydropteroate	   synthase	   (dhps)	   and	   dehydrofolate	   reductase	   (dhfr)	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genes	  respectively	  of	  the	  folate	  biosynthesis	  pathway	  in	  the	  parasite	  (Prajapati	  et	  al.	  2011).	  	  
SP	   resistance	   (SPR)	   developed	   and	  was	   also	   first	   reported	   in	   Thailand-­‐Burma	   border	   and	  
spread	  to	  fixation	  in	  approximately	  6	  years	  through	  mutations	  in	  each	  of	  the	  genes	  encoding	  
pfdhps	   (chromosome	   8)	   and	  pfdhfr	   (chromosome	   4)	   (Nair	   et	   al.	   2003;	   Plowe	   et	   al.	   1997;	  
Nash	  et	  al.	  2005;	  Roper	  et	  al.	  2004).	  PYR	  being	  a	  competitive	   inhibitor	  of	  pfdhfr,	  displaces	  
the	   natural	   folate	   substrate	   and	   resistance	   occurs	   when	   specific	   point	   mutations	   occur:	  
S108N	  (serine	  to	  asparagine	  at	  codon	  108)	  only	  confer	  a	  small	  amount	  of	  resistance,	  while	  
additional	  mutations	  in	  pfdhfr	  at	  N51I	  (asparagine	  to	  isoleucine),	  C59R	  (cysteine	  to	  arginine)	  
and	   I164R	   (isoleucine	   to	   arginine)	   act	   synergistically	   to	   increase	   levels	   of	   PYR	   resistance	  
(Vasconcelos	  et	   al.	   2000;	  Plowe	  et	  al.	   1997).	   The	  pfdhfr	   quartet	  mutant	  of	  N51I	  +	  C59R	  +	  
S108N	   +	   I164R	   has	   the	   highest	   levels	   of	   PYR	   resistance.	   Resistance	   to	   SDX	   is	   due	   to	  
mutations	  on	  the	  pfdhps	  gene	  that	  decrease	  the	  enzyme	  binding	  affinity	  to	  SDX	  (Triglia	  et	  al.	  
1998).	   Similar	   to	   the	   pfdhfr,	   an	   amino	   acid	   change	   in	   pfdhps	   at	   position	   437	   (A437G)	  
represents	  the	  initial	  mutation	  for	  SDX	  resistance.	  An	  additional	  mutation(s)	  at	  positions	  436	  
(S436A,	  serine	  to	  alanine),	  540	  (K540E,	  lysine	  to	  glutamine),	  581	  (A581G,	  alanine	  to	  glycine),	  
and/or	   613	   (A613S,	   serine	   to	   threonine)	   causes	   elevated	   levels	   of	   SDX	   resistance	   in	   vitro	  
(Triglia	  et	  al.	  1998).	  
CNV	   and	   SNPs	   at	   pfmdr1	   have	   also	   been	   associated	   with	   parasite	   responses	   to	  
several	  drugs	  including	  mefloquine	  (MQ),	  quinine	  (QN),	  artemisinin	  (ART),	  lumefantrine	  (LF)	  
and	   halofantrine	   (HF)	   (Sidhu	   et	   al.	   2006).	   In	   addition,	   mutations	   in	   a	   gene	   encoding	   a	  
putative	   Na+/H+	   exchanger	   (pfnhe)	   and	   pfatp6	   have	   been	   associated	   with	   parasite	  
responses	   to	  MQ	  and	  ART	   respectively	   (Jambou	  et	   al.	   2005;	   Ferdig	  et	   al.	   2004),	   but	  need	  
further	  proof.	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In	  the	  last	  decade	  ART	  have	  been	  deployed	  as	  first-­‐line	  treatment	  of	  uncomplicated	  
P.	   falciparum	  malaria	   in	   endemic	   countries	   in	   combination	  with	   other	   drugs	   such	   as	  MF,	  
amodiaquine	  (AMQ),	  piperaquine	  (PPQ),	  PYR/SDX,	  or	  LF,	  collectively	  known	  as	  artemisinin-­‐
based	   combination	   therapies	   (ACTs)	   (WHO.	  World	  Malaria	   Report	   2012).	   ART	   has	   a	   short	  
half-­‐life	   but	   acts	   extremely	   very	   quickly	   in	   reducing	   parasite	   densities	   and	   symptoms.	  
Together	   with	   other	   control	   measures	   ACTs	   have	   resulted	   in	   a	   remarkable	   decrease	   in	  
malaria	  morbidity	  and	  mortality	  (Jambou	  et	  al.	  2005;	  Barnes	  et	  al.	  2005).	  However,	  recent	  
confirmed	  reduced	  parasite	  in	  vivo	  susceptibility	  to	  artesunate	  in	  western	  Cambodia	  has	  led	  
to	  concerns	  that	  the	  efficacy	  of	  ACT	  could	  be	  declining	  through	  emergence	  of	  drug	  resistant	  
genotypes	  (Noedl	  et	  al.	  2008,	  2009;	  Das	  et	  al.	  2009).	  The	  resistant	  phenotype	  has	  not	  been	  
well	  characterized	  nor	  any	  molecular	  marker	  identified	  (Cheeseman	  et	  al.	  2012;	  Miotto	  et	  al.	  
2013)	   and	   this	   impedes	   surveillance	   studies	   to	   monitor	   the	   spread	   of	   the	   resistant	  
phenotype.	   Thus,	   there	   is	   urgent	   need	   to	   identify	   molecular	   markers	   underlying	   such	  
phenotypic	  traits	  in	  order	  to	  give	  insight	  into	  the	  mechanism	  of	  ART	  antimalarial	  action	  and	  
parasite	  resistance.	  	  
However,	  mutations	   in	   certain	  genes	  have	  been	  postulated	   to	   confer	   resistance	   to	  
ACT	  including:	  (a)	  The	  pfmdr1,	  a	  4.2-­‐kb	  long	  gene	  whose	  decreasing	  copy	  number	  is	  thought	  
to	  confer	  susceptibility	  to	  MQ,	  LF,	  HFX,	  QN	  and	  ART.	  In	  vivo	  selection	  of	  Y86N	  allele	  has	  also	  
been	   observed	   after	   artemether-­‐lumefantrine	   (LA)	   treatment	   in	   Africa.	   The	   Y86N	   was	  
considered	  as	  a	  potential	  marker	  for	  LF	  resistance	  in	  vivo	  (Sidhu	  et	  al.	  2006;	  Sisowath	  et	  al.	  
2005).	   (b)	   The	   pfatp6,	   a	   4.3-­‐kb	   gene	   on	   chromosome	   1	   encoding	   calcium	   dependent	  
sarcoplasmic/endoplasmic	  reticulum	  calcium	  ATPase,	  has	  been	  shown	  to	  be	  a	  target	  of	  ART	  
drugs	  in	  Xenopus	  oocytes	  through	  a	  single	  amino	  acid	  change,	  L263E	  (Eckstein-­‐Ludwig	  et	  al.	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2003;	  Uhlemann	  et	  al.	  2005).	  Another	  amino	  acid	  change	  S769N	   is	  also	  associated	  with	   in	  
vitro	   sensitivity	   (Jambou	  et	  al.	  2005).	   (c)	  A	  gene	   (cytochrome	  b)	   in	   the	  6-­‐kb	  mitochondrial	  
genome	  contain	  mutations	  that	  can	  potentially	  change	  susceptibility	  to	  ART	  (Imwong	  et	  al.	  
2010).	  (d)	  The	  pfubp1,	  a	  3.3-­‐kb	  gene	  on	  chromosome	  2	  contain	  mutations	  V739F	  and	  V770F	  
that	   have	   been	   shown	   to	   confer	   ART	   resistance	   in	   P.	   chabaudi	   (Hunt	   et	   al.	   2007).	   (e)	  
Potential	   involvement	   of	   CQR	   mutations	   acting	   as	   a	   prerequisite	   for	   subsequent	  
development	   of	   ART	   resistance	   as	   observed	   in	  P.	   chabaudi	   (Hunt	   et	   al.	   2007).	   (f)	   A	   large	  
region	  on	  chromosome	  13	  is	  also	  associated	  with	  slow	  ART	  clearance	  rates	  (Cheeseman	  et	  
al.	  2012).	  
1.8 Malaria	  epidemiology	  in	  Malawi	  
	  
Malawi	   is	   a	   landlocked	  country	   located	   in	   southeast	  Africa.	   In	  Malawi,	  malaria	   is	   a	  
major	  public	  health	  problem,	  with	  the	  entire	  population	  (15	  million)	  at	  risk	  and	  an	  estimated	  
6	  million	  cases	  occurring	  annually.	  Children	  less	  than	  five	  years	  of	  age	  and	  pregnant	  women	  
are	   mostly	   affected.	   P.	   falciparum	   is	   the	   major	   Plasmodium	   species,	   with	   Anopheles	  
funestus,	   A.	   gambiae,	   and	   A.	   arabiensis	   the	   primary	   mosquito	   vectors	   (Mzilahowa	   et	   al.	  
2012;	   Malawi	   National	   Malaria	   Indicator	   Survey,	   2010).	   The	   Malawi	   National	   Malaria	  
Strategic	   plan	   2005-­‐2010	  main	   goal	   was	   to	   scale	   up	  malaria	   interventions	   to	   reduce	   the	  
burden	   including	   prioritizing	   effective	   antimalarial	   usage,	   ITNs,	   IRS,	   and	   prevention	   in	  
pregnancy	  (IPTp).	   ITNs	  have	  been	  the	  primary	  control	  strategy	  for	  malaria	  both	  in	  children	  
and	   pregnant	  women,	  with	   58.2%	  of	   households	   having	   at	   least	   one	   ITN.	   IPTp	   is	   used	   to	  
prevent	  MIP	  and	  was	  adopted	  in	  1993.	  As	  of	  2007,	  LA	  has	  been	  used	  as	  first-­‐line	  treatment	  
for	   uncomplicated	   falciparum	   malaria,	   AS+AQ	   used	   for	   treatment	   failure	   and	   QN	   for	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treatment	  of	  severe	  cases.	  IRS	  was	  adopted	  in	  2007	  and	  coverage	  has	  reached	  40%.	  (Malawi	  
National	  Malaria	  Indicator	  Survey,	  2010;	  WHO.	  2012).	  	  
Malawi	   experiences	   year	   round	   transmission	  with	   a	   peak	  during	   the	   rainy	   seasons	  
between	  December	   and	  May	   (Ewing	  et	   al.	   2011).	  As	   at	   2010,	   parasite	  prevalence	   rate	  by	  
slide	   microscopy	   was	   43.3%	   nationally	   and	   severe	   anaemia	   prevalence	   (haemoglobin	   <	  
8g/dl)	  at	  12.3%	  in	  children	  under	  five	  years	  of	  age.	  Malaria	  parasitemia	  among	  children	  was	  
higher	  in	  rural	  (46.9%)	  than	  urban	  areas	  (14.7%),	  and	  parasite	  prevalence	  increased	  with	  age	  
while	   prevalence	   of	   severe	   anaemia	   showed	   an	   opposite	   trend	   (Malawi	   National	  Malaria	  
Indicator	  Survey	  2010).	  	  
There	   is	   high	   resistance	   to	   SP	   drug,	   with	   over	   90%	   of	   infections	   carrying	   the	  
‘quintuple	  mutant’	  (pfdhfr	  mutations	  N51I,	  C59R	  and	  S108N,	  and	  pfdhps	  mutations	  A437G	  
and	  K540E)	  (Nkhoma	  et	  al.	  2007).	  Since	  withdrawal	  of	  CQ	  in	  1993,	  prevalence	  of	  K76T	  pfcrt	  
has	  fallen	  to	  0%,	  and	  the	  re-­‐emergence	  of	  CQ	  sensitive	  genotypes	  raises	  the	  possibility	  that	  
CQ	  might	  be	  used	  again	   to	   treat	  malaria	   (Nkhoma	  et	  al.	  2007).	  However,	  no	   report	  on	  LA	  
treatment	  failure/resistance	  has	  been	  observed	  in	  Malawi	  to	  date.	  
1.9 Advances	  in	  investigating	  P.	  falciparum	  genetic	  diversity	  
	  
With	   the	   advent	   of	   in	   vitro	   culturing	   systems	   (Trager	   and	   Jensen	  1976),	   studies	   of	  
parasite	   diversity	   took	   centre	   stage	   and	   initially	   focused	   on	   enzyme	   and	   antigen	   protein	  
variability	  due	  to	  technological	  limitations.	  Observations	  of	  genetic	  diversity	  in	  P.	  falciparum	  
using	  enzyme	  protein	  polymorphisms	  (particularly	  in	  the	  6-­‐phosphogluconate	  hydrogenase	  
and	   glucose-­‐6-­‐phosphate	   isomerase)	   were	   based	   on	   electrophoretic	   variations	   in	   these	  
enzymes	   to	   reflect	   genetic	   differences	   (Knowles	   et	   al.	   1981;	  Walliker	   1983;	   Hempelmann	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and	  Dluzewski	  1981).	  Soluble	  antigens	  were	  also	  used	  to	  observe	  antigenic	  diversity	  and	  this	  
was	  established	  in	  sera	  of	  infected	  patients	  from	  the	  Gambia	  (Wilson	  et	  al.	  1969)	  where	  50	  
patients	   showed	   highly	   diverse	   S-­‐antigens	  with	   18	   distinct	   forms.	   These	   procedures	  were	  
later	   improved	   to	   incorporate	   use	   of	  monoclonal	   antibodies	   and	   immunofluorescence	   to	  
study	  diversity	  in	  worldwide	  parasite	  populations	  (McBride	  et	  al.	  1982).	  	  
Developed	   in	  1983,	   gene	  amplification	  using	  polymerase	   chain	   reaction	   (PCR),	  was	  
introduced	  as	  a	  way	  of	  assessing	  P.	   falciparum	   genetic	  diversity	  and	  population	  structure,	  
first	   by	   looking	   at	   antigenic	   locus	   size	   polymorphisms	   (Scherf	   et	   al.	   1991;	   Ntoumi	   et	   al.	  
1995).	  The	  commonly	  used	  polymorphic	  genes	  for	  PCR	  genotyping	  became	  msp1,	  msp2	  and	  
glurp,	  with	  msp2	  as	  the	  most	  informative	  and	  used	  to	  differentiate	  between	  recrudescence	  
and	  reinfection	  (Cattamanchi	  et	  al.	  2003;	  Färnert	  et	  al.	  2001).	  In	  1987,	  the	  first	  P.	  falciparum	  
genetic	  cross	  was	  established	  between	  two	  parent	   lab	  clones,	  HB3	  and	  3D7	  to	  distinguish	  
the	  two	  parents	  and	  identify	  recombinant	  progeny	  (Walliker	  et	  al.	  1987).	  In	  this	  study,	  PYR	  
resistance	  was	  used	  as	  a	  phenotypic	  marker	  and	  was	  linked	  to	  an	  amino	  acid	  change	  in	  the	  
pfdhfr	   gene	   (S108N	   mutation)	   (Peterson	   et	   al.	   1988).	   This	   work	   demonstrated	   that	  
recombination	   could	   provide	   a	  mechanism	   for	   producing	   parasites	   with	   novel	   genotypes	  
bearing	   important	   clinical	   phenotypes	   such	   as	   drug	   resistance.	   In	   1990,	   another	   genetic	  
cross	  between	  CQ	  resistant	  clone,	  Dd2	  and	  CQ	  sensitive,	  HB3	  was	  established	  (Wellems	  et	  
al.	   1990)	   and	   led	   to	   identification	   of	   CQR	   molecule	   (Fidock	   et	   al.	   2000).	   Further	   work	  
through	   development	   of	   restriction	   fragment	   length	   polymorphisms	   	   (RFLP)	   markers	  
localised	  the	  CQR	  locus	  to	  a	  ~	  400-­‐kb	  segment	  on	  chromosome	  7	  (Wellems	  et	  al.	  1991)	  and	  
later	  with	  genomic	  advances,	  microsatellite	  (MS)	  markers	  were	  used	  to	  fine	  map	  CQR	  gene	  
to	   a	   36-­‐kb	   segment	   (Su	   et	   al.	   1999;	   Su	   et	   al.	   1997).	   MS	   marker	   genotyping	   become	   a	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valuable	   and	   widely	   used	   approach,	   because	   the	   markers	   have	   high	   mutation	   rates	   and	  
polymorphisms,	  multiple	  alleles	  and	  are	  selectively	  neutral	  (Su	  et	  al.	  1999).	  	  
In	   2002,	   completion	   of	   P.	   falciparum	   3D7	   genome	   sequence	   provided	   further	  
advancement	   and	   enabled	   identification	   of	   SNP	  markers	   (Gardner	   et	   al.	   2002)	   that	   have	  
since	  become	  the	  marker	  of	  choice	  for	  high	  throughput	  genotyping	  (Su	  et	  al.	  2007).	  SNPs	  are	  
abundant	   in	   the	  P.	   falciparum	  genome	  and	  their	  distribution	  vary	  greatly	   (Mu	  et	  al.	  2007)	  
between	   chromosomes	   and	   genes,	   with	   high	   frequencies	   seen	   in	   surface	   proteins	   and	  
putative	   transporters	   thought	   to	   be	   under	   drug	   and	   immune	   selection.	   With	   the	  
development	   of	   MS	   and	   SNPs,	   came	   new	   methods	   for	   exploiting	   P.	   falciparum	   genetic	  
diversity.	  Genotyping	   arrays	  were	  developed	  which	  provided	  a	   fast,	   relatively	   inexpensive	  
way	   to	   examine	   genome-­‐wide	   SNPs	   and	  CNV	  and	  depending	  on	   the	   technology,	   genomic	  
variation	   could	   now	   be	   captured	   at	   SNP,	   MS,	   INDEL	   and	   CNV	   level	   and	   have	   been	  
successfully	  used	  in	  P.	  falciparum	  (Kidgell	  et	  al.	  2006;	  Jiang	  et	  al.	  2008a,2008b;	  Ribacke	  et	  al.	  
2007;	  Hayton	  and	  Su	  2008).	  These	  arrays	  explored	  hybridization	  techniques	  where	  labelled	  
parasite	  genomic	  DNA	  is	  hybridized	  to	  an	  array	  containing	  millions	  of	  probes	  sequences.	  For	  
example,	   a	   difference	   (substitution)	   in	   a	   probe	   sequence	   between	   3D7	   and	   test	   sample	  
would	  reduce	  signal	  from	  the	  test	  sample	  compared	  to	  that	  of	  3D7	  and	  inferred	  mutation.	  
Some	  commonly	  used	  arrays	   include	  PFSANGER	   tiling	   array	   (Sanger	   Institute,	  UK)	  used	   to	  
identify	  single	  feature	  polymorphisms	  and	  CNV	  (Mu	  et	  al.	  2007;	  Jiang	  et	  al.	  2008b;	  Kidgell	  et	  
al.	  2006;	  Mourier	  et	  al.	  2008)	  and	  molecular	   invasion	  probe	  that	  was	  used	   to	   identify	   loci	  
under	   positive	   selection,	   variation	   in	   population	   recombination	   events	   and	   population	  
structure	  (Mu	  et	  al.	  2010)	  (Table	  1.1).	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Table	  1.1:	  List	  of	  arrays	  developed	  and	  used	  in	  detecting	  polymorphisms	  in	  P.	  falciparum	  
Type	  of	  array	   Polymorphism	  	   Reference	  
Affymetrix	  array	   CNV	   Carret	  et	  al.	  2005	  
	  
CNV	  and	  SNPs	   Dharia	  et	  al.	  2010	  
	  
Single	  feature	  polymorphism	   Kidgell	  et	  al.	  2006	  
UltraGAPS	  printed	  glass	  slides	   CNV	   Ribacke	  et	  al.	  2007	  
PSANGER	  affymetrix	  GeneChip/CGH	  array	   SNPs	  and	  CNV	   Jiang	  et	  al.	  2008a,	  2008b	  
PSANGER	  affymetrix	  GeneChip	   CNV	   Cheeseman	  et	  al.	  2005	  
Affymetrix	  3,000	  SNP	  chip	   SNPs	   Neafsey	  et	  al.	  2008	  
4.8	  M	  probe	  affymetrix	  CGH	  array	   CNV	  and	  SNPs	   Dharia	  et	  al.	  2009	  
Gene	  expression	  array	   Transcription	  and	  CNV	   Mackinnon	  et	  al.	  2009	  
Affymetrix	  microarray/molecular	  invasion	  probe	   SNPs	   Mu	  et	  al.	  2010	  
Custom	  NimbleGen	  385K	  array	   CNV	   Samarakoon	  et	  al.	  2011a	  
Affymetrix	  array	  containing	  74,656	  SNPs	   SNPs	   Amambua	  et	  al.	  2012	  
	  
However,	  tiling	  arrays	  have	  a	  disadvantage	  that	  they	  can	  only	  type	  known	  SNPs	  and	  
usually	  require	  species-­‐specific	  customization.	  The	  high	  AT	  rich	  P.	  falciparum	  genome	  with	  
an	   abundance	   of	   repeat	   elements,	   makes	   it	   difficult	   to	   design	   suitable	   probes	   for	   the	  
majority	   of	   noncoding	   regions	   (Hayton	   and	   Su	   2008).	   Tiling	   arrays	   also	   require	   large	  
amounts	   of	  P.	   falciparum	   DNA	  which	   is	   often	   obtained	   by	   culture	   adaptation	   of	   sampled	  
parasites	  which	   in	   turn	  may	   lead	  to	  copy	  number	   fluctuations,	  altering	  naturally	  occurring	  
CNV	  (Anderson	  et	  al.	  2009;	  Mackinnon	  et	  al.	  2009).	  Contamination	  of	  human	  DNA	  is	  another	  
problem	   as	   it	   can	   inhibit	   hybridization	   and	   since	   human	  DNA	   accounts	   for	   approximately	  
100-­‐fold	  more	  than	  parasite	  DNA,	  it	  is	  important	  to	  deplete	  samples	  of	  human	  white	  blood	  
cells	  prior	  to	  DNA	  extraction.	  Multiclonal	  infections	  of	  P.	  falciparum	  offer	  another	  challenge	  
(Hayton	  and	  Su	  2008).	  
	  	   Next	   generation	   sequencing	   techniques	   (NGS),	   also	   called	   massive	   parallel	  
sequencing	   (MPS),	   are	   increasingly	   becoming	   popular.	  With	   the	   ability	   to	   produce	   dense	  
variation,	   allowing	   identification	   of	   almost	   whole	   genome	   variation,	   they	   are	   highly	  
informative.	  The	  inexpensive	  production	  of	  large	  volumes	  of	  sequence	  data	  also	  adds	  to	  its	  
advantage	  over	  other	  methods	  (such	  as	  PCR	  and	  arrays).	  Applications	  of	  NGS	  have	  ranged	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from	  studies	  of	  whole-­‐genome	  sequencing	  (studies	  of	  entire	  genomes),	  exome	  sequencing	  
(investigations	   of	   smaller	   functional	   portions	   of	   the	   genome),	   RNA-­‐seq	   (analysis	   of	   the	  
transcribed	   genome)	   and	   ChIP-­‐seq	   (protein-­‐DNA	   binding	   sites).	   The	   widely	   used	   whole	  
genome	  sequencing	  platforms	   include	   Illumina/Solexa	   (GA1,	  GA2,	  HiSeq	  2000,	  HiSeq2500,	  
MiSeq	  platforms),	  Ion	  torrent	  (PGM)	  and	  Roche	  (454-­‐platforms).	  These	  are	  also	  referred	  to	  
as	  second	  generation	  sequencers,	  and	  are	  capable	  of	  generating	  millions	  of	  DNA	  fragments	  
using	  a	  highly	  parallel	  sequencing-­‐by-­‐synthesis	  process	  (Metzker	  2010;	  Sboner	  et	  al.	  2011).	  
The	   overall	   cost	   of	   sequencing	   has	   immensely	   dropped,	   for	   example,	   the	   first	   human	  
genome	   was	   sequenced	   at	   an	   approximate	   cost	   of	   $3	   billion	   and	   it	   took	   13	   years	   to	  
complete.	   In	   2009,	   the	   cost	   had	   dropped	   to	   $100,000	   and	   achieving	   the	   $1,000	   genome	  
looks	  feasible	  (Sboner	  et	  al.	  2011).	  It	  currently	  takes	  approximately	  11	  days	  to	  sequence	  the	  
P.	  falciparum	  genome	  on	  an	  Illumina	  HiSeq	  2000.	   	  Several	  factors	  have	  contributed	  to	  this	  
reduction	   in	   cost	   including	   improvement	   in	   experimental	   design	   and	   sample	   collection,	  
sample	  sequencing,	  data	  reduction	  and	  management	  (Figure	  1.3).	  As	  sequencing	  techniques	  
improve,	   costs	   and	   stringency	   of	   DNA	   sample	   quality	   falls,	   as	   such	   new	   effective	   and	  
cheaper	   methods	   of	   sample	   processing	   are	   developed	   while	   at	   the	   same	   time	   meeting	  
sequencing	   threshold.	   CF11	   columns	   have	   become	   common	   in	   processing	   P.	   falciparum	  
samples	  (either	  cultured	   in	  vitro	  or	  processed	  directly	   from	  a	  patient	  without	  culturing)	  to	  
deplete	  human	  DNA	   from	  parasitized	  blood	  and	  has	  been	   implemented	   in	   large	   genome-­‐
wide	  sequencing	  studies,	  especially	  in	  field	  sites	  with	  minimal	  facilities	  (Auburn	  et	  al.	  2011).	  
In	  case	  of	  low	  blood	  volumes	  or	  parasite	  densities	  resulting	  into	  less	  starting	  material,	  whole	  
genome	  amplification	  (WGA)	  after	  DNA	   isolation	  has	  been	  employed	  to	  boost	  the	  starting	  
material	  (Oyola	  et	  al.	  2012;	  Kozarewa	  et	  al.	  2009).	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Table	   1.2:	   Specifications	   of	   different	   Illumina	   sequencing	   methods	   and	   Ion	   torrent.	  
Adapted	  from	  (Quail	  et	  al.	  2012).	  
	  
	  As	  at	  2013,	  Solexa/Illumina	  Hiseq	  (Illumina,	  Inc)	  technology	  is	  the	  most	  widely	  used	  
platform	  and	  is	  capable	  of	  generating	  billions	  of	  bases	  of	  high	  quality	  DNA	  sequence	  per	  run	  
in	  short	  stretches	  of	  DNA	  (paired-­‐end	  reads),	  which	  are	  mapped	  on	  to	  a	  reference	  genome	  
(usually	   3D7	   in	  P.	   falciparum,	   (Manske	   et	   al.	   2012)),	   thus	   allowing	   accurate,	   reproducible	  
and	  cost	  effective	  whole	  genome	  analysis	  (Table	  1.2).	  Although	  it	  covers	  almost	  the	  entire	  
genomic	  sequence	  of	  the	  parasite,	  it	  provides	  less	  and	  inaccurate	  measurement	  of	  mapped	  
sequence	  in	  difficult	  stretches	  of	  DNA	  such	  as	  repeats	  and	  subtelomeric	  regions	  containing	  
highly	  polymorphic	  genes.	  Thus,	  the	  repetitive	  nature	  of	  the	  P.	  falciparum	  genome	  and	   its	  
biased	   base	   composition	   (high	   AT	   content)	   is	   a	   great	   challenge	   in	   sequencing,	   read	  
alignment	  or	  assembly	  producing	  uneven	  read	  coverage	  across	  AT	  and	  GC	  rich	  regions	  which	  
can	   lead	   to	   problems	   in	   variation	   analyses	   (Oyola	   et	   al.	   2012).	   However,	   continual	  
improvement	  in	  read	  length	  and	  optimization	  of	  sequencing	  library	  construction	  has	  greatly	  
improved	   data	   output.	   	   The	   high	   amount	   of	   sequence	   data	   produced	   also	   require	   high	  
computing	  power	  and	  capabilities	  which	  has	  been	  enhanced	  by	  the	  continual	  advancement	  
in	   bioinformatics	   and	   new	   computational	  methods	   (some	   adapted	   from	   analysis	   of	   other	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organisms)	  to	  help	  reduce	  the	  cost	  of	  data	  processing,	  storage	  and	  summaries	  of	  raw	  data	  




Figure	   1.3:	   Left:	   the	   four	   major	   components	   of	   sequencing:	   experimental	   design	   and	  
sample	   collection,	   sequencing,	   data	   management	   and	   downstream	   analysis.	   Right:	  
relative	   impact	  of	  the	  four	  major	  components	  on	  sequencing	  over	  time.	  Adapted	  from	  
(Sboner	  et	  al.	  2011):	  
	  
1.10 	  Illumina	  sequencing	  
	  
The	   Illumina	   sequencing-­‐by-­‐synthesis	   technology	   uses	   cyclic	   reversible	   termination	  
chemistry	  described	  by	  (Bentley	  et	  al.,	  2008)	  and	   involves	  three	  main	  steps	  namely	   library	  
preparation,	   cluster	   generation	   and	   sequencing.	   The	   length	   of	   short	   sequences	   (reads)	  
generated	  by	  the	  platform	  is	  determined	  by	  the	  number	  of	  cycles.	  	  
In	  library	  preparation,	  a	  sample	  DNA	  is	  fragmented	  using	  nebulization	  or	  sonication	  
followed	  by	  an	  end-­‐repairing	  step	   to	  generate	  blunt-­‐ended	   fragments.	  A	  single	  nucleotide	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Adenine	   (A)	   base	   is	   then	   added	   to	   the	   3’	   end	   of	   both	   DNA	   strands	   to	   produce	   A-­‐tailed	  
fragments	  that	  are	  then	  ligated	  with	  sequencing	  adaptors.	  The	  adaptors	  have	  a	  3’	  Thymine	  
(T)	   overhang	   that	   complements	   the	   A-­‐tails	   of	   template	   fragments.	   Only	   fragments	  
containing	  the	  sequence	  adaptors	  are	  size-­‐selected	  and	  quantified.	  The	  sequencing	  library	  is	  
then	  transferred	  to	  flow	  cells	  that	  contain	  oligonucleotides	  that	  are	  complementary	  to	  the	  
sequencing	  adaptors	  ligated	  at	  the	  end	  of	  the	  templates	  such	  that	  template	  fragments	  bind	  
to	  the	  surface	  where	  both	  cluster	  generation	  and	  sequencing	  take	  place.	  By	  sequencing	  the	  
template	  fragments	  from	  both	  ends,	  paired-­‐end	  reads	  separated	  by	  a	  known	  fragment	  size	  
are	   generated.	   There	   are	   eight	   lanes	   in	   Illumina’s	   flow	   cells	   that	   are	   capable	   of	   taking	  
independent	  samples	  (libraries)	  or	  up	  to	  96	  multiplexed	  libraries.	  
In	   cluster	   generation	   step,	   fragments	   are	   first	   denatured	   into	   single	   stranded	  
templates	  followed	  by	  cycles	  of	  a	  bridge-­‐amplification	  step,	  where	  each	  template	  is	  clonally	  
amplified	   into	   thousands	   of	   templates	   per	   cluster	   and	  millions	   of	   clusters	   per	   lane.	   Each	  
cluster	  corresponds	  to	  a	  single	  template	  molecule.	  
The	   cyclic	   sequencing	   process	   involves	   addition	   of	   four	   fluorescently	   labelled	  
nucleotides	   (dNTPs),	   to	   the	   growing	   chain	   of	   sequenced/synthesized	   bases	   for	   each	  
template	   of	   a	   cluster.	   This	   hybridization	   is	   followed	   by	   measuring	   the	   intensity	   of	   the	  
fluorescent	  dye	  via	  imaging	  techniques	  to	  determine	  the	  exact	  base	  for	  each	  cluster.	  Once	  
done,	  the	  terminators	  containing	  the	  fluorophore	  are	  removed	  to	  allow	  for	  another	  cycle	  of	  
hybridization.	   The	   signal	   from	   each	   template	   in	   a	   cluster	   is	   analysed	   using	   a	   base	   calling	  
software	  called	  Bustard	   in	  order	   to	  establish	   the	  correct	  base	  call	  after	  each	  hybridization	  
cycle.	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1.11 P.	  falciparum	  evolution,	  population	  structure	  and	  LD	  
	  
Studies	   of	   genetic	   variation	   in	   malaria	   parasites	   have	   helped	   to	   understand	   the	  
parasite’s	  adaptive	  mechanisms	  to	  natural	  and	  artificial	  selective	  pressure,	  which	  in	  turn	  has	  
had	   practical	   significance	   in	   advancing	   vaccine	   development	   and	   surveillance	   of	   drug	  
targets.	  Understanding	  genetic	  variation	  in	  P.	  falciparum	  requires	  knowledge	  of	  the	  parasite	  
population	  structure,	  including	  variation	  in	  allele	  frequencies	  between	  populations	  and	  how	  
these	   alleles	   remain	   correlated	   with	   neighbouring	   variants	   by	   LD.	   Principal	   component	  
analysis	   (PCA),	   from	  which	  one	  can	   infer	  sample	   relatedness,	  has	  been	  used	  to	  determine	  
population	  structure.	  	  
The	   extensive	   genetic	   variation	   in	  P.	   falciparum	   has	   also	   been	   used	   to	   deduce	   its	  
evolution	  history	  (Table	  1.3),	  with	  some	  studies	  inferring	  that	  P.	  falciparum	  separated	  from	  
the	   chimpanzee	   parasite,	   P.	   reichenowi,	   5	   to	   7	   million	   years	   ago	   when	   the	   humans	   and	  
chimpanzees	  diverged	  (Su	  et	  al.	  2003).	  However,	  a	  more	  recent	  study	  concluded	  that	  it	  is	  of	  
gorilla	  and	  not	  of	  chimpanzee,	  bonobo	  or	  ancient	  human	  origin	  (Liu	  et	  al.	  2010)	  and	  that	  all	  
known	   human	   strains	  might	   have	   resulted	   from	   a	   single	   cross-­‐species	   transmission	   event	  
which	  could	  have	  also	   resulted	   in	  a	  population	  bottleneck.	  What	   still	   remains	  unknown	   is	  
the	  exact	  time	  when	  the	  gorilla	  P.	  falciparum	  entered	  the	  human	  population	  and	  whether	  
the	  present	  ape	  population	  provided	  a	  source	  of	  recurring	  human	  infection	  (Liu	  et	  al.	  2010).	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Table	  1.3:	   Tracing	  P.	   falciparum	   population	  history	   through	  genetic	   variation.	  Adapted	  
from	  (Hartl	  2004).	  
	  
By	   looking	   at	   genomic	   variation	   and	   structure,	   P.	   falciparum	   parasites	   have	   been	  
genetically	  clustered	  according	  to	  their	  continental	  origins	  with	  major	  branches	  observed	  in	  
Africa,	   Southeast	   Asia,	   Papua	   New	   Guinea	   and	   South	   America	   (Mu	   et	   al.	   2005,	   2010;	  
Volkman	   et	   al.	   2007;	   Manske	   et	   al.	   2012).	   Within	   Africa,	   there	   are	   little	   population	  
differences	   between	   countries	   compared	   to	   Southeast	   Asia	   and	   the	   western	   hemisphere	  
where	   it	   is	   more	   pronounced	   even	   within	   a	   single	   country	   (Conway	   et	   al.	   2001,	   1999;	  
Pumpaibool	  et	  al.	  2009;	  Mu	  et	  al.	  2005;	  Anderson	  et	  al.	  2000;	  Manske	  et	  al.	  2012).	  Extensive	  
genetic	  diversity	  is	  observed	  in	  parasites	  from	  Africa	  and	  lowest	  in	  America	  and	  is	  reflected	  
in	   observed	   patterns	   of	   LD	   that	   is	   also	   inversely	   proportional	   to	   the	   population	  
recombination	   rate.	   Observed	   LD	   extends	   for	   shorter	   physical	   distances	   in	   Africa	  
(approximately	  1.5-­‐kb),	  higher	  in	  Asian	  parasites	  and	  South	  America	  (approximately	  16-­‐kb)	  
(Mu	   et	   al.	   2005;	   Volkman	   et	   al.	   2007).	   The	   difference	   in	   this	   LD	   also	   reflects	   the	  
demographic	  history	  of	  these	  populations.	  For	  example,	  in	  high	  malaria	  transmission	  areas	  
there	  is	  frequent	  occurrence	  of	  ‘super-­‐infection’	  with	  multiple	  genotypes	  produced	  through	  
multiple	  bites	  from	  distinct	  P.	  falciparum-­‐infected	  mosquitoes	  resulting	  in	  a	  high	  multiplicity	  
of	   infection	   (MOI).	   This	   allows	   for	   mixing	   of	   genetically	   distinct	   gametocytes	   (through	  
outcrossing)	  during	  the	  sexual	  phase	  and	  thereby	  producing	  short	  block	  of	  LD.	  By	  contrast,	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in	  low	  malaria	  transmission	  areas,	  identical	  gametocytes	  and	  the	  lack	  of	  recombination	  will	  
preserve	  LD	  (Figure	  1.4)	  (Conway	  et	  al.	  1999;	  Volkman	  et	  al.	  2012).	  High	  LD	  outside	  Africa	  is	  
thought	  to	  be	  as	  a	  result	  of	  population	  bottlenecks	  that	  eliminate	  many	  allele	  combinations	  
leaving	  strong	  correlations	  (and	  high	  LD),	  a	  smaller	  effective	  population	  size	  can	  only	  sustain	  
fewer	  allele	  combinations.	  
MOI	  also	  has	  some	  significance	  in	  malaria	  pathogenesis	  (D’Alessandro	  1997).	  Human	  
malaria	  parasites	  in	  low	  endemic	  areas	  have	  evolved	  a	  lower	  level	  of	  virulence	  (due	  to	  less	  
co-­‐infection),	   than	   those	   in	   high	   endemic	   areas	   (Conway	   et	   al.	   2007).	   Contrary	   to	   this,	  
another	   study	   of	   controlled	   comparisons	   within	   populations	   in	   high	   endemic	   areas	   also	  
showed	   that	   different	   numbers	   of	   genotypes	   in	   multiple	   infections	   are	   not	   generally	  
associated	   with	   different	   clinical	   symptoms	   or	   severity	   of	   malaria	   (Robert	   et	   al.	   1996;	  
Conway	   and	   McBride	   1991;	   Kun	   et	   al.	   1998).	   In	   fact,	   they	   showed	   that	   the	   numbers	   of	  
genotypes	   per	   infection	   were	   similar	   between	   clinical	   groups,	   with	   severe	   cases	   often	  
having	  only	   a	   single	   clone	   (Robert	   et	   al.	   1996).	  Another	   study	  of	   post-­‐mortem	  analysis	   of	  
parasites	  in	  multiple	  organs	  of	  Malawian	  children	  observed	  that	  cerebral	  malaria	  cases	  are	  
less	  genetically	  mixed	  (Montgomery	  et	  al.	  2006).	  
	  
	   	  28	  
	  
Figure	  1.4:	  P.	  falciparum	  population	  genetics	  and	  multiplicity	  of	  infections.	  (A):	  Levels	  of	  
heterozygosity	  (the	  probability	  that	  two	  randomly	  drawn	  alleles	  are	  different	  at	  a	  locus)	  
rare	  in	  South	  America,	  intermediate	  in	  SE	  Asia	  and	  highest	  in	  some	  African	  populations.	  
Heterozygosity	  measures	   levels	   of	   genetic	   diversity,	   which	   correlates	   to	  MOI	   –	   and	   is	  
highest	   in	   Africa	   	   (B)	   Multiplicity	   of	   infections.	   Percentage	   of	   infections	   containing	  
multiple	  clones	  higher	  in	  Africa	  (reaching	  70%	  in	  Congo)	  than	  in	  South	  America	  (<20%	  in	  
Columbia,	  Bolivia	  and	  Brazil)	  and	  South	  East	  Asia	  populations	  (approximately	  40	  to	  50%	  
in	  Thailand	  and	  Papua	  New	  Guinea).	  (C-­‐D)	  Dynamics	  of	  population	  genetics	  between	  low	  
malaria	   transmission,	   C	   and	   high	   transmission	   settings,	   D.	   Low	   transmission	   areas	   are	  
characterised	  by	  small	  effective	  population	  size,	  low	  biting	  rates,	  few	  multiple	  infections,	  
inbreeding,	   low	   recombination	   and	   detectable	   structured	   populations	   the	   opposite	   is	  
true	  for	  high	  transmission	  area.	  Adapted	  from	  (Anderson	  et	  al.	  2004).	  
	  
	  
	   	  29	  
1.12 Signatures	  of	  selection	  in	  P.	  falciparum	  genome	  
	  
P.	  falciparum	  has	  two	  distinctive	  hosts,	  human	  and	  mosquito.	  The	  major	  sources	  of	  
selection	   acting	   on	   the	   parasite	   in	   its	   hosts	   are	   immunity,	   drugs,	   vector	   availability,	   host	  
death	  and	  co-­‐infection	  (Mackinnon	  and	  Marsh	  2010).	  These	  selective	  forces	  have	  an	  impact	  
on	   the	   parasite’s	   transmissibility	   and	   so	   it	   must	   adapt	   amidst	   this	   highly	   heterogeneous	  
environment	  in	  order	  to	  survive.	  In	  the	  human	  host,	  the	  parasite	  is	  subject	  to	  the	  strongest	  
selection	   from	   immune	   responses	   and	   drugs	   and	   it	   undergoes	   severe	   population	  
bottlenecks.	  The	  two	  most	  widely	  studied	  classes	  of	  selection	  in	  P.	  falciparum	  are	  balancing	  
and	  directional	  selection	  which	  are	  discussed	  below.	  
1.12.1 Balancing	  selection	  and	  identification	  of	  vaccine	  targets	  in	  P.	  falciparum	  
genome	  
	  
A	   major	   factor	   in	   the	   evolution	   of	   malaria	   parasites	   is	   to	   evade	   host	   immune	  
responses.	   Parasite	   antigens	   recognised	   by	   the	   host	   immune	   system	   will	   usually	   evolve	  
under	   frequency	   dependent	   immune	   selection	   (where	   rare	   alleles	   are	   favoured	   simply	  
because	   they	   are	   of	   low	   frequency),	   exhibiting	   extensive	   genetic	   polymorphism	   coupled	  
with	   a	   bias	   for	   non-­‐synonymous	   mutations	   that	   is	   maintained	   by	   balancing/diversifying	  
selection.	   In	   an	   infection,	   host	   variant-­‐specific	   antibodies	   raised	   against	   an	   antigen	   will	  
afford	  a	  new	  variant	  a	  competitive	  advantage	  which	  in	  turn	  will	  rise	  in	  frequency	  enough	  to	  
induce	   production	   of	   specific	   antibodies	   against	   itself	   and	   thus	   causing	   diversifying	  
selection.	  This	  strategy	  therefore	  offers	  the	  parasite	  the	  potential	  to	  encode	  immunological	  
identities	   that	   are	   kept	   at	   intermediate	   frequencies.	   The	   distinctive	   patterns	   of	   genetic	  
polymorphism	   arising	   from	   immune	   selection	   should	   depart	   from	   those	   predicted	   under	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neutral	  evolution	  models	  and	  can	  be	  tested	  using	  population	  genetic	  methods	  that	  test	  for	  
signatures	  of	  balancing	  selection.	  	   	  
1.12.2 Testing	  for	  balancing	  selection	  using	  Tajima’s	  D	  test	  
	  
Developed	  by	  and	  named	  after	  a	  Japanese	  researcher	  Fumio	  Tajima,	  Tajima’s	  D	  is	  a	  
widely	  used	   test	  of	  neutrality	   (Tajima	  1989).	   It	   tests	   the	  hypothesis	   that	  all	  mutations	  are	  
selectively	  neutral	  and	  of	  no	   importance.	  The	  purpose	  of	   this	   test	   is	   to	   therefore	   look	   for	  
departures	   from	   this	   neutral	   model	   to	   distinguish	   between	   a	   DNA	   sequence	   evolving	  
randomly	  (“neutrally”)	  and	  one	  evolving	  under	  non-­‐random	  process	  including	  balancing	  and	  
directional	   selection,	   population	   expansion	   and	   sub-­‐division	   and	   genetic	   hitch-­‐hiking.	  
Tajima’s	  D	  test	  is	  based	  on	  the	  differences	  between	  the	  number	  of	  segregating	  sites	  (S)	  and	  
the	   average	  number	  of	   pairwise	  nucleotide	  differences	   (π).	  Under	  neutral/null	   hypothesis	  
model,	  expectations	  of	  S	  and	  π	  are,	  	  
	   	   	   	  
Where	  θ	  =	  2Nµ,	  2N	  is	  the	  haploid	  population	  size	  and	  µ	  is	  the	  mutation	  rate	  per	  generation	  
and	  a1	  defined	  as,	  
	   	   	   	  
Under	  the	  neutral	  model	  of	  DNA	  sequence	  evolution	  the	  number	  of	  segregating	  sites	  
(S)	   and	   pairwise	   differences	   (π)	   equals	   to	  θ	   (S/a1	   =	  θ	   and	  π	   =	  θ)	   so	   they	   are	   statistically	  
indistinguishable	   from	   one	   another.	   If	   they	   are	   not	   then	   they	   deviate	   from	   the	   neutral	  
	   	  31	  
model	  and	   their	  difference	   is	   the	  basis	  of	  Tajima’s	  D	   test.	  However,	  S/a1	   and	  π	  vary	   from	  
sample	  to	  sample	  and	  this	  variance	  is	  accounted	  for	  in	  the	  equation	  below:	  
	   	   	   	  
Where	   V	   denotes	   the	   sampling	   variance	   of	   the	   difference	   between	   the	   two	   estimates.	  
Tajima’s	  D	  is	  then	  calculated	  as:	  
	   	   	   	  
Tajima’s	  D	  is	  therefore	  based	  on	  the	  difference	  between	  S/a1	  and	  π.	  High	  sequence	  diversity	  
and	   excess	   polymorphism/rare	   alleles	   selected	   for	   and	   maintained	   at	   intermediate	  
frequency	  increases	  π	  above	  the	  neutral	  expectation,	  more	  than	  S,	  so	  D	  is	  positive	  (π	  -­‐	  S/a1)	  	  
>	  0	  (Figure	  1.5A)	  and	  this	  suggests	  balancing	  selection.	  However,	  population	  admixture	  can	  
also	  lead	  to	  positive	  D.	  Low	  sequence	  diversity	  and	  excess/high	  frequency	  of	  rare	  alleles	  for	  
example	  after	  a	  selective	  sweep	  or	  selection	  against	  genotypes	  carrying	  deleterious	  variants	  
reduces	  π,	   so	  D	   <	   0	   (Figure	   1.5C).	  Otherwise,	   under	   neutrality,	  D	   =	   0	   (Figure	   1.5B).	   Thus,	  
under	   positive	   diversifying	   selection,	   an	   excess	   of	   intermediate	   frequency	   polymorphisms	  
and	  lower	  number	  of	  singletons	  make	  the	  value	  of	  Tajima’s	  D	  positive,	  with	  values	  greater	  
than	   +2	   or	   less	   than	   -­‐2	   likely	   to	   be	   significant.	   However,	   this	   is	   never	   a	   critical	   value	   of	  
significance	  and	  as	  such	  D	  values	  that	  greatly	  deviate	  from	  the	  bulk	  of	  empirical	  distribution	  
are	  thought	  to	  be	  interesting.	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Figure	   1.5:	   Principle	   of	   balancing	   selection	   and	   Tajima’s	  D.	   Horizontal	   lines	   represent	  
segregating	   sites	   (sequences)	   and	   dots	   represent	   nucleotides	   variants.	   (A)	   High	   allelic	  
diversity,	   π	   >S:	   D	   >0.	   (B)	   Neutral	   genetic	   drift,	   D=0.	   (C)	   Low	   allelic	   diversity,	   new	  
polymorphisms	  rare,	  and	  π	  <S:	  D	  <0.	  Adapted	  from	  (Weedall	  et	  al.	  2010).	  
	  
1.12.3 Testing	  for	  balancing	  selection	  and	  population	  differentiation	  using	  FST	  	  
	  
Wright’s	  F-­‐statistics,	  especially	  FST,	  is	  a	  measure	  of	  population	  differentiation	  due	  to	  
the	   structure	   of	   genetic	   variation	   within	   and	   between	   populations.	   Estimates	   of	   FST	   can	  
identify	   genomic	   regions	   that	   are	   target	   of	   selection,	   and	   comparing	   FST	   from	   different	  
genomic	  regions	  can	  infer	  demographic	  history	  of	  those	  populations.	  It	  is	  directly	  related	  to	  
the	   variance	   in	   allele	   frequencies	   among	   populations	   and	   conversely	   to	   the	   resemblance	  
among	  individuals	  within	  populations.	  FST	  is	  calculated	  as:	  
	   	   	   FST	  =	  1-­‐(HS/HT)	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Where,	   HT	   =	   total	   gene	   diversity	   or	   expected	   heterozygosity	   in	   the	   total	   population	   as	  
estimated	   from	   the	   pooled	   allele	   frequencies	   and	   HS	   =	   average	   expected	   heterozygosity	  
estimated	  from	  each	  sub-­‐population	  
If	  FST	  is	  small	  (0	  –	  0.05),	  it	  means	  allele	  frequencies	  within	  each	  population	  are	  very	  
similar/maintained	   against	   the	   tendency	   for	   neutral	   drift	   to	   decay,	   little	   genetic	  
differentiation;	   if	   it	   is	   very	   large	   (>	   0.25),	   the	   allele	   frequencies	   are	   very	   different;	   FST	   is	  
moderate	  (0.05	  –	  0.15);	  FST	  is	  large	  (0.15	  –	  0.25).	  Very	  large	  FST	  indicate	  positive	  directional	  
selection	   rapidly	   fixing	   an	   advantageous	   allele	   in	   a	   population	   thus	   showing	   low	  diversity	  
and	   high	   divergence	   (Figure	   1.6B	   and	   1.7).	   Very	   low	   FST	   potentially	   indicate	   loci	   evolving	  
under	  balancing	  selection	  showing	  elevated	  diversity	  with	  low	  divergence	  (Figure	  1.6C	  and	  
1.7).	   The	   genes	   under	   balancing	   selection	   are	   unlikely	   to	   diverge	   as	   rapidly	   as	   others	  
because	  the	  selection	  prevents	  differences	  from	  differentially	  fixing	  between	  populations.	  
1.12.4 Other	  tests	  of	  balancing	  selection	  
	  
Other	   tests	   of	   balancing	   selection	   include	   Fu	   and	   Li’s	  F	   and	  D	   (Fu	   and	   Li	   1993;	   Fu	  
1997),	  which	  is	  quite	  similar	  to	  Tajima’s	  D,	  McDonald	  and	  Kreitman’s	  (MK)	  test	  (McDonald	  
and	  Kreitman	  1991),	  Hudson,	  Kreitman	  and	  Aguade’s	  (HKA)	  test	  (Hudson	  et	  al.	  1987),	  dN/dS	  
and	   πN/πS	   (Nei	   and	   Gojobori	   1986).	   dN/dS	   and	   πN/πS	   compare	   non-­‐synonymous	   (NS)	  
nucleotide	   differences	   per	   NS	   site	   (dN,	   πN)	   to	   their	   synonymous	   equivalents	   (dS,	   πS)	  
between	   species	   (d)	   or	  within	   species	   (π)	   (Weedall	   and	   Conway	   2010).	   Because	  most	   NS	  
mutations	  are	  deleterious	  dN/dS	  <	  1.	  However,	  if	  NS	  mutation	  is	  advantageous	  (e.g.,	  in	  the	  
case	   of	   an	   anti-­‐drug	   allele)	   it	   rapidly	   becomes	   fixed	   in	   the	   population	   than	   neutral	   ones,	  
then	   dN/dS	   >	   1.	   Within	   a	   species,	   high	   recombination	   rates	   will	   make	   sites	   evolve	  
independently	   of	   one	   another.	   In	   the	   case	   of	   immune	   selection,	   balancing	   selection	   will	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maintain	  NS	  mutations	  for	  longer	  than	  synonymous	  (S)	  leading	  to	  excess	  of	  πN	  compared	  to	  
πS.	  MK	   test	   compares	   ratios	   of	   NS	   to	   S	   changes	   within	   and	   between	   species	   over	   long	  
periods	   (Weedall	   and	   Conway	   2010).	   HKA	   tests	   compares	   ratio	   of	   polymorphism	   to	  
divergence	  for	  different	  loci	  to	  detect	  those	  with	  abnormal	  ratios.	  	  
From	   analyses	   of	   Tajima’s	   D	   and	   FST,	   antigens	   and	   vaccine	   candidates	   have	   been	  
identified	   including	   AMA1	   (Polley	   and	   Conway	   2001;	  Mu	   et	   al.	   2007),	   MSP3.8	   and	   TRAP	  
(Amambua-­‐Ngwa	  et	  al.	  2012a).	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Figure	   1.6:	   Signatures	   of	   selection.	   Large	   grey	   circles	   represent	   a	   given	   population,	  
square	   matrix	   of	   circles	   represents	   individuals	   and	   red	   or	   yellow	   circles,	   alleles.	   (A)	  
Diversity	   refers	   to	   amount	   of	   allelic	   variation	   among	   individuals	   in	   a	   given	   population	  
and	   divergence	   refers	   to	   amount	   of	   variation	   between	   populations.	   (B)	   Positive	  
directional	   selection:	   low	   allelic	   diversity	   and	   high	   divergence.	   (C)	   Balancing	   selection:	  




Figure	   1.7:	   Schematic	   representation	   of	   FST	   in	   two	   populations.	   Dots	   represent	  
nucleotide	   variants.	   Allele	   frequencies	   in	   the	   central	   region	   are	   maintained	   in	   both	  
populations	   by	   balancing	   selection,	   resulting	   in	   very	   low	   FST.	   Detectable	   between	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1.13 	  Positive	  directional	  selection	  and	  drug	  resistance	  in	  P.	  falciparum	  
	  
In	  P.	   falciparum	   populations,	   introduction	   of	   a	   successful	   drug	   usually	   results	   in	   a	  
strong	   positive	   directional	   selection	   on	   the	   parasite	   population.	   To	   overcome	   the	   drug	  
pressure,	   the	   parasite	   undergoes	   evolution	   resulting	   into	   emergence	   of	   drug	   resistant	  
alleles.	  An	  advantageous	  allele	  will	  spread	  rapidly	  (increase	  in	  frequency)	  in	  the	  population	  
and	  become	  fixed.	  As	   this	  happens	  neighbouring	  alleles	  also	  hitchhike	   to	  high	   frequencies	  
and	   spread	   through	   the	   parasite	   population	   and	   remain	   in	   LD	   with	   the	   resistance	   allele,	  
eventually	  leading	  to	  valleys	  of	  reduced	  allelic	  variation	  (selective	  sweeps)	  with	  increased	  LD	  
in	   the	   regions	   surrounding	   the	   resistance	   loci	   (Figure	   1.8).	   After	   drug	   selection,	  
recombination	  and	  mutation	  gradually	  restore	  variation	  and	  break	  down	  LD.	  	  
	  
Figure	   1.8:	   Drug	   selection	   effect.	   Results	   in	   directional	   selection	   leaving	   a	   distinctive	  
selective	  sweep,	  consisting	  of	   reduced	  polymorphism	  and	  enhanced	  LD.	  Adapted	   from	  
(Volkman	  et	  al.	  2012).	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Patterns	   of	   genetic	   variation	   around	   drug	   resistant	   loci	   have	   been	   revealed	   by	  
assessing	   LD,	   and	   tests	  of	  positive	   selection	   such	  as	   FST	   and	   	   ‘haplotype-­‐based’	   tests,	   e.g.,	  
integrated	   haplotype	   test	   (iHS),	   long-­‐range	   haplotype	   test	   (LRH)	   and	   cross	   population	  
extended	   haplotype	   homozygosity	   test	   (XP-­‐EHH)	   (Sabeti	   et	   al.	   2002,	   2007;	   Voight	   et	   al.	  
2006).	  There	  is	  generally	  short	  LD	  in	  P.	  falciparum	  due	  to	  high	  recombination	  rates	  (Jiang	  et	  
al.	  2011).	  But	  in	  response	  to	  drug	  pressure	  long	  haplotypes	  with	  extended	  LD	  arise	  around	  
the	  advantageous	  variant	  (Figure	  1.8	  and	  1.9).	  	  
Genome	   scans	   for	   selective	   sweeps	   have	   been	   performed	   by	   several	   studies	   and	  
have	   identified	   both	   known	   and	   unknown	   drug	   targets;	   some	   of	   the	   most	   notable	   and	  
referenced	   studies	   are	   discussed	   below.	   Wotton	   et	   al	   analysed	   342	   polymorphic	  
microsatellite	  markers	   from	  87	  parasites	   from	  South	  America,	   South	   East	  Asia,	  Africa	   and	  
Papua	   New	   Guinea	   and	   observed	   that	   mutations	   in	   pfcrt	   evolved	   on	   four	   independent	  
occasions	  (2	  origins	  in	  S.	  America,	  single	  origin	  in	  Asia	  that	  spread	  to	  Africa	  and	  one	  in	  Papua	  
New	  Guinea)	   and	   that	   these	  mutations	   spread	  across	   the	   globe	   through	   selective	   sweeps	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Figure	   1.9:	   Effect	   of	   positive	   selection	   on	   haplotype	   structure	   visualized	   using	   a	  
haplotype	  bifurcation	  diagram.	  During	  a	  drug	  selection	   (causing	  A	  to	  T	  SNP	  shift)	   long-­‐
range	   haplotypes	   would	   arise	   similar	   to	   B	   and	   stand	   out	   from	   the	   normal	   haplotype	  
structure	  of	  the	  genomic	  background,	  A.	  Adapted	  from	  (Volkman	  et	  al.	  2007).	  
	  
	  
Figure	   1.10:	   Drug	   selection	   effect.	   Reduced	   allelic/microsatellite	   diversity	   around;	   (A)	  
pfcrt	  in	  CQR	  isolates	  (Black	  line,	  Asia	  and	  Africa;	  green	  line,	  South	  America)	  compared	  to	  
CQS	   isolates	   from	  Asia	  and	  Africa	   (red	   line)	  and	   (B)	  100-­‐kb	  around	  the	  pfdhfr	   locus	  on	  
chromosome	  4	  of	  P.	  falciparum	   isolates	  from	  Thailand-­‐Myanmar	  border.	  Adapted	  from	  
(Wootton	  et	  al.	  2002;	  Nair	  et	  al.	  2003).	  
	  
By	  comparing	  genetic	  variation	  in	  CQR	  and	  CQ	  sensitive	  (CQS)	  parasites	  from	  these	  
locations,	   he	   observed	   a	   dramatic	   reduction	   in	   genetic	   diversity	   and	   extensive	   LD	   around	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pfcrt	   in	  CQR	  parasites	   (Figure	  1.10A)	   (Wootton	  et	  al.	  2002).	  The	   following	  year,	  Nair	  et	  al,	  
also	  used	  the	  same	  principle	  to	  examine	  MS	  variation	  across	  chromosome	  4	  while	  trying	  to	  
study	   the	   impact	   of	   PYR	   resistance	   around	   the	  pfdhfr	  gene.	   They	   discovered	   reduced	  MS	  
length	   variation	   in	   a	   12-­‐kb	   region	   flanking	   the	   pfdhfr	   and	   diminished	   variation	   for	  
approximately	   100-­‐kb	   around	   the	   same	   gene	   (Figure	   1.10B)	   (Nair	   et	   al.	   2003).	   More	  
recently,	  genome-­‐wide	  scans	  of	  selective	  sweeps	  across	  P.	  falciparum	  genomes	  have	  been	  
performed	  to	  describe	  regions	  under	  positive	  directional	  selection.	  These	  studies	  have	  been	  
successful	  in	  validating	  previously	  identified	  anti-­‐drug	  loci	  and	  in	  detecting	  novel	  loci.	  	  Mu	  et	  
al	  used	   the	  molecular	   invasion	  probe	  array	  and	   tests	   for	   selective	   sweeps	   (REHH,	   iHS	   and	  
XP-­‐EHH)	  to	  generate	  genome-­‐wide	  maps	  of	  selection	  from	  parasite	  populations	  from	  Asia,	  
Africa	  and	  America	  and	  identified	  multiple	  loci	  under	  significant	  positive	  selection	  including	  
pfcrt,	   pfama1,	   pfmdr1,	   surfin	   (Mu	  et	   al.	   2010).	   Additional	   studies	   using	   similar	   tests	   have	  
concurring	  results	  (Van	  Tyne	  et	  al.	  2011;	  Amambua-­‐Ngwa	  et	  al.	  2012b;	  Park	  et	  al.	  2012).	  
1.13.1 Identifying	  positive	  selection	  using	  EHH,	  iHS	  and	  XP-­‐EHH	  	  	  
	  
Metrics	   that	   are	   used	   to	   identify	   selective	   sweeps	   probe	   for	   regions	  with	   reduced	  
haplotype	  diversity.	  The	  Extended	  haplotype	  homozygosity	   test	   (EHH)	  measures	   reduction	  
in	  haplotype	  diversity	  by	  computing	  the	  probability	  as	  a	  function	  of	  distance	  from	  the	  core	  
region	   that	   two	   randomly	   chosen	   chromosomes	   that	   share	   the	   core	   allele	   are	   identical	  
(Sabeti	  et	  al.	  2002).	   It	  heavily	  relies	  on	  the	  relationship	  between	  an	  allele’s	   frequency	  and	  
the	  extent	  of	  LD	  surrounding	  it,	  such	  that	  under	  neutral	  evolution	  a	  new	  variant	  will	  require	  
a	   longer	  time	  to	  reach	  high	  frequency	  and	  recombination	  will	  substantially	  break	  down	  LD	  
around	  it.	  Under	  positive	  selection,	  the	  new	  variant	  will	  rapidly	  reach	  high	  frequencies	  over	  
a	  short	  time	  that	  recombination	  does	  not	  substantially	  break	  down	   long-­‐range	  association	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or	  LD	  with	  other	  SNPs.	  Because	  of	  this,	  EHH	  needs	  to	  control	  for	  local	  recombination	  rates.	  
This	   is	   usually	   achieved	   by	   genotyping	   dense	   SNPs	   and	   collecting	   samples	   from	   same	  
locality.	   EHH	   will	   therefore	   involve	   finding	   a	   core	   haplotype	   with	   a	   combination	   of	   high	  
frequency	  and	  high	  EHH	  score	  compared	  to	  the	  core	  haplotypes	  at	  the	  same	  locus	  (Sabeti	  et	  
al.	  2002).	  
For	  bi-­‐allelic	  SNP	  with	  alleles	  a	  (ancestral)	  and	  A	  (derived),	  the	  EHH	  is	  computed	  as	  follows:	  
	   	   	   	  
Where	  na	  and	  nA	  are	  number	  of	  haplotypes	  with	  alleles	  a	  and	  A	  respectively,	  ni	  is	  the	  count	  
of	  the	  ith	  haplotype	  in	  a	  population	  and	  hx	  is	  the	  number	  of	  distinct	  haplotypes	  in	  a	  genomic	  
region	  up	  to	  a	  distance	  x	  from	  the	  locus.	  	  
Integrated	   haplotype	   score	   (iHS)	   compares	   log	   of	   the	   ratio	   of	   the	   integrated	   EHH	  
score	   (profiles)	   for	   haplotypes	   containing	   the	   ancestral	   allele	   to	   the	   integrated	   EHH	   for	  
haplotypes	   containing	   the	   derived	   allele.	   Under	   neutral	   decay,	   rates	   of	  EHH	   for	   ancestral	  
allele	  and	  derived	  allele,	  EHHa/EHHA	  ≈	  1	  and	   iHS	  ≈	  0.	  High	  values	  of	   iHS	   indicate	  a	  reduced	  
and	   extended	  haplotype	   diversity	  with	   a	   slower	   fall-­‐off	  EHH	   around	   selected	   allele.	   Large	  
negative	   iHS	   values	   indicate	  unusually	   long	  haplotypes	   containing	   the	  derived	  allele	  while	  
large	  positive	  values	  indicate	  long	  haplotypes	  containing	  ancestral	  allele	  (for	  example	  when	  
selection	  favours	  ancestral	  allele/s	  or	  if	  they	  hitchhike	  within	  the	  ‘sweep’	  region).	  Identifying	  
regions	   that	   contain	   clusters	   of	   high	   scoring	   SNPs	   gives	   a	   better	   indicator	   of	   a	   selective	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sweep	  because	  selective	  sweeps	  produce	  clusters	  of	  extreme	  scores	  across	  the	  swept	  region	  
(Voight	  et	  al.	  2006).	  
Unstandardized	  iHS	  =	  ln(EHHa/EHHA)	  
The	  iHS	  is	  a	  local	  measure	  of	  selection	  and	  therefore	  both	  the	  ancestral	  and	  derived	  
allele	   will	   share	   same	   genomic	   environment,	   thus	   making	   it	   insensitive	   to	   variations	   in	  
population	  demography	  such	  as	  recombination	  rates,	  demographic	  history	  and	  bottlenecks.	  
It’s	  also	  very	  reliable	  when	  one	  cannot	  find	  a	  good	  reference,	  but	  has	  low	  power	  to	  detect	  
alleles	   that	   are	   fixed	   or	   close	   to	   fixation.	   However,	   XP-­‐EHH	   (Sabeti	   et	   al.	   2007),	   which	  
compares	  EHH	   profiles	   between	   two	  populations	   at	   the	   same	   SNP,	   is	   insensitive	   to	   allele	  
frequencies,	   more	   reliable	   when	   a	   reference	   population	   with	   similar	   demographics	   is	  
available	   and	  has	  high	  power	   to	  detect	   alleles	   that	   are	   fixed	   in	  one	  of	   the	  populations	   in	  
comparison.	   Computing	   XP-­‐EHH	   requires	   computation	   of	   EHH	   in	   each	   population	   and	   is	  
defined	  as	  follows:	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1.14 Rationale	  and	  objectives	  
	  
Malaria	  is	  a	  major	  cause	  of	  morbidity	  and	  mortality	  in	  Malawi,	  mostly	  in	  children	  under	  
five	  of	  age	  who	  are	  particularly	  at	  risk	  of	  developing	  severe	  disease.	  Genetic	  variation	  in	  P.	  
falciparum,	   is	   key	   to	   its	   pathogenesis,	   as	   it	   allows	   the	   parasite	   to	   evolve	   rapidly	   and	  
overcome	  host	   immune	   systems,	   drugs	   and	   vaccines,	   all	   of	  which	   generally	   aim	   to	   curtail	  
infections	  and	  reduce	  the	  parasite’s	  transmission	  potential	  (Volkman	  et	  al.	  2007;	  Kidgell	  et	  
al.	  2006;	  Mackinnon	  and	  Marsh	  2010).	  	  Therefore,	  understanding	  and	  characterizing	  genetic	  
variation	  will	  help	  explore	  the	  complex	  nature	  of	  host-­‐parasite	  interaction,	  co-­‐evolution	  and	  
the	  parasite	  response	  to	  malaria	  interventions.	  Since	  the	  first	  full	  genome	  sequence	  in	  2002,	  
rapid	   developments	   in	   genomics	   and	   genetics	   have	   accelerated	   studies	   of	   P.	   falciparum	  
genetic	  diversity	  and	  several	  genotyping	  platforms	  have	  demonstrated	  a	  rich	  diversity	  from	  
SNP	  discovery,	  identifying	  loci	  potentially	  under	  immune	  and	  drug	  selection	  (Gardner	  et	  al.	  
2002;	  Kidgell	  et	  al.	  2006;	  Mu	  et	  al.	  2007,	  2010;	  Volkman	  et	  al.	  2007).	  It	  has	  been	  observed	  
that	  positive	  natural	  selection	  at	  drug-­‐resistant	  loci	  (pfdhps,	  pfcrt)	  causes	  reduction	  in	  allelic	  
diversity	   while	   diversifying	   selection	   produces	   highly	   polymorphic	   regions	   at	   candidate	  
vaccine	  targets	  such	  as	  ama1,	  msp1,	  msp2,	  csp	  and	  eba175	  (Nair	  et	  al.	  2003;	  Wootton	  et	  al.	  
2002;	   Polley	   et	   al.	   2003;	   Baum	   et	   al.	   2003;	   Ferreira	   et	   al.	   2003).	   Immune	   evasion	   and	  
emergence	  of	  drug	  resistant	  genotypes	  are	  largely	  driven	  by	  acquisition	  of	  genetic	  changes	  
in	  the	  parasite	  genome.	  	  
This	   thesis	   describes	   a	   study	   designed	   to	   observe	   P.	   falciparum	   genetic	   population	  
changes	  and	  identification	  of	  CNV,	  with	  the	  following	  features:	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1 Children	   aged	   between	   6-­‐48	   months	   were	   recruited	   at	   one	   site,	   Chikwawa	   (a	   high	  
transmission	  area),	  at	  a	  time	  when	  maternal	  immunity	  to	  malaria	  is	  waning	  or	  finished,	  
and	  at	  0-­‐2	  months	  in	  another	  site,	  Zomba	  (a	  relatively	  low	  malaria	  transmission	  but	  with	  
neighbouring	   high	   transmission	   areas)	   when	   the	   children	   were	   still	   under	   maternal	  
protection.	   Therefore,	   the	   age	   range	   would	   cover	   a	   fairly	   large	   variation	   in	   immune	  
response	   with	   some	   children	   near	   immunological	   naivety	   to	   malaria	   and	   could	  
potentially	  be	   infected	  with	  malaria	  parasites	  of	  any	  genetic	  background.	  However,	  for	  
this	   thesis,	   no	  Zomba	   samples	  were	   included,	   as	   they	  had	  not	  been	   sequenced	  at	   the	  
time	  of	  analysis.	  
2 The	  longitudinal	  nature	  of	  the	  study	  allowed	  us	  to	  investigate	  multiple	  malaria	  episodes	  
in	  these	  children.	  As	  they	  develop	  resistance	  to	  particular	  genetic	  types,	  we	  hypothesise	  
that	  each	  malaria	  episode	  will	  consist	  of	  parasites	  of	  different	  genetic	  backgrounds.	  
3 Recent	   rollout	   of	   LA,	   bed-­‐net	   and	   IRS	   schemes	   will	   put	   pressure	   on	   the	   parasite	  
population,	   potentially	   causing	  population	  bottlenecks.	   	   Parasites	   of	   particular	   genetic	  
backgrounds	  will	   only	   survive	   these	  pressures	   through	  advantageous	  phenotypic	   traits	  
or	  through	  favourable	  circumstances.	  	  
	  
In	  this	  study,	  we	  aimed	  to	  use	  MPS,	  leveraging	  Illumina	  short	  read	  technology:	  	  
1. To	   sequence	   uncultured	   P.	   falciparum	   paediatric	   isolates	   obtained	   from	   a	   3-­‐year	  
longitudinal	   study	   of	   a	   Malawian	   population	   after	   a	   selective	   sweep	   with	   SP	   and	  
continuous	  selective	  pressure	  from	  intensive	  use	  of	  LA,	  ITNs	  and	  IRS;	  
2. To	   identify	   genetic	   variants	   including	   SNPs,	   and	   large	   structural	   variants	   (e.g.,	   CNV,	  
INDELs)	  and	  provide	  a	  map	  of	  genomic	  variation;	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3. To	  use	  the	  SNP	  variation,	  to	  identify	  regions	  under	  selection	  pressure	  specific	  to	  this	  P.	  
falciparum	  population;	  
4. To	   compare	  Malawi	   genetic	   variation	   to	   other	   populations	   of	   disperse	   origins	   (Kenya,	  
Burkina	  Faso,	  Mali,	  Thailand	  and	  Cambodia);	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Chapter	  2	  
Whole-­‐genome	  scans	  for	  selection	  and	  changing	  
antimalarial	  drug	  pressure	  in	  Malawi	  Plasmodium	  
falciparum	  clinical	  isolates	  
	  
2.1 	  	  	  Introduction	  
	  
An	  estimated	  3.3	  billion	  people	  are	  at	  risk	  of	  malaria	  with	  sub-­‐Sahara	  Africa	  having	  the	  
majority	  of	  cases	  (81%)	  and	  deaths	  (91%),	  mostly	  in	  children	  less	  than	  five	  years	  of	  age	  and	  
pregnant	  women	  (WHO.	  World	  Malaria	  Report	  2012).	  Malawi	  grapples	  with	  a	  heavy	  burden	  
of	   endemic	   falciparum	   malaria	   with	   year	   round	   transmission	   that	   peaks	   during	   the	   long	  
rainy	   season	   from	  early	  December	   to	  May	   (Ewing	  et	   al.	   2011).	   Since	  2005,	   use	  of	   ITNs	   in	  
Malawian	  households	  has	  reached	  ~60%	  saturation,	  and	  the	  government's	  campaign	  for	  IRS	  
has	   targeted	   transmission	   hotspots.	   ACT	   were	   adopted	   as	   first	   line	   treatment	   for	  
uncomplicated	  malaria	  in	  2007,	  replacing	  SP	  (WHO.	  World	  Malaria	  Report	  2012;	  Roca-­‐feltrer	  
et	  al.	  2012).	  Despite	  the	  scaling	  up	  of	  interventions,	  malaria	  still	  accounts	  for	  up	  to	  30	  -­‐	  40%	  
of	   all	   outpatient	   visits,	   and	   childhood	   cases	   between	   2001	   and	   2010	   (Roca-­‐Feltrer	   2012)	  
have	  not	  declined.	  This	  chapter	  assesses	  evolutionary	  driven	  genetic	  changes	  in	  the	  local	  P.	  
falciparum	   population	   that	  may	  both	   reflect	   and	  affect	  malaria	   control	   interventions,	   and	  
provide	   a	   baseline	   genetic	   characterisation	   of	   variation	   and	   selection	   to	   inform	   further	  
surveys	  of	  anti-­‐malarial	  resistance	  and	  population	  structure.	  
Genetic	  variation	  in	  P.	  falciparum	  is	  central	  to	  its	  survival	  and	  threatens	  to	  undermine	  
malaria	   control	   interventions.	   This	   evolutionary	   process	   enables	   parasite	   populations	   to	  
rapidly	   overcome	   host	   immune	   responses	   and	   antimalarial	   drugs	   to	   establish	   persistent	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infections	   and	   increase	   transmission	   (Volkman	  et	   al.	   2007;	   Kidgell	   et	   al.	   2006;	  Mackinnon	  
and	   Marsh	   2010).	   Surveying	   evolutionarily	   driven	   genetic	   changes	   in	   P.	   falciparum	   and	  
investigating	  parasite	  responses	  to	  antimalarial	  interventions	  are	  therefore	  crucial	  to	  efforts	  
to	  reduce	  the	  malaria	  burden.	  Since	  the	  first	  P.	  falciparum	  genome	  sequence	  was	  completed	  
in	  2002,	  rapid	  advances	  in	  genomics	  and	  genetics	  have	  accelerated	  studies	  of	  P.	  falciparum	  
genetic	   diversity.	   Several	   genotyping	   platforms	   have	   discovered	   a	   rich	   diversity	   of	   SNPs,	  
which	  have	  helped	  to	  identify	   loci	  potentially	  under	  drug	  or	   immune	  selection	  (Gardner	  et	  
al.	   2002;	   Kidgell	   et	   al.	   2006;	  Mu	   et	   al.	   2010,	   2007;	   Volkman	   et	   al.	   2007).	  While	   positive	  
natural	   selection	   at	   drug-­‐resistance	   loci	   (e.g.,	   pfdhfr	   and	   pfcrt)	   reduces	   allelic	   diversity,	  
diversifying	   selection	   produces	   highly-­‐polymorphic	   regions	   in	   genes	   encoding	   targets	   of	  
naturally-­‐acquired	   immunity	   and	   thus	   of	   candidate	   vaccine	   antigens	   (e.g.,	   ama1,	  msp1,	  
msp2,	  csp	  and	  eba175)	  (Nair	  et	  al.	  2003;	  Wootton	  et	  al.	  2002;	  Polley	  et	  al.	  2003;	  Baum	  et	  al.	  
2003;	  Ferreira	  et	  al.	  2003).	  	  
Here	  I	  have	  used	  massive	  parallel	  sequencing	  (MPS,	  Illumina	  short	  read)	  technology	  to	  
identify	  >100,000	  SNPs	  in	  an	  initial	  set	  of	  93	  sequenced	  clinical	  P.	  falciparum	   isolates	  from	  
Malawi.	  These	  parasites	  were	  obtained	  directly	  from	  children	  in	  a	  3-­‐year	  longitudinal	  study	  
of	   a	   Malawian	   P.	   falciparum	   rural	   population	   in	   the	   Chikwawa	   district,	   one	   of	   twelve	  
sentinel	   sites	   in	   the	   country	   chosen	   for	   intensive	   antimalarial	   intervention.	   Samples	  were	  
collected	  between	  December	  2010	  and	  July	  2011	  and	  patients	  were	  young	  (average	  age	  11	  
months),	  with	  moderate	  parasitemia	  (1,000	  -­‐	  10,000	  parasites/µL)	  and	  only	  slightly	  anaemic	  
with	   an	   average	   haemoglobin	   concentration	   of	   9	   g/dl.	   	   All	   samples	   except	   two	   were	  
uncomplicated	  malaria	  cases.	  In	  analysing	  SNP	  variation,	  this	  sought	  to	  identify	  signatures	  of	  
selection	   for	  potential	   targets	  of	  antimalarial	  drugs,	  host	   immune	  responses	  and	  vaccines.	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Specifically,	  we	  used	  the	  allele	  frequency-­‐based	  Tajima's	  D	  approach	  (Tajima	  1989)	  to	  detect	  
balancing	   selection,	   and	   the	   integrated	  Haplotype	   Score	  |iHS|	   to	   detect	   selective	   sweeps	  
(Voight	  et	  al.	  2006).	  
2.2 Materials	  and	  Methods	  
2.2.1 Ethics	  statement	  
This	  project	  was	  approved	  by	   the	  College	  of	  Medicine	  Research	  Ethics	  Committee,	  
University	  of	  Malawi	  (Ref.	  no.	  P.10/09/831)	  and	  the	  Liverpool	  School	  of	  Tropical	  Medicine.	  
All	  samples	  were	  collected	  with	  written	  informed	  consent	  from	  a	  parent	  or	  guardian	  of	  the	  
patients.	   Participants	   in	   this	   study	  were	   part	   of	   an	   ACTia	   clinical	   trial	   (Reference	   number	  
P.10/08/707)	   in	   Chikwawa	   and	  MaRCH	   study	   (Reference	   number	   P.05/10/954)	   in	   Zomba	  
district.	  	  
2.2.2 Study	  area	  
This	  study	  was	  carried	  out	   in	  Chikwawa	  and	  Zomba	  districts	  of	  Malawi	   (Figure	  2.1)	  
(which	  generally	   receives	  763	   to	  1,143	  mm	  rainfall	  per	  annum).	  Chikwawa	   falls	  within	   the	  
lowland	   zones	   of	   Malawi,	   in	   the	   lower	   Shire	   valley	   where	   the	   altitude	   is	   a	   few	   metres	  	  
(approximately	   50	  metres)	   above	   sea	   level.	   During	   the	   rainy	   season	   (December	   to	  May),	  
rising	   of	   water	   leads	   to	   formation	   of	   ponds	   and	   marshes,	   also	   present	   are	   permanent	  
wetlands	  with	  stagnant	  water	  and	  together	  with	  temperatures	  that	  are	  generally	  above	  21	  
degrees	  Celsius	  (with	  mean	  annual	  temperatures	  at	  25	  degrees	  Celsius),	  Chikwawa	  provides	  
good	   breeding	   sites	   for	   mosquitoes.	   This	   leads	   to	   high	   malaria	   transmission	   with	   peaks	  
between	   December	   and	   May.	   The	   study	   area	   covered	   24	   villages	   within	   a	   radius	   of	   10	  
kilometres	   in	  Chikwawa.	  Recruitment	  of	  patients	   (which	  was	  part	  of	   a	   larger	   study	   in	   this	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area,	  ACTia	  study)	  was	  continuously	  done	  from	  2010	  –	  2011.	  Samples	  were	  collected	  from	  
2010	  –	  2013	  and	  covered	  three	  malaria	  seasons.	  	  
	  
Figure	   2.1:	   Study	   area	   showing	   location	   of	   the	   Chikwawa	   district.	   Key	   features	   of	   this	  
study	  site	  are	  described.	  
Zomba	  district	  falls	  partly	  within	  the	  highlands	  and	  lowland	  zones	  of	  Malawi	  (Figure	  
2.2).	  Higher	  rainfalls	  are	  experienced	  in	  Zomba	  where	  malaria	  transmission	  is	  perennial	  but	  
increases	  during	  the	  rainy	  season	  when	  pools	  of	  stagnant	  water	  are	  created.	  Between	  2010	  
and	  2013,	  40	  samples	  were	  collected	  from	  this	  location	  but	  none	  included	  in	  this	  analysis,	  as	  
they	  had	  not	  been	  sequenced.	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Figure	  2.2:	  Map	  of	  Zomba	  district	  showing	  study	  site.	  Most	  samples	  were	  collected	  from	  
TA	  Mwambo,	  TA	  Kuntumanji,	  TA	  Chikowi	  and	  TA	  Mkumbira	  villages.	  
	  
2.2.3 Type	  of	  study	  
This	  is	  an	  ongoing	  prospective	  cohort	  study	  nested	  within	  a	  randomised	  control	  trial	  
(ACTia)	   and	   a	   cohort	   observational	   study	   (MaRCH).	   Within	   ACTia,	   participants	   were	  
recruited	   between	   6-­‐48	   months	   and	   randomized	   treated	   with	   LA	   or	   dehydroartemisinin	  
piperaquine	   (DHA-­‐PPQ)	   for	   any	   confirmed	   clinical	   malaria	   episode.	   When	   a	   participant	  
presented	  with	  a	  febrile	  illness,	  a	  malaria	  smear	  was	  made	  from	  a	  finger-­‐prick	  blood	  sample	  
and,	  if	  positive,	  treated	  according	  to	  the	  study	  arm.	  In	  MaRCH,	  two	  cohorts	  of	  participants	  
(aged	   0-­‐2	   months)	   -­‐	   an	   HIV	   exposed	   group	   on	   cotrimoxazole	   (CMX)	   prophylaxis	   for	   12	  
months	  and	  a	  non-­‐HIV-­‐exposed	  group	  -­‐	  were	  followed	  up	  until	  2	  years.	  500	  HIV	  exposed	  and	  
500	  non-­‐HIV	  exposed	  were	  recruited	  simultaneously	  from	  the	  area	  of	  residence	  of	  each	  HIV	  
exposed	   child.	   Following	   blood	   smear	   reading,	   any	   participant	   with	   a	   minimum	   parasite	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density	   of	   100	   –	   1000	   parasites/µL	  was	   included	   in	   this	   study.	   Clinical	   information	   on	   all	  
participants	  was	  kept	  within	  rules	  and	  regulations	  of	  both	  ACTia	  and	  MaRCH	  studies.	  
Experiments	  performed	  at	  Malawi-­‐Liverpool-­‐Wellcome	  Trust	  Labs	  by	  myself:	  
2.2.4 Materials,	  equipment,	  reagents	  and	  chemicals	  
	  
• Whatman	  CF11	  cellulose	  powder	  (Whatman	  catalogue	  no.	  4021-­‐	  050)	  	  
• Whatman	  Grade	   105	   lens	   cleaning	   tissue	   (100	   x	   150	  mm,	  Whatman	   catalogue	  no.	  
2105-­‐841)	  	  
• 10	  cc	  plastic	  syringes,	  centred	  (Becton-­‐	  Dickinson	  catalogue	  no.	  309604)	  	  
• RPMI-­‐1640,	  with	  HEPES	  and	  L-­‐Glutamine	  (Invitrogen	  catalogue	  no.	  21875-­‐091)	  	  
• 15	  ml	  centrifuge	  tubes	  (Fisher	  catalogue	  no.	  FB55950)	  
• 5	  ml	  pipettes	  (Fisher	  catalogue	  no.	  FB51889)	  
• 10	  ml	  pipettes	  (Fisher	  catalogue	  no.	  FB55484)	  
• Cryotubes	  (Fisher	  catalogue	  no.	  12-­‐565-­‐298)	  	  
• Needles,	  23G	  (NHS	  Supplies	  catalogue	  no.	  FTR052)	  
• Vacuette,	  EDTA,	  4	  ml	  (NHS	  Supplies	  catalogue	  no.	  454009)	  
• Blood	   collection	   set,	   23g	   with	   push	   button	   adaptor	   (NHS	   Supplies	   catalogue	   no.	  
KFK323)	  
• Pipetboy	  Acu	  Pipette	  controller	  (Fisher	  catalogue	  no.	  PMR-­‐100-­‐070H)	  
• 10X	  PBS	  (Life	  technologies	  catalogue	  no	  AM9625)	  
• Centrifuge	  	  
• Water	  bath	  
• Gloves	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• QIAGEN	  blood	  midi-­‐kit	  (Qiagen	  catalogue	  no.	  51185)	  
• 1-­‐200	  µL	  tips	  (Fisher	  catalogue	  no.	  FB34551)	  
• 1000	  µL	  tips	  (Fisher	  catalogue	  no.	  FB34611)	  
• DNA	  LoBind	  tubes,	  1.5	  ml	  (Fisher	  catalogue	  no.	  TUL-­‐145-­‐020D)	  
2.2.5 Blood	  sample	  collection	  
During	  any	  confirmed	  clinical	  malaria	  episode,	  3	  mls	  of	  whole	  blood	  at	  a	  minimum	  
parasite	   density	   of	   100-­‐1000	   parasites/µL	  was	   collected	   intravenously	   in	   EDTA	   vacutainer	  
prior	  to	  patient	  treatment	  with	  either	  LA	  or	  DHA-­‐PPQ	  (ACTia),	  or	  CMX	  (MaRCH)	  under	  the	  
two	  study	  guidelines.	  Vacutainers	  were	  labelled	  with	  study	  ID	  and	  patient	  unique	  identifier	  
and	  inverted	  gently	  to	  mix	  well.	  These	  samples	  were	  stored	  at	  4	  degrees	  Celsius	  until	  time	  
for	  white	  blood	  cell	  depletion,	  within	  24	  hours	   to	  avoid	  haemolysis	  and	  release	  of	  human	  
DNA.	  A	  total	  of	  400	  malaria	  positive	  paediatric	  samples	  were	  collected	  by	  June	  2013.	  	  
2.2.6 WBC	  depletion	  of	  whole	  blood	  using	  CF11	  column	  (Sriprawat	  et	  al.	  2009)	  
2.2.6.1 Purpose	  and	  scope	  
	  
The	   purpose	   of	   this	   procedure	   was	   to	   reduce	   the	   amount	   of	   human	   DNA	   in	   P.	  
falciparum	   infected	   whole	   blood	   samples	   for	   genomic	   studies	   by	   removing	   human	  
leukocytes.	  	  
2.2.6.2 Preparation	  of	  CF11	  cellulose	  columns	  
This	   procedure	   was	   performed	   in	   the	   hood	   to	   avoid	   inhalation	   of	   CF11	   powder.	  
Using	  a	  razor	  blade,	  1cm2	  square	  of	  Whatman	  lens	  cleaning	  tissue	  (approximately	  the	  size	  of	  
the	   bottom	  of	   the	   syringe	   barrel)	  was	   cut.	   The	   plunger	  was	   removed	   from	   a	   syringe	   and	  
using	   forceps,	   two	  1cm2	  squares	  of	   lens	  paper	  were	   laid	   flat	  at	   the	  bottom	  of	   the	  syringe	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barrel	   to	   cover	   the	   tip	   opening.	   10	  ml	   of	   loosely	   packed	   CF11	   powder	  was	   added	   to	   the	  
syringe	  barrel.	  The	  plunger	  was	  put	  back	  and	  CF11	  powder	  packed	  down	  to	  approximately	  
the	  5	  ml	  mark.	  Pre-­‐made	  columns	  were	  stored	  until	  use.	  	  
2.2.6.3 Procedure	  for	  leukocyte	  depletion	  
	  
	   The	   plunger	   was	   removed	   from	   the	   CF11	   column	   and	   if	   the	   cellulose	   powder	   was	  
displaced	  by	  air,	   it	  was	  pushed	  back	  to	  restore	  the	  cellulose	  powder	  within	  the	  5	  ml	  mark.	  
The	  columns	  were	  suspended	  over	  an	  uncapped	  15	  ml	   tube	  using	  a	  clamp.	  6	  mls	  of	  RPMI	  
was	   added	   to	   the	   top	  of	   the	   column	  and	  allowed	   to	   flow-­‐through.	  Whole	  blood	   (sample)	  
was	  added	  to	  a	  15	  ml	  centrifuge	  tube	  and	  an	  equal	  volume	  (same	  volume	  as	  original	  blood	  
sample)	   of	   RPMI	   added	   to	   the	   blood.	   	   The	   sample	   was	   gently	   pipetted	   up	   and	   down	   to	  
create	  a	  homogenous	  mix	  of	  whole	  blood	  and	  RPMI.	  Sample	  was	  added	  to	   the	  top	  of	   the	  
column	  and	  allowed	  to	  pass	  through	  by	  gravity	  into	  a	  clean	  15	  ml	  collection	  centrifuge	  tube.	  
Once	  drops	  no	  longer	  passed	  into	  the	  collection	  tube,	  additional	  3	  mls	  of	  RPMI	  was	  added	  to	  
the	  top	  of	  the	  column	  and	  allowed	  to	  pass	  through.	  The	  filtered	  sample	  was	  spun	  at	  1000	  
times	  g	  at	   room	   temperature	   for	   10	  minutes,	   to	   create	   a	   clear	   separation	   of	   pellet	   from	  
supernatant.	  The	  supernatant	  was	  discarded	  without	  disrupting	  the	  red	  blood	  cell	  pellet	  by	  
leaving	  a	  small	  amount	  of	  supernatant.	  Blood	  pellet	  was	  stored	  in	  a	  cryotube	  at	  –70	  degrees	  
Celsius	  until	  DNA	  extraction.	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2.2.7 DNA	  extraction	  from	  Whole	  Blood	  Using	  the	  QIAamp	  Blood	  Midi	  Kit	  
(adapted	  from	  QIAGEN	  handbook	  with	  minor	  changes)	  
	  
2.2.7.1 Steps	  performed	  before	  DNA	  extraction	  
	  
• All	  centrifuge	  steps	  were	  carried	  out	  at	  room	  temperature	  (RT)	  15	  –	  25	  degrees	  
Celsius.	  
• DNA	  samples	  were	  equilibrated	  at	  room	  temperature	  to	  thaw.	  
• Water	  bath	  at	  70	  degrees	  Celsius	  was	  prepared.	  
• Buffer	  AW1,	  AW2	  and	  QIAGEN	  protease	  were	  prepared	  according	  to	  manufacturer’s	  
instructions.	  
2.2.7.2 Procedure	  for	  DNA	  extraction	  
	  
One	  hundred	  and	  twenty	  μL	  of	  QIAGEN	  protease	  was	  pipetted	  into	  the	  bottom	  of	  a	  
15	  ml	  centrifuge	  tube.	  Samples	  with	  less	  than	  1	  ml	  blood	  pellet,	  were	  topped	  up	  with	  1X	  PBS	  
to	  bring	  the	  volume	  to	  1	  ml.	  Sample	  (PBS	  and	  blood	  pellet)	  was	  added	  to	  the	  protease	  and	  
mixed	  properly	  by	  pipetting	  up	  and	  down.	  A	  total	  of	  1.2	  mls	  of	  Buffer	  AL	  was	  added	  to	  the	  
sample	  and	  mixed	  thoroughly	  to	  produce	  a	  homogenous	  solution	  by	  inverting	  the	  tube	  15	  
times,	   followed	  by	   additional	   vigorous	   shaking	   for	   at	   least	   1	  minute.	  Multiple	   tubes	  were	  
inverted	   simultaneously	  by	  clamping	   them	   into	  a	   rack	  using	  another	  empty	   rack,	  grasping	  
both	  racks.	  The	  sample	  was	  then	   incubated	  at	  70	  degrees	  Celsius	  for	  10	  minutes,	  to	  allow	  
lysis	  of	  cells	   for	  maximum	  DNA	  yield.	  After	   incubation,	  1	  ml	  of	  99%	  ethanol	  was	  added	  to	  
the	   sample,	   and	   mixed	   by	   inverting	   the	   tube	   10	   times,	   followed	   by	   additional	   vigorous	  
shaking	   to	   produce	   a	   homogenous	   solution.	   The	   solution	  was	   transferred	  onto	   a	  QIAamp	  
Midi	  column	  placed	  in	  a	  15	  ml	  centrifuge	  tube,	  taking	  care	  not	  to	  moisten	  the	  rim.	  The	  cap	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was	  closed	  and	  centrifuged	  at	  1850	  times	  g	  for	  3	  minutes.	  If	  the	  solution	  had	  not	  completely	  
passed	   through	   the	  membrane,	   it	   was	   centrifuged	   again	   at	   a	   slightly	   higher	   speed	   (2000	  
times	  g)	   for	  3	  minutes.	  To	  avoid	  any	  spillage	  of	   liquid	  through	  the	  ventilation	  slots	  on	  the	  
rims	  of	  the	  columns	  we	  held	  the	  QIAamp	  Midi	  columns	  in	  an	  upright	  position.	  The	  QIAamp	  
Midi	  column	  was	  removed,	  the	  filtrate	  discarded	  and	  placed	  back	  into	  the	  15	  ml	  centrifuge	  
tube.	  Without	   moistening	   the	   rim,	   2	   mls	   of	   Buffer	   AW1	   was	   added,	   the	   cap	   closed	   and	  
centrifuged	  at	  4000	  times	  g	  for	  2	  minutes.	  Without	  moistening	  the	  rim,	  2	  mls	  of	  Buffer	  AW2	  
was	  added	  to	  the	  QIAamp	  Midi	  column,	  the	  cap	  closed	  and	  centrifuged	  at	  4000	  times	  g	  for	  
30	  min.	   This	   increased	   centrifugation	  enabled	   removal	   of	   all	   traces	  of	   Buffer	  AW2	  before	  
elution.	   The	   sample	  was	   incubated	   for	   10	  minutes	   at	   70°C	   to	   evaporate	   residual	   ethanol.	  
Ethanol	  in	  the	  eluate	  may	  cause	  inhibition	  in	  the	  PCR	  leading	  to	  false	  positives	  results.	  The	  
QIAamp	  Midi	  column	  was	  placed	   in	  a	  clean	  15	  ml	  centrifuge	   tube	  and	   the	  collection	   tube	  
containing	  the	  filtrate	  discarded.	  300	  μl	  of	  Buffer	  AE	  equilibrated	  to	  room	  temperature,	  was	  
added	  directly	  onto	  the	  membrane	  of	  the	  QIAamp	  Midi	  column,	  cap	  closed	  and	  incubated	  at	  
room	   temperature	   for	   5	   minutes,	   and	   centrifuged	   at	   4000	   times	   g	   for	   4	   minutes.	   For	  
maximum	  yield,	  300	  μl	  fresh	  Buffer	  AE	  equilibrated	  to	  room	  temperature,	  was	  pipetted	  onto	  
the	  membrane	  of	  the	  QIAamp	  Midi	  column,	  cap	  closed	  and	  centrifuged	  at	  4000	  times	  g	  for	  4	  
min.	  The	  resulting	  filtrate	  (DNA	  solution)	  was	  pipetted	  into	  a	  1.5	  ml	  Lo-­‐Bind	  eppendorf	  tube	  
and	  kept	  at	  4	  degrees	  Celsius	  ready	  for	  shipping	  to	  WTSI	  for	  sequencing.	  
Summary	  of	  experiments	  performed	  by	  collaborators	  at	  WTSI	  (sequencing):	  
2.2.8 Sample	  preparation	  and	  sequencing	  
• Ninety-­‐three	  purified	  DNA	  samples	  were	  sent	  to	  WTSI	  malaria	  laboratories	  for	  MPS	  
sequencing.	  Total	  DNA	  in	  each	  sample	  was	  quantified	  on	  the	  Invitrogen	  Qubit	  as	  per	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the	   manufacturer’s	   standard	   protocol	   (Quant-­‐iTTM).	   Quantitative	   real-­‐time	   PCR	  
analysis	  was	  undertaken	  on	  all	  DNA	  samples	  to	  determine	  the	  quantities	  of	  human	  
to	  Plasmodium	  DNA,	  with	  primers	  specific	  to	  human	  (PLAT1),	  P.	  falciparum	  (AMA1)	  
and	  P.	  vivax	  (VIV3)	  using	  Lightcycler	  480	  qPCR.	  
2.2.9 Quantification	  of	  human	  to	  P.	  falciparum	  DNA	  concentrations	  	  
2.2.9.1 Reagents/consumables,	  primers	  and	  probes	  
• DNA	  free	  water	  	  
• Q/RT-­‐PCR	  probe	  mix	  (Roche	  or	  Kappa)	  	  
• Sample	  DNA	  (0.1-­‐10ng)	  	  
• Control	  DNA	  mix	  (0.1-­‐10ng)	  	  
• 96	  well	  qPCR	  plate	  (Starlab	  I1402-­‐9909)	  	  
• Optically	  clear	  plate	  seal	  (Starlab	  E2796-­‐9795)	  	  
• Lightcycler	  480	  qPCR	  
Forward	  and	  reverse	  primer	  sequences	  for	  VIV3,	  AMA1	  and	  PLAT1:	  
Name	  	   Type	  	   Sequence	  	  
VIV3	   Primer-­‐	  forward	  	   AAA	  GAT	  TCG	  TAG	  CTG	  TCG	  GTG	  GGT	  	  
	  
Primer-­‐reverse	  	   TTC	  CAT	  TAA	  GTG	  CGC	  GTA	  CCG	  AGA	  	  
	  
Probe	  	   ACA	  GCG	  ACG	  ACT	  CCA	  GAT	  CCG	  ATT	  TA	  	  
AMA1	   Primer-­‐forward	  	   TGC	  CAT	  ATA	  TTC	  CGT	  CCA	  TGG	  	  
	  
Primer-­‐reverse	  	   ACG	  CAT	  ATC	  CAA	  TAG	  ACC	  ACG	  	  
	  
Probe	  	   CGA	  ACC	  CGC	  ACC	  ACA	  AGA	  ACA	  AAA	  	  
PLAT1	   Primer-­‐forward	  	   CTT	  ACC	  ACA	  TCC	  GCT	  CCA	  TC	  	  
	  
Primer-­‐reverse	  	   TTC	  ACA	  CTC	  TCC	  GTC	  ACA	  TTG	  	  
	  









Component	  	   Volume	  (μl)	  
Probe	  Mix	  	   10	  	  
AMA1	  Primer/probe	  mix	  	   1	  
PLAT1	  Primer/probe	  mix	  	   1	  	  
VIV3	  Primer/probe	  mix	  	   1	  
Water	  	   6	  	  
The	  probes	  used	  dyes	  from	  integrated	  DNA	  technologies	  (IDT),	  FAM	  for	  VIV3,	  Lightcycler	  
640	  for	  AMA1	  and	  HEX	  for	  PLAT1.	  In	  addition	  to	  this,	  the	  performance	  of	  certain	  dye	  types	  
were	  improved	  with	  the	  addition	  of	  an	  internal	  quencher,	  ZEN	  with	  both	  HEX	  and	  FAM	  dyes.	  
Master	  mix	  was	  prepared	  as	  above.	  19μl	  of	  master	  mix	  was	  pipetted	   into	   (3x	  sample)	  +	  6	  
wells	  (3	  wells	  each	  for	  control	  mix	  and	  water),	  i.e.,	  for	  10	  samples,	  36	  wells	  were	  used.	  1μl	  
of	  each	  sample	  was	  pipetted	  into	  3	  wells	  and	  1μl	  of	  control	  mix	  into	  a	  separate	  3	  wells.	  After	  
adding	  1μl	  DNA/RNA-­‐free	  water	   into	   the	   rest	  of	   the	   remaining	  3	  wells,	   the	  PCR	  plate	  was	  
sealed	   and	   loaded	   into	   the	   qPCR	   machine	   that	   was	   run	   using	   the	   following	   cycling	  
conditions:	  
Cycling	  conditions:	  
Stage	  	   Temperature	  (oC)	   Time	  (Min:Sec)	  
Activation	  	   95	   05:00	  
Amplification	  (45	  cycles)	  	   57	   00:20	  
	  
72	   00:01	  
	  
95	   00:10	  
Storage	  	   40	   Infinite	  
	  
Standard	   curves	  are	  generated	  using	   the	   Lightcycler	  480	   software	   from	  a	  5	   times	  dilution	  
series	   (5	  replicates	  of	  each).	  A	  known	  concentration	  standard	   is	   then	   included	   in	  each	  run	  
and	   mapped	   onto	   the	   previously	   generated	   standard	   curves,	   the	   unknown	   samples	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concentrations	  are	  then	  subsequently	  calculated	  based	  on	  this	  standard.	  Human	  percentage	  
is	   calculated	  using	  excel,	   triplicates	  are	  used	   for	  each	  unknown	  and	  averages	  of	   these	   for	  
human,	  P.	  falciparum	  and	  (if	  appropriate)	  P.	  vivax	  were	  analyzed	  to	  determine	  percentage	  
composition.	  
2.2.10 Library	  preparation	  and	  sequencing	  
Standard	   sequencing	   libraries	   for	   all	   DNA	   samples	   were	   prepared	   following	   the	  
manufacturer’s	   recommended	   protocol	   by	   the	   WTSI	   core	   library	   preparation	   and	  
sequencing	   team	   (Bentley	   et	   al.	   2008).	   All	   samples	   with	   less	   than	   60%	   human	   DNA	  
contamination	  and	  sufficient	  DNA	  (>	  1μg/1000ng)	  underwent	  whole	  genome	  sequencing	  on	  
the	  Illumina	  HiSeq2000	  machines	  without	  any	  PCR	  amplification	  (Kozarewa	  et	  al.	  2009)	  with	  
76	  to	  100-­‐bp	  paired-­‐end	  sequencing	  reads.	  The	  entire	  short	  read	  sequence	  data	  have	  been	  
deposited	  in	  European	  Nucleotide	  Archive.	  	  
2.2.11 Data	  processing	  –	  Alignment,	  SNP	  discovery	  and	  quality	  filtering	  
Short	   reads	   for	   all	   93	   samples	   were	   mapped	   to	   3D7	   reference	   genome	   (version	   3.0)	  
using	  Smalt	  (http://www.sanger.ac.uk/resources/software/smalt).	  Twenty-­‐four	  samples	  had	  
low	   coverage	   (average	   genome-­‐wide	   coverage	   less	   than	   10-­‐fold),	   and	  were	   excluded.	   For	  
the	   remaining	  samples	   (n=69,	  average	  coverage	  genome-­‐wide	  >35-­‐fold),	  SNPs	  were	  called	  
using	  samtools	  and	  bcf/vcftools	  with	  default	  settings	  (http://samtools.sourceforge.net).	  This	  
process	   identified	   115,965	   SNPs	   across	   the	   69	   samples.	   	  We	   retained	   88,655	   high	   quality	  
SNPs	  in	  the	  nuclear	  genome	  that	  met	  the	  following	  criteria:	  (i)	  biallelic,	  (ii)	  quality	  scores	  in	  
excess	  of	  30	   (error	   rate	   less	   than	  1	  per	  1000-­‐bp),	   (iii)	  average	  coverage	  across	  all	   samples	  
between	   10-­‐	   and	   2000-­‐fold	   (Li	   et	   al.	   2009),	   (iv)	   not	   located	   in	   sub-­‐telomeric	   regions,	   the	  
hypervariable	  var,	  rifin	  and	  stevor	  gene	  families,	  or	  regions	  of	  low	  uniqueness,	  and	  (v)	  had	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no	  more	  than	  two	  missing	  or	  mixed	  called	  genotypes	  across	  the	  samples.	  Uniqueness	  was	  
calculated	   by	   a	   sliding	   50-­‐bp	   window	   of	   contiguous	   sequence	   across	   the	   3D7	   reference	  
genome	  and	  detecting	  the	  presence	  of	  this	  motif	  elsewhere	  in	  the	  genome.	  SNPs	  were	  only	  
retained	   if	   they	  were	   in	   a	   unique	   position.	  Genotypes	   at	   SNP	   positions	  were	   called	   using	  
ratios	   of	   coverage	   and	   heterozygous	   calls	   converted	   to	   the	   majority	   genotype	   on	   80:20	  
coverage	  ratio	  or	  greater	  (Robinson	  et	  al.	  2011;	  Manske	  et	  al.	  2012).	  Population	  data	  from	  
other	  populations	  (Kenya,	  n=37;	  Burkina	  Faso,	  n=40;	  Mali,	  n=40;	  Cambodia,	  n=80,	  Thailand,	  
n=80;	  294,187	  SNPs;	  Preston	  et	  al.	  2013,	  SRA	  study	  ERP000190)	  were	  processed	  in	  the	  same	  
way.	   The	   four	  mitochondrial	   SNPs	   (mt772,	  mt1692,	  mt4179	   and	  mt4952)	   were	   extracted	  
from	  the	  alignments	  and	  genotypes	  called	  as	  described	  above.	  Public	  accession	  numbers	  for	  
sequence	   data	   are	   contained	   in	   SRA	   studies	   at	   www.ebi.ac.uk/ena/data/view/ERP000190	  
and	   www.ebi.ac.uk/ena/data/view/ERP000199,	   as	   well	   as	   accessible	   from	  
www.malariagen.net.	  We	  obtained	  permission	  to	  use	  additional	  metadata	  information	  from	  
relevant	  investigators	  who	  are	  included	  on	  this	  thesis.	  
2.2.12 Population	  genetics	  analysis	  and	  selection	  metrics	  
For	   the	  analysis	  of	   SNPs	   (n=88,655)	   in	   the	  Malawian	  populations,	  we	  computed	   the	  allele	  
frequency-­‐based	  Tajima's	  D	   approach	   (Tajima	  1989)	   at	   the	   gene	   level	   to	  detect	   balancing	  
selection.	   The	   integrated	   Haplotype	   Score	   iHS	   was	   applied	   to	   detect	   selective	   sweeps	  
(Voight	   et	   al.	   2006).	   For	   this,	   a	   recombination	   map	   was	   generated	   using	   LDhat	   2.1	   as	  
previously	  described	  (Chang	  et	  al.	  2012),	  and	  P-­‐values	  computed	  from	  standardised	  values	  
based	   on	   a	   two-­‐tailed	   conversion	   from	   a	   Gaussian	   distribution	   	   (Chang	   et	   al.	   2012).	   A	  
threshold	  of	  iHS	  (P<0.0006)	  was	  determined	  to	  account	  for	  multiple	  testing,	  and	  calculated	  
using	   the	   actual	   nominal	   5%	   cut-­‐off	   from	   re-­‐running	   the	   algorithm	   on	   10,000	   bootstrap	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samples.	   To	   assess	   the	   effects	   of	   low	   frequency	   alleles	   potentially	   due	   to	   population	  
expansion,	  the	  iHS	  was	  also	  applied	  to	  SNP	  data	  with	  a	  minor	  allele	  frequency	  of	  5%.	  There	  
was	  no	  notable	  difference	  in	  results,	  especially	  the	  hits	  identified.	  To	  assess	  if	  there	  was	  any	  
population	   structure	  within	   the	  Malawian	   population,	   principal	   component	   analysis	   (PCA)	  
was	   conducted	   using	   SMARTPCA	   (EIGENSOFT	   3.0,	   Patterson,	   Price,	   and	   Reich	   2006).	   We	  
applied	   a	   local	   LD	   correction	   (nsnpldregress	   =	   2)	   and	   calculated	   the	   top	   25	   eigenvectors,	  
with	   corresponding	   P-­‐values.	   For	   comparisons	   between	   populations	   (Malawi	   vs.	   other,	  
n=294,187	  SNPs),	  we	  applied	  the	  across	  population	  long	  range	  LD	  method	  XP-­‐EHH	  (Sabeti	  et	  
al.	  2007)	  and	  the	  population	  differentiation	  metric	  FST	   (Holsinger	  and	  Weir	  2009).	  P-­‐values	  
for	  the	  XP-­‐EHH	  estimates	  were	  calculated	  using	  a	  Gaussian	  approximation,	  and	  a	  Bonferroni	  
threshold	   of	   P<0.00006	   was	   established	   for	   reporting.	   A	   threshold	   for	   FST	   (>0.2)	   was	  
established	  as	  a	  benchmark	  for	  reporting	  by	  looking	  at	  the	  99.9-­‐ile	  across	  all	  comparisons.	  A	  
PCA	  based	  on	  a	  matrix	  of	  pairwise	  identity	  by	  state	  values	  was	  used	  to	  cluster	  all	  samples.	  
We	   used	   the	   ranked	   FST	   statistics	   to	   identify	   the	   informative	   polymorphism	   driving	   the	  
clustering.	  	  
2.3 Results	  A	  
2.3.1 Summary	  characteristics	  of	  sampled	  Malawi	  isolates	  
	  
Between	  December	  2010	  and	   June	  2013,	  duration	   covering	   three	  malaria	   seasons,	  
we	   collected	   400	   malaria	   positive	   samples.	   Out	   of	   these,	   93	   samples	   collected	   between	  
December	  2010	  and	  June	  2012	  were	  sequenced	  at	  the	  WTSI	  and	  data	  included	  in	  this	  thesis.	  
The	   remaining	   samples	  were	   either	   still	   in	   the	   sequencing	   pipeline	   or	   their	   data	   released	  
late	   and	   were	   not	   included	   in	   this	   thesis.	   Samples	   patients	   were	   young	   (average	   age	   11	  
	   	  60	  
months),	  with	  high	  parasitemia	   (1,000	   -­‐	  10,000	  parasites/µL)	  and	  average	  haemoglobin	   (9	  
g/dl).	  	  Most	  samples	  (>	  97%)	  were	  from	  uncomplicated	  malaria	  cases.	  	  
2.3.2 Quantification	  of	  human	  DNA	  content	  using	  quantitative	  real	  time	  PCR	  
	  
To	  date,	  we	  have	  quantified	  human	  DNA	  content	   in	  309	  samples	   (including	   the	  93	  
samples	   used	   in	   this	   thesis)	   out	   of	   the	   400	   available	   for	   sequencing.	   Total	   DNA	  
concentration	   ranged	   from	   0	   –	   238	   ng/µL	   (in	   100-­‐500	   µL	   sample	   volumes)	   and	   ratios	   of	  
human	  DNA	  concentrations	  ranged	  from	  0	  –	  100%.	  	  Samples	  with	  less	  than	  60%	  human	  DNA	  
contaminations	  and	  with	  at	  least	  1000	  ng	  total	  DNA	  were	  sequenced	  (Table	  2.1).	  
Table	  2.1:	  Summary	  of	  proportion	  of	  DNA	  concentrations	  in	  the	  samples.	  
	  




Figure	  2.3:	  Frequency	  distribution	  of	  (A)	  total	  DNA	  concentrations	  and	  (B)	  total	  human	  
DNA	  concentrations	  in	  the	  total	  sample	  as	  estimated	  by	  quantitative	  real-­‐time	  PCR.	  90%	  
of	  samples	  had	  <30%	  human	  DNA	  contamination	  and	  were	  sequenced.	  
	  
	  	  
Total	  DNA	  concentration	  
(ng/µl)	  
%	  Human	  DNA	  
concentration	  
Minimum	   0	   0	  
Median	   3.97	   0.78	  
Mean	   16.92	   9.8	  
Maximum	   238	   100	  
(A)  Frequency distribution of total DNA concentrations



























(B)    Frequency distribution of human DNA concentrations
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2.3.3 Summary	  of	  sequence	  results	  and	  SNP	  quality	  filtering	  steps	  
	  
A	   total	   of	   115,965	   SNPs	   across	   69	   samples	   were	   identified	   and	   quality	   control	   was	  
performed	   as	   described	   in	   the	   methods	   section.	   The	   median	   number	   of	   individual	   SNP	  
differences	   from	  the	   reference	  genome	  and	  genomic	  coverage	  across	   samples	  before	  and	  
after	  QC	  are	  provided	  (Table	  2.2,	  2.3	  and	  Figure	  2.4).	  In	  addition,	  distribution	  of	  mixed	  calls	  
and	   “missingness”	   in	   isolates	   and	  SNPs	  are	   given	   (Figure	  2.5-­‐2.7).	   Both	   the	  non-­‐reference	  
and	   minor	   allele	   frequency	   spectrum	   are	   dominated	   by	   rare	   derived	   alleles.	   Only	   1,446	  
(1.1%)	  SNPs/alleles	  were	  >	  95%	  different	  from	  the	  reference	  (Figure	  2.8	  and	  2.9).	  
Table	  2.2:	  Summary	  of	  sequence	  results	  across	  93	  samples	  for	  the	  nuclear	  genome.	  Poor	  
sequencing	  of	  some	  samples	  resulted	  in	  very	  low	  coverage	  and	  poor	  SNP	  calling.	  
	  	   Coverage	   Read	  depth	   Mapped	  Reads	   %	  	  Mapped	   SNPs	  
SNPs	  	  
(Q30)	  
Mean	   34	   612.4	   13,535,495	   97.5	   23,411	   19,429	  
	  Median	  
(range)	  
34	   514	   11,848,299	   98.2	   26,834	   21,633	  
(0-­‐158)	   (78-­‐2401)	   (99,473-­‐52,221,597)	   (78.5-­‐99.2)	   (23-­‐41,245)	   (9-­‐34,747)	  
	  
Table	  2.3:	  Summary	  of	  sequence	  results	  across	  69	  samples	  for	  the	  nuclear	  genome.	  
	  
Coverage	   Read	  depth	   Mapped	  reads	   %	  	  Mapped	   SNPs	  
SNPs	  	  
(Q30)	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Figure	   2.4:	   Proportion	   of	   candidate	   SNPs	   in	   all	   isolates.	   (A)	   Candidate	   SNPs	   identified	  
before	   applying	   mapping	   score	   quality.	   (B)	   Candidates	   SNPs	   identified	   with	   good	  
mapping	  quality	  of	  Q30	  (1	  error	  per	  1000-­‐bp).	  	  	  
	  
	  
Figure	   2.5:	   Isolates	  missing	   genotypes.	   69	   samples	  with	   less	   than	   10,000	  missing	   calls	  
were	  retained.	  Samples	  (n=24)	  with	  high	  missing	  calls	  were	  discarded.	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Figure	   2.7:	   Proportion	   of	  mixed	   calls	   in	  Malawi	   isolates.	   88,655	   (83.2%)	   biallelic	   SNPs	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Figure	  2.8:	  Non-­‐reference	  allele	   frequency	   in	  Malawi	   isolates.	  Rare	  alleles	  dominate	   in	  




Figure	  2.9:	  Minor	  allele	   frequency	   in	  Malawi	   isolates.	  The	  allele	   frequency	  spectrum	   is	  
dominated	   by	   rare	   derived	   SNPs,	   the	   majority	   (82%)	   of	   which	   have	   a	   minor	   allele	  
frequency	  (MAF)	  <5%.	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2.3.4 Population	  structure	  in	  Malawi	  P.	  falciparum	  population	  
	  
An	   examination	   of	   the	   structure	   or	   stratification	   within	   and	   between	   populations	  
could	   reveal	   insights	   into	   their	  evolutionary	  history.	  Previous	   studies	   (Manske	  et	  al.	  2012;	  
Miotto	  et	  al.	  2013;	  Preston	  et	  al.	  2013)	  show	  that	  population	  structure	  of	  P.	   falciparum	   is	  
geographically	  dispersed,	  as	  a	  result	  of	  adaptation	  to	  different	  environments	  and	  differing	  
selection	   pressures.	   Before	   analyzing	   the	   sequencing	   data	   from	   the	   nuclear	   genome	   for	  
population	   structure,	  mitochondrial	   (mt)	   genome	   (~6-­‐kb)	   SNPs	  were	  used	   to	   confirm	   that	  
the	   Malawian	   samples	   were	   of	   African	   origin.	   Haplotypes	   were	   formed	   using	   four	  
established	   continental	   specific	   polymorphisms	   (mt772,	   mt1692,	   mt4179	   and	   mt4952)	  
(Conway	   et	   al.	   2000).	   Two	   haplotypes	   were	   present	   CGCC	   (identical	   to	   3D7,	   90.8%)	   and	  
CACC	   (9.2%)	   –	   both	   of	   African	   origin.	  High	   read	   depth	   coverage	   in	   the	  mt	   (median/mean	  
~1560/1245-­‐fold,	  ~19/23-­‐fold	  greater	  than	  the	  nuclear	  genome)	  is	  also	  consistent	  with	  the	  
known	  multiple	  copies	  of	  the	  organelle	  in	  a	  P.	  falciparum	  cell	  (Vaidya	  and	  Mather	  2009).	  We	  
investigated	  population	  structure	  within	  the	  Malawian	  population,	  and	  detected	  no	  strong	  
evidence	  of	  structure,	  SMARTPCA	  principal	  components	  P>0.1	  (Patterson	  et	  al.	  2006)	  (Figure	  
2.10).	  This	  may	  be	  expected	  because	  all	  samples	  were	  recruited	  within	  the	  same	  season	  and	  
geographical	  region.	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Figure	   2.10:	   Population	   structure	   of	  Malawi	   parasites	   assessed	   by	   PCA	   on	   SNPs.	   SNPs	  
show	  no	  structure.	  
	  
2.4 Results	  B	  
	  
2.4.1 Inferring	  balancing	  selection	  in	  a	  Malawi	  P.	  falciparum	  population	  
	  
Whole-­‐genome	  application	  of	  the	  Tajima’s	  D	  metric	  reveals	  a	  high	  proportion	  (83%)	  
of	   alleles	  with	   “negative”	   Tajima’s	  D	   values,	   indicative	   of	   an	   excess	   of	   low-­‐frequency	   and	  
singleton	   polymorphisms,	  which	  may	   have	   arisen	   from	  historical	   population	   expansion	   or	  
purifying	  selection	  (Weedall	  and	  Conway	  2010;	  Amambua-­‐Ngwa	  et	  al.	  2012b).	  This	  analysis	  
also	   identified	   19	   genes	   (Table	   2.5)	   with	   positive	   Tajima’s	   D	   values	   (i.e.,	   ≥1.0)	   as	   loci	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and	  potential	  as	  targets	  for	  immunity	  and	  drug	  intervention	  such	  as	  msp3.8,	  msp3,	  dbl-­‐msp,	  
eba175,	  ama1	  and	  surfin4.2	  (Table	  2.5,	  Figure	  2.11).	  Many	  of	  these	  genes	  have	  had	  positive	  
indices	  of	  balancing	  selection	  in	  previous	  studies	  of	  African	  populations	  (Ochola	  et	  al.	  2010;	  
Amambua-­‐Ngwa	  et	  al.	  2012b).	  Immuno-­‐epidemiological	  studies	  of	  MSP	  and	  AMA1	  proteins	  
have	   particularly	   identified	   allele-­‐specific	   antibody	   responses	   associated	   with	   protection	  
from	   malaria	   (Polley	   et	   al.	   2007;	   Osier	   et	   al.	   2008).	   The	   surfin4.2	   gene	   encodes	   SURFIN	  
protein,	   expressed	   on	   infected	   erythrocytes	   or	   merozoites	   and	   thus	   exposed	   to	   host	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Figure	   2.11:	   Genome-­‐wide	   distributions	   of	   Tajima’s	   D	   across	   P.	   falciparum	   genome,	  
showing	  genes	  subject	  to	  balancing	  selection	  in	  Malawi	  parasite	  isolates.	  Coloured	  dots	  
represent	   individual	   genes.	   The	   solid	   horizontal	   line	   indicates	   genomic	   threshold	   for	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Table	  2.4:	  Genetic	  loci	  under	  balancing	  selection	  (Tajima’s	  D	  ≥1.0).	  
Gene	   Tajima's	  D	   Start	   Stop	   Gene	  description	  
PF3D7_1036300	   3.26	   1432702	   1434553	   Merozoite	  surface	  protein	  3.8	  
PF3D7_0710000	   2.52	   447902	   457801	   Conserved	  Plasmodium	  protein,	  UF	  
PF3D7_0425400	   2.06	   1144011	   1144822	   Plasmodium	  exported	  protein	  (PHISTa),	  UF	  	  
PF3D7_0221000	   1.98	   848124	   849107	   Plasmodium	  exported	  protein,	  UF	  
PF3D7_0709300	   1.96	   414302	   421420	   Cg2	  protein	  
PF3D7_0710200	   1.94	   463705	   471598	   Conserved	  Plasmodium	  protein,	  UF	  
PF3D7_0424400	   1.85	   1100085	   1102381	   Surface-­‐associated	  interspersed	  protein	  4.2	  (SURFIN	  4.2)	  
PF3D7_0630800	   1.83	   1288574	   1290718	   Conserved	  Plasmodium	  protein,	  UF	  
PF3D7_1133400	   1.72	   1293957	   1295622	   Apical	  membrane	  antigen	  1	  	  
PF3D7_1149600	   1.59	   2001079	   2003312	   DnaJ	  protein,	  P	  	  
PF3D7_1126100	   1.57	   1018557	   1021025	   Autophagy-­‐related	  protein	  7,	  P	  
PF3D7_0731500	   1.56	   1358502	   1362925	   Erythrocyte	  binding	  antigen-­‐175	  
PF3D7_0104100	   1.49	   178094	   180554	   Conserved	  Plasmodium	  membrane	  protein,	  UF	  
PF3D7_0516300	   1.39	   679096	   680745	   tRNA	  pseudouridine	  synthase,	  P	  
PF3D7_1035400	   1.37	   1404453	   1405160	   Merozoite	  surface	  protein	  3	  
PF3D7_0113800	   1.24	   527113	   536327	   DBL	  containing	  protein,	  UF	  	  
PF3D7_0630300	   1.15	   1260750	   1269383	   DNA	  polymerase	  epsilon,	  catalytic	  subunit	  a,	  P	  
PF3D7_0103600	   1.03	   161480	   165521	   ATP-­‐dependent	  RNA	  helicase,	  P	  
PF3D7_1035700	   1.01	   1413250	   1415182	   Duffy	  binding-­‐like	  merozoite	  surface	  protein	  
UF	  =	  Unknown	  function	  and	  P	  =	  putative	  
	  
2.4.2 Inferring	  positive	  selection	  in	  a	  Malawi	  P.	  falciparum	  population	  
	  
To	   examine	   evidence	   for	   signatures	   of	   positive	   directional	   selection	   integrated	  
haplotype	   score	   (iHS)	   was	   computed.	   Seven	   contiguous	   loci	   (Table	   2.6,	   Figure	   2.12,	  
P<0.0006)	  of	  strong	  selection	  were	  identified	  including	  areas	  surrounding	  SP	  drug	  resistance	  
loci	  pfdhps	  and	  pfgch1.	  Additional	  regions	  include	  areas	  on	  chromosomes	  1,	  2,	  4,	  10	  (msp6	  
and	  msp3.8),	  11	  (pfama1),	  13	  (trap)	  and	  14	  (msp7).	  Evidence	  of	  positive	  directional	  selection	  
in	   antigenic	   loci,	   thought	   to	   be	   primarily	   under	   balancing	   selection,	   is	   consistent	   with	  
previous	   reports	   (Mu	   et	   al.	   2010;	   Amambua-­‐Ngwa	   et	   al.	   2012a,	   Borrmann	   et	   al.	   2013),	  
where	   long	  haplotype	  signals	   in	  ama1	  and	   trap	  have	  also	  been	  detected	   in	  Asia,	  east	  and	  
west	  African	  parasites.	  It	  is	  possible	  there	  are	  non-­‐immune	  pressures	  acting	  on	  these	  loci	  or	  
that	  positive	  directional	  selection	  may	  be	  a	  result	  of	  a	  variant	  unfamiliar	  to	  the	  host	  immune	  
system	  rising	  from	  very	  low	  frequencies	  in	  the	  population.	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Figure	  2.12:	  Recent	  positive	  directional	  selection	   in	  a	  Malawi	  P.	  falciparum	  population.	  
Dashed	   line	   indicates	   genome-­‐wide	   significant	   iHS	   values	   (P<0.0006).	   Vertical	   lines	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Table	  2.5:	  Regions	  under	  recent	  positive	  directional	  selection	  in	  Malawi,	  iHS	  (P<0.0006).	  	  
Chromosome	   Start	   Stop	   Size	   Comment	  
1	   178726	   180317	   1591	  
	  
	  
512851	   558256	   45405	   Contains	  DBL	  containing	  protein,	  UF	  
2	   842699	   855734	   13035	  
	  4	   1065176	   1144415	   79239	   Contains	  deveral	  Plasmodium	  exported	  proteins	  
5	   966314	   1181373	   215059	   Approximately	  4-­‐kb	  from	  pfmdr1	  
	  
1320756	   1325021	   4265	  
	  7	   409122	   470642	   61520	   Approximately	  3-­‐kb	  from	  pfcrt	  
	  
507357	   665385	   158028	  
	  
	  
1358889	   1380385	   21496	  
	  8	   449188	   585854	   136666	   Surrounding	  pfdhps	  
10	   1389354	   1434268	   44914	   Contains	  msp6	  and	  msp3.8	  
11	   1294082	   1295369	   1287	   Contains	  ama1	  
12	   800894	   1059078	   258184	   Surrounds	  pfgch1;	  several	  transcription	  factors	  
13	   102848	   106661	   3813	   Contains	  trap	  
	  
1419420	   1466484	   47064	  
	  14	   2982003	   3149504	   167501	   Contains	  msp7	  
UF	  =	  unknown	  function	  
	  
2.5 Results	  C	  
	  
2.5.1 Placing	  Malawi	  parasites	  in	  the	  global	  population	  structure	  of	  P.	  falciparum	  
	  
Using	   the	   same	   raw	   sequence-­‐processing	   pipeline	   applied	   to	   the	   Malawi	   data,	   SNPs	  
were	  called	  across	  all	  six	  populations.	  A	  total	  of	  294,187	  SNPs	  were	  identified	  across	  the	  six	  
populations:	  Chikwawa,	  Malawi	   (n=71,	  46%	  polymorphic);	  Kilifi,	  Kenya	   (n=37,	  30%);	  Bobo-­‐
Dioulasso,	   Burkina	   Faso	   (n=40,	   33%);	   Bamako,	   Mali	   (n=40,	   37%);	   Pailin,	   west	   Cambodia	  
(n=80,	  22%)	  and	  Mae	  Sot,	  Thailand	   (n=80,	  23%),	  with	  8%	  being	  specific	   to	  Malawi	  only.	  A	  
principal	   component	   analysis	   (PCA)	   of	   the	   SNPs	   revealed	   modest	   population	   differences	  
between	  Africa	  and	  Asia,	  within	  Southeast	  Asia,	  and	  small	  differences	  within	  Africa	  (Figure	  
2.13).	  These	  PCA	  results	  are	  also	  consistent	  with	  those	  previously	  published	  (Manske	  et	  al.	  
2012;	  Preston	  et	  al.	  2013).	  We	  further	  applied	  the	  SNP-­‐wise	  FST	  metric	  to	  measure	  genomic	  
divergence	  across	  the	  six	  populations.	  At	  a	  stringent	  genome-­‐wide	  cut-­‐off	  value	  (FST	  ≥0.2),	  
pairwise	   comparisons	   identified	   the	  most	   divergent	   alleles	   between	  Malawi	   and	   the	   five	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populations	   (Table	   2.7).	   Overall,	   there	   is	   high	   level	   of	   divergence	   in	   clag3.1	   and	   clag3.2	  
(genes	  implicated	  in	  the	  process	  of	  parasite	  invasion).	  Alleles	  encoding	  known	  drug	  targets	  
(e.g.,	  pfcrt-­‐K76T,	  pfdhps-­‐K540E,	  pfdhps-­‐A436G	  and	  pfmdr1-­‐N86Y)	  showed	  large	  divergence	  
between	   populations	   (Table	   2.8).	   These	   inter-­‐population	   differences	   may	   reflect	   local	  
historical	   parasite	   adaptation	   to	   anti-­‐malarial	   drug	   pressure,	   leading	   to	   fixation	   or	   near	  
fixation	  of	  the	  implicated	  drug	  resistant	  alleles.	  	  
	  
Figure	  2.13:	  Principal	  components	  analysis	  using	  SNPs	  differentiates	  P.	  falciparum	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Table	   2.6:	   Genes	   with	   multiple	   alleles	   with	   FST	   ≥0.2	   (P<0.001),	   stratified	   by	   parasite	  
population.	  Integers	  refer	  to	  the	  number	  of	  alleles	  per	  gene	  with	  FST	  ≥0.2.	  Blank	  entries	  
refer	  to	  lack	  of	  differentiating	  alleles	  in	  a	  given	  gene	  between	  populations	  compared.	  
Gene	  ID	   Gene	  product	   KENYA	   BFASO	   MALI	   CAMBODIA	   THAI	  
PF3D7_0113000	   Glutamic	  acid-­‐rich	  protein	    4	      
PF3D7_0202000	   Knob-­‐associated	  histidine-­‐rich	  protein	   2	       PF3D7_0209000	   6-­‐cysteine	  protein	    3	   4	     PF3D7_0302200	   Cytoadherence	  linked	  asexual	  protein	  3.2	       39	  PF3D7_0302500	   Cytoadherence	  linked	  asexual	  protein	  3.1	      36	   10	  PF3D7_0320400	   Oocyst	  capsule	  protein	      11	    PF3D7_0419900	   Phosphatidylinositol	  4-­‐kinase,	  P	      17	    
PF3D7_0501200	   Parasite-­‐infected	  erythrocyte	  surface	  protein	    3	      
PF3D7_0523000	   Multidrug	  resistance	  protein	  	   2	       
PF3D7_0525100	   Acyl-­‐CoA	  synthetase	  	    4	   4	     PF3D7_0527200	   Ubiquitin	  carboxyl-­‐terminal	  hydrolase,	  P	  	   2	       PF3D7_0628100	   HECT-­‐domain	  (ubiquitin-­‐transferase),	  P	     3	   12	   12	  PF3D7_0629500	   Amino	  acid	  transporter,	  P	  	   2	       PF3D7_0629700	   SET	  domain	  protein,	  P	   2	       
PF3D7_0704600	   Ubiquitin	  transferase,	  P	      10	   10	  
PF3D7_0709000	   Chloroquine	  resistance	  transporter	  	   2	    3	   1	   7	  
PF3D7_0709100	   Cg1	  protein	     3	   12	   11	  PF3D7_0709300	   Cg2	  protein	      19	   16	  PF3D7_0710000	   Conserved	  Plasmodium	  protein,	  UF	      19	   14	  PF3D7_0810800	   Dihydropteroate	  synthetase	    3	   3	   3	   2	  PF3D7_0824400	   Nucleoside	  transporter	  2	    3	   3	     
PF3D7_0826100	   E3	  ubiquitin-­‐protein	  ligase,	  P	  	      23	   27	  
PF3D7_0911300	   Cysteine	  repeat	  modular	  protein	  1	  	    3	   3	     
PF3D7_0927200	   Zinc	  finger	  protein,	  P	      10	    PF3D7_0929400	   High	  molecular	  weight	  rhoptry	  protein	  2	  	    5	   5	     PF3D7_1004800	   ADP/ATP	  carrier	  protein,	  P	       16	  PF3D7_1110200	   Pre-­‐mRNA-­‐processing	  factor	  6,	  P	       10	  PF3D7_1125700	   Kelch	  protein,	  P	    4	   4	     
PF3D7_1149000	   Antigen	  332,	  DBL-­‐like	  protein	       12	  
PF3D7_1221000	   Histone-­‐lysine	  N-­‐methyltransferase	      10	   12	  
PF3D7_1222600	   Transcription	  factor	  with	  AP2	  domain(s)	   2	    5	     
PF3D7_1223100	   cAMP-­‐dependent	  protein	  kinase	  regulatory	  subunit	  	   2	       PF3D7_1223300	   DNA	  gyrase	  subunit	  A	   2	       PF3D7_1223400	   Phospholipid-­‐transporting	  ATPase,	  P	  	   2	   4	   4	     PF3D7_1223500	   Conserved	  Plasmodium	  protein,	  UF	    3	   3	     PF3D7_1231800	   Asparagine-­‐rich	  protein,	  P	      10	    
PF3D7_1431200	   Conserved	  Plasmodium	  protein,	  UF	      15	   14	  
PF3D7_1452000	   Rhoptry	  neck	  protein	  2	  	     6	   5	       
KENYA	  (FST	  between	  Malawi	  and	  Kenya),	  B	  FASO	  (FST	  between	  Malawi	  and	  Burkina	  Faso	  (B	  FASO)),	  MALI	  (FST	  
between	  Malawi	  and	  Mali),	  CAMBODIA	  (FST	  between	  Malawi	  and	  Cambodia)	  and	  THAI	  (FST	  between	  Malawi	  
and	  Thailand	  (Thai)).	  Integers	  refer	  to	  number	  of	  alleles/gene	  with	  FST	  ≥0.2	  (P<0.001).	  UF	  =	  Unknown	  function,	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Table	  2.7:	  FST	  of	  known	  antimalarial	  drug-­‐resistance	  loci.	  Blanks	  infer	  very	  low	  FST.	  
Locus	   Mutation	   KENYA	   B	  FASO	   MALI	   CAMBODIA	   THAI	  
CRT	   K76T	   0.22	   0.25	   0.49	   1	   1	  
	   Q271E	   	   	   0.46	   0.98	   1	  
	   N326S	   	   	   	   0.82	   1	  
	   I356T	   	   	   	   0.83	   1	  
	   	   	   	   	   	   	  DHPS	   S436A	   	   0.35	   0.47	   	   	  
	   A437G	   	   0.28	   0.49	   	   	  
	   K540E	   	   0.91	   0.91	   0.34	   	  
	   A581G	   	   	   	   0.37	   0.61	  
	   	   	   	   	   	   	  MDR1	   N86Y	   0.37	   	   	   	   	  
	   N1226Y	   	   	   	   	   0.37	  	  	   D1246Y	   0.32	   	  	   	  	   	  	   	  	  
KENYA	  (FST	  between	  Malawi	  and	  Kenya),	  B	  FASO	  (FST	  between	  Malawi	  and	  Burkina	  Faso	  (B	  FASO)),	  MALI	  (FST	  
between	  Malawi	  and	  Mali),	  CAMBODIA	  (FST	  between	  Malawi	  and	  Cambodia)	  and	  THAI	  (FST	  between	  Malawi	  
and	  Thailand	  (Thai)).	  
	  
Table	  2.8:	  Allele	  frequencies	  of	  common	  drug	  resistant	  SNPs	  across	  all	  six	  populations.	  
Locus	   Mutation	   Malawi	   Kenya	   Mali	   Burkina	  Faso	   Thailand	   Cambodia	  
CRT	   K76T	   0	   0.306	   0.615	   0.364	   1	   1	  
	  
Q271E	   0	   0.226	   0.59	   0.231	   1	   0.993	  
	  
N326S	   0	   0.048	   0.013	   0.048	   1	   0.913	  
	  
I356T	   0	   0	   0.183	   0.087	   1	   0.917	  
DHPS	   S436A	   0.007	   0.025	   0.611	   0.489	   0.178	   0.329	  
	  
A437G	   1	   0.825	   0.386	   0.609	   1	   0.977	  
	  
K540E	   0.965	   0.808	   0	   0	   0.868	   0.406	  
	  
A581G	   0	   0	   0	   0	   0.782	   0.565	  
MDR	   N86Y	   0.028	   0.55	   0.256	   0.272	   0.012	   0.0176	  
	  
N1226Y	   0	   0.014	   0	   0	   0.575	   0.006	  
	  
D1246Y	   0	   0.425	   0.022	   0.065	   0	   0	  
	  
2.5.2 Inferring	  positive	  selection	  in	  Malawi	  P.	  falciparum	  using	  XPEHH	  
	  
The	   across	   population	   long-­‐range	   haplotype	   method,	   XP-­‐EHH,	   was	   applied	   to	  
compare	   Malawi	   to	   each	   of	   the	   other	   populations,	   to	   identify	   regions	   potentially	   under	  
recent	   directional	   selection.	   Several	   genes	   detected	   with	   extended	   haplotypes	   in	  Malawi	  
include	  pfdhps,	  ron2	  and	  trap,	  and	  near	  pfdhfr,	  pfmdr1	  and	  pfgch1,	  mostly	  consistent	  with	  
iHS	   results	   (Table	  2.10	  and	  P<0.00006).	   In	   the	  other	  populations,	  signals	  were	  detected	  at	  
pfdhps	  and	  pfcrt.	  Selective	  sweeps	  at	  pfdhps	  and	  pfcrt	   respectively	  are	  probable	  effects	  of	  
high	   SP	   drug	   pressure	   (in	  Malawi)	   and	   chloroquine	   (in	  Mali,	   Burkina	   Faso,	   Cambodia	   and	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Thailand).	   Interestingly,	   pfcrt	   and	   pfdhps	   extended	   haplotypes	   were	   observed	   between	  
Malawi-­‐Kenya	  and	  Malawi-­‐Thailand	  respectively;	  this	  is	  probably	  indicative	  of	  relatively	  high	  
prevalence	  of	  pfcrt	  mutations	   in	   Kenya	   as	   previously	   observed	   (Mwai	   et	   al.	   2009)	   and	   an	  
increase	  in	  prevalence	  of	  pfdhps	  mutations	  in	  Thailand.	  The	  lack	  of	  evidence	  for	  a	  selective	  
sweep	   in	   pfcrt	   in	   Malawi	   reflects	   the	   withdrawal	   of	   CQ	   and	   subsequent	   increase	   in	   the	  
ancestral	   CQ-­‐sensitive	   allele	   frequency	   from	   the	   re-­‐expansion	   of	   the	   minority	   of	   drug	  
susceptible	  parasites	   that	  may	  have	   survived	   in	   the	  population.	   This	  observation	   suggests	  
that	  parasites	  carrying	  the	  ancestral	  pfcrt	  alleles	  have	  greater	  fitness	   in	  the	  absence	  of	  CQ	  
pressure	   (Laufer	   et	   al.	   2006).	   The	   observed	   selective	   sweep	   surrounding	   the	   GTP	  
cyclohydrolase	  gene	  (pfgch1,	  PF3D7_1224000)	  on	  chromosome	  12	  is	  only	  unique	  to	  Malawi	  
in	   this	   study.	   The	   pfgch1	   gene	   is	   the	   first	   gene	   in	   the	   folate	   biosynthesis	   pathway,	   and	  
adaptive	  selection	  could	  result	  from	  SP	  drug	  pressure	  (Nair	  et	  al.	  2008).	  However,	  previous	  
studies	  of	  Thai	  parasites	  have	  also	  detected	  reduced	  microsatellite	  diversity	  and	   increased	  
LD	  flanking	  the	  pfgch1	  locus	  (Nair	  et	  al.	  2008).	  Across	  the	  Malawian	  population	  there	  did	  not	  
appear	  to	  be	  excess	  genomic	  coverage	   in	  the	  pfgch1	  gene	  (that	  could	  explain	  the	  positive	  
selection	  at	  this	  locus),	  but	  additional	  investigations	  should	  determine	  whether	  the	  locus	  is	  
amplified	   because	   it	  may	   indicate	   rapid	   recent	   spread	   of	   chromosomes	   carrying	  multiple	  
copies	  of	  pfgch1	  (Nair	  et	  al.	  2008).	  Positive	  directional	  selection	  in	  the	  trap	  gene	  is	  thought	  
to	   reflect	   genetic	   adaptation	   to	   divergent	   host	   ligands	   (Amambua-­‐Ngwa	   et	   al.	   2012a),	  
whose	   product	   have	   roles	   in	   the	   motility	   of	   sporozoites,	   invasion	   of	   hepatocytes	   and	  
mosquito	  salivary	  glands	  (Ejigiri	  et	  al.	  2012).	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Table	  2.9:	  Regions	  under	  directional	  selection	   in	  all	  six	  populations	   identified	  using	  XP-­‐
EHH	  (P<0.00006)	  
Population	   Chromosome	   Start	   End	   Size	  (bp)	   Comment	  
MALAWI	   1	   180314	   193846	   13532	  
 
  
487895	   489460	   1565	  
 
  
512383	   513033	   650	  
 
 
4	   755433	   881703	   126270	   Approximately	  6-­‐kb	  from	  pfdhfr	  
  
990908	   991327	   419	  
 
 
5	   1042259	   1109432	   67173	   Approximately	  8-­‐kb	  from	  pfmdr1	  
 
8	   532499	   585854	   53355	   Contains	  pfdhps	  
 
10	   1326109	   1327397	   1288	  
 
 
12	   461137	   473836	   12699	  
 
  
946416	   954490	   8074	   Approximately	  30-­‐kb	  from	  pfgch1	  
  
983440	   1016281	   32841	  
 
  
1004000	   1022661	   18661	  
 
 
13	   1465713	   1465965	   252	   Contains	  trap	  
 
14	   1688102	   1688881	   779	  
 
  
2135779	   2137007	   1228	   Contains	  rhoptry	  neck	  protein	  2	  
KENYA	   6	   1116365	   1222963	   106598	   Acetyl-­‐CoA	  synthetase,	  putative	  	  
 
7	   376423	   417661	   41238	   Contains	  pfcrt	  
 
8	   467328	   468623	   1295	   Asparagine-­‐rich	  antigen	  Pfa55-­‐14	  	  
MALI	   6	   1205649	   1290486	   84837	  
 
 
7	   376423	   470941	   94518	   Contains	  pfcrt	  
  
505661	   614698	   109037	  
 
  
1100440	   1326844	   226404	  
 
 
8	   468447	   469357	   910	  
 
 
11	   1006055	   1383842	   377787	  
 B	  FASO	   1	   487895	   489267	   1372	  
 
 
7	   432780	   507284	   74504	  
 
  
908940	   918733	   9793	  
 
 
8	   416971	   422505	   5534	   Plasmepsin	  X	  	  
THAILAND	   4	   709512	   771505	   61993	  
 
 
6	   1114625	   1289592	   174967	   Acetyl-­‐CoA	  synthetase,	  putative	  	  
 
7	   339092	   451640	   112548	   Contains	  pfcrt	  
 
8	   468447	   586054	   117607	   Contains	  pfdhps	  
  
703454	   712742	   9288	  
 
  
1108501	   1117018	   8517	  
 CAMBODIA	   6	   1109423	   1135810	   26387	   Acetyl-­‐CoA	  synthetase,	  putative	  	  
  
1287468	   1289915	   2447	  
 
 
7	   332719	   453986	   121267	   Contains	  pfcrt	  
  
875300	   931176	   55876	  
 
  
989974	   993421	   3447	  
  8	   468669	   479732	   11063	   Asparagine-­‐rich	  antigen	  Pfa55-­‐14	  	  
KENYA	   (XP-­‐EHH	  between	  Malawi	  and	  Kenya),	  B	  FASO	  (XP-­‐EHH	  between	  Malawi	  and	  Burkina	  Faso	   (B	  FASO)),	  
MALI	  (XP-­‐EHH	  between	  Malawi	  and	  Mali),	  CAMBODIA	  (XP-­‐EHH	  between	  Malawi	  and	  Cambodia)	  and	  THAILAND	  
(XP-­‐EHH	  between	  Malawi	  and	  Thailand).	  	  
	  
	  
2.6 Discussion	   	  
	  
	   	  77	  
This	  work	  has	  applied	  current	  sequencing	  technologies	  and	  genomics	  to	  investigate	  
genetic	  diversity,	  and	  the	  effect	  of	  immunity	  and	  antimalarial	  drugs	  selection	  on	  Malawi	  P.	  
falciparum	   genomes.	   Studies	   of	   this	   kind	   have	   successfully	   identified	   drug-­‐resistance	  
mechanisms	   and	   targets	   of	   naturally-­‐acquired	   immunity	   as	   candidate	   vaccine	   targets	  
(Kidgell	   et	   al.	   2006;	   Mackinnon	   and	   Marsh	   2010),	   but	   have	   not	   yet	   been	   conducted	   in	  
Malawi	   P.	   falciparum	   populations.	   Here	   examination	   of	   genetic	   variation	   is	   provided	   in	  
parasites	   from	   Chikwawa	   district,	   Malawi,	   where	   the	   parasite	   population	   is	   exposed	   to	  
naturally-­‐acquired	   immunity	  and	  was	  recently	  exposed	  to	   intense	  pressure	  from	  IRS,	   ITNs,	  
and	   ACTs.	   Previous	   studies	   have	   shown	   that	   human	   immune	   pressure	   produces	   genomic	  
regions	  with	  high	   levels	  of	  nucleotide	  diversity,	  while	  antimalarial	  drug	  pressure	   results	   in	  
regions	   with	   low	   diversity	   and	   extended	   haplotypes	   (Mu	   et	   al.	   2007,	   2010;	   Sabeti	   et	   al.	  
2006;	   Dharia	   et	   al.	   2010;	   Volkman	   et	   al.	   2007).	   This	   work	   has	   used	   population	   genetics	  
metrics	  exploiting	  these	  two	  principles	  to	  detect	  loci	  under	  balancing	  and	  positive	  selection	  
in	   a	   Malawi	   P.	   falciparum	   population.	   This	   population	   was	   also	   compared	   to	   five	  
geographically	   dispersed	   others	   using	   FST	   and	   XP-­‐EHH	   to	   detect	   regions	   of	   genetic	  
divergence	  and	  signatures	  of	  recent	  selective	  sweeps,	  respectively.	   In	  particular,	  searching	  
for	  high-­‐scoring	  SNP	  clusters	  gave	  strong	  indicators	  of	  positive	  selection.	  	  
Analysis	   using	   Tajima’s	   D	   identified	   potential	   genomic	   regions	   under	   balancing	  
selection,	   including	  six	  genes	  encoding	  merozoite	  invasion	  ligands:	  msp3.8,	  msp3,	  dbl-­‐msp,	  
eba175,	   ama1	   and	   surfin4.2.	   These	   antigens	   are	   exposed	   to	   the	   immune	   system	   on	   the	  
surface	   of	   merozoites	   or	   during	   erythrocyte	   invasion,	   and	   are	   highly	   polymorphic.	   Thus,	  
balancing	  selection	  at	   these	  genes	  maybe	  mediated	  by	  host	   immune	  system	  as	  previously	  
reported	  and	  have	  also	  been	   listed	  as	  possible	  candidates	   for	  vaccines	   in	  previous	  studies	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(Alexandre	   et	   al.	   2011;	   Baum	   et	   al.	   2003;	   Polley	   and	   Conway	   2001;	   Ochola	   et	   al.	   2010;	  
Tetteh	  et	  al.	  2009;	  Mu	  et	  al.	  2010;	  Amambua-­‐Ngwa	  et	  al.	  2012b).	  	  
Positive	  directional	   selection	  was	  detected	   in	  genomic	   regions	  near	  or	   surrounding	  
drug	   targets	   (pfmdr1,	  pfcrt,	   pfdhps	   and	   gch1)	   and	   in	   surface	   antigens	   such	   as	   trap,	   ron2,	  
msp3.8,	   ama1	   and	  msp7	   genes	   with	   important	   roles	   in	   invasion	   of	   host	   cells	   (Vulliez-­‐Le	  
Normand	  et	  al.	  2012;	  Tufet-­‐Bayona	  et	  al.	  2009;	  Ghosh	  et	  al.	  2009).	  Interestingly,	  several	  FST	  
test	  results	  reflect	  parasite	  adaptation	  to	  local	  drug	  selection.	  First,	   low	  FST	  values	  in	  pfcrt-­‐
K76T	   between	  Malawi	   and	   Kenya	  may	   reflect	   the	  withdrawal	   of	   CQ	   in	   these	   regions	   and	  
subsequent	   disparity	   in	   the	   reduction	   in	   the	   prevalence	   of	   resistance	   alleles	   to	   2-­‐4%	   in	  
Malawi	  and	  60%	  in	  Kenya	  (Nkhoma	  et	  al.	  2007;	  Mwai	  et	  al.	  2009).	  Second,	  the	  FST	  values	  in	  
pfcrt-­‐K76T	  between	  Malawi	  and	  Burkina	  Faso,	  and	  Malawi-­‐Mali	  are	  heterogeneous	  and	  may	  
suggest	  varying	  allele	  frequencies	  of	  K76T	  allele	  between	  Mali	  and	  Burkina	  Faso.	  Third,	  high	  
FST	  values	  in	  pfcrt-­‐K76T	  between	  Malawi	  and	  Cambodia,	  and	  Malawi-­‐Mali,	  suggest	  that	  this	  
mutation	  has	  reached	  fixation	  in	  Cambodia	  and	  Thailand;	   indeed,	  CQ	  remains	  the	  first-­‐line	  
treatment	   for	  P.	  vivax	  malaria	   in	   these	   two	  countries	  and	   thus	  may	  continue	   to	  select	   for	  
the	  resistant	  genotype	  (Setthaudom	  et	  al.	  2011).	  Fourth,	  fixation	  of	  pfdhps-­‐K540E	  between	  
Malawi	  and	  Mali,	  and	  Malawi-­‐Burkina	  Faso	  may	  reflect	  the	  use	  of	  SP	  for	  the	  treatment	  of	  
uncomplicated	  malaria	   and	   as	   intermittent	   preventive	   treatment	   in	   the	   two	  west-­‐African	  
countries,	  where	  the	  pfdhps-­‐K540E	  mutation	   is	  rare	  (Pearce	  et	  al.	  2009;	  Somé	  et	  al.	  2010;	  
Dicko	   et	   al.	   2010).	   High	   prevalence	   of	   pfdhps-­‐K540E	   and	   A437G	   is	   consistent	   with	   90%	  
prevalence	  of	  quintuple	  mutants	  in	  Malawi	  (Nkhoma	  et	  al.	  2007)	  and	  while	  437G	  is	  found	  all	  
over	   Africa	   the	   540E	   is	   largely	   absent	   in	   west	   Africa	   (Table	   2.8).	   Whilst,	   FST	   may	   reflect	  
differences	   in	  allele	   frequency	  due	   to	  differential	   selective	  pressure,	   they	  may	  also	   reflect	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simply	   random	  genetic	  drift.	   FST	   is	  dependent	  on	  absolute	  diversity,	  where	   regions	  of	   low	  
diversity	  in	  either	  population	  (or	  both)	  can	  result	  in	  high	  values,	  even	  if	  those	  regions	  have	  
not	  been	  selected	  differently.	  	  
Positive	  directional	  selection	  in	  chromosome	  12	  containing	  pfgch1	  and	  transcription	  
factors	  is	  also	  particularly	  interesting.	  In	  P.	  vivax	   it	   is	  thought	  to	  result	  from	  drug	  selection	  
(Dharia	  et	  al.	  2010).	  Mutations	  in	  these	  transcription	  factors	  are	  thought	  to	  be	  a	  source	  of	  
increased	   genetic	   variability	   that	   regulate	   gene	   expression	   whose	   products	   may	   include	  
drug-­‐resistance	   genes	   (Levine	   and	   Tjian	   2003).	   Increased	   expression	   levels	   of	   pvcrt	   have	  
been	   observed	   in	   CQ-­‐resistant	   parasites	   (Fernández-­‐Becerra	   et	   al.	   2009),	   and	   higher	  
expression	  levels	  of	  pvdhfr	  occurred	  in	  P.	  vivax	  isolates	  relative	  to	  P.	  falciparum,	  resulting	  in	  
the	  proposal	   that	  evolution	   in	   response	   to	  drug	  and	   immune	  pressure	  might	  be	  driven	  by	  
genetic	  changes	  in	  the	  corresponding	  transcription	  factors	  (Westenberger	  et	  al.	  2010).	  	  
In	   conclusion,	   this	   chapter	   describes	   the	   sequencing	   of	   93	   P.	   falciparum	   clinical	  
isolates	   sourced	   from	   uncomplicated	   malaria	   cases	   in	   Malawi	   and	   identification	   of	   loci	  
under	  selection.	  In	  addition,	  positive	  selection	  signals	  are	  identified	  by	  comparing	  Malawi	  to	  
five	   other	   dispersed	   P.	   falciparum	   populations.	   Further	   work	   could	   evaluate	   the	   role	   of	  
these	  loci	  in	  malaria	  intervention	  strategies.	  For	  example,	  the	  genetic	  variation	  may	  enable	  
monitoring	  of	  P.	  falciparum	  transmission	  dynamics	  as	  the	  epidemiology	  of	  malaria	  changes	  
over	  time	  in	  response	  to	  interventions	  (Volkman	  et	  al.	  2012).	  In	  particular,	  by	  using	  XP-­‐EHH	  
and	  FST	  it	  is	  shown	  that	  selection	  differences	  between	  geographically	  dispersed	  populations	  
reflect	  the	  history	  of	  antimalarial	  drug	  use	  and	  selection	  at	  any	  given	  time,	  whereas	  during	  
intense	   drug	   selection,	   wild-­‐type	   alleles	   are	   increasingly	   replaced	   by	   mutant	   alleles.	   The	  
ability	   to	   use	   this	   strategy	   to	   monitor	   local	   adaptation	   to	   drug	   pressure,	   monitoring	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transmission,	  and	  inform	  the	  type	  and	  timing	  of	  interventions	  is	  appealing.	  This	  knowledge	  
will	  now	  be	  used	  in	  Malawi	  to	  monitor	  the	  impact	  of	  ACTs,	  ITNs	  and	  IRS	  on	  the	  local	  parasite	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Chapter	  3	  
Genome-­‐wide	  identification	  of	  copy	  number	  variations	  in	  




Structural	   variation	   generally	   refers	   to	   polymorphisms	   that	   affect	   the	   genomic	  
structure,	  resulting	  into	  abnormal	  number	  of	  copies	  of	  one	  or	  more	  sections	  of	  the	  DNA.	  In	  
humans,	  it	  was	  initially	  thought	  that	  genome	  variation	  was	  mostly	  due	  to	  SNPs,	  but	  it	  later	  
become	  apparent,	  that	  structural	  variation	  of	  large	  scale	  duplication	  and	  insertions,	  occur	  at	  
a	  much	  greater	  extent	  (12%)	  than	  SNPs	  (Iafrate	  et	  al.	  2004;	  Redon	  et	  al.	  2006;	  Tuzun	  et	  al.	  
2005;	   Feuk	   et	   al.	   2006b).	   Their	   roles	   in	   determining	   natural	   phenotypic	   variations	   with	  
human	   health,	   disease	   and	   evolution	   have	   also	   been	   highlighted	   (Zhang	   et	   al.	   2009;	  
Stankiewicz	   and	   Lupski	   2010).	   Structural	   variation	   was	   originally	   defined	   as	   insertions,	  
deletions	   and	   inversions	   greater	   than	   1kb	   in	   size	   (Feuk	   et	   al.	   2006a)	   but	   has	   since	   been	  
widened	   to	   include	   smaller	   structural	   variants	   (for	   example,	   those	   >50-­‐bp	   in	   length),	  
particularly	  in	  the	  human	  genome.	  Currently,	  >50-­‐bp	  is	  used	  as	  an	  operational	  demarcation	  
between	   INDELs	   and	   copy	   number	   variants	   (CNV)	   (Feuk	   et	   al.	   2006a).	   In	   P.	   falciparum,	  
structural	   variation,	   particularly,	   CNV	   are	   increasingly	   being	   studied	   using	   techniques	   and	  
bioinformatics	  software	  mostly	  adopted	  from	  human	  genome	  projects.	  Application	  of	  these	  
methods	  has	  shown	  that	  CNV	  are	  also	  prevalent	   in	   this	  eukaryotic	  cell	  and	  act	  as	  a	  major	  
source	   of	   genomic	   variation	   determining	   key	   phenotypes	   such	   as	   drug	   resistance	   and	  
disease	  pathogenesis.	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3.2 Causes	  of	  structural	  variation	  
	  
P.	  falciparum	  is	  known	  to	  display	  vast	  genetic	  diversity	  throughout	  the	  genome	  and	  
especially	  in	  the	  subtelomeric	  compartments	  of	  the	  14	  chromosomes,	  accounting	  for	  up	  to	  
76%	  of	   polymorphisms	   (Gardner	   et	   al.	   2002;	  Volkman	  et	   al.	   2002).	   In	  P.	   falciparum	   these	  
subtelomeric	  regions	  are	  typified	  by	  blocks	  of	  repeat	  regions,	  large	  multi-­‐gene	  families	  (var,	  
rifin,	   stevor),	   are	   host-­‐spots	   of	   inter-­‐chromosomal	   recombination	   events	   and	   segmental	  
duplications	  and	  share	  considerable	  sequence	  homology	  amongst	  chromosomes	  (Ribacke	  et	  
al.	  2007;	  Kidgell	  et	  al.	  2006).	  Similar	  to	  smaller	  organisms	  such	  as	  S.	  cerevisiae	  where	  large	  
polymorphic	   variations	   have	   been	   mapped	   to	   subtelomeric	   regions,	   P.	   falciparum	   also	  
contain	   a	   number	   of	   large	   polymorphisms	   (>500-­‐bp)	   that	   are	   produced	   by	   various	  
mechanisms.	  During	  mitotic	  expansion	  of	  parasite	  populations,	  chromosome	  breakage	  and	  
healing	   provides	   a	  mechanism	   for	   loss	   of	   subtelomeric	   sequences	   and	   genes	   (Scherf	   and	  
Mattei	  1992).	  Expansion	  of	   large	  tandem	  repeated	  units	   ('amplicons')	  also	  generates	   large	  
chromosome	   size	   polymorphisms	   (Triglia	   et	   al.	   1991).	   Generation	   of	   polymorphic	  
variation/genetic	   diversity	   has	   also	   been	   observed	   through	   homologous	   recombination	  
among	  large	  blocks	  of	  subtelomeric	  repetitive	  elements	  (Corcoran	  et	  al.	  1988).	  	  
High	  recombination	  rates	  observed	   in	  P.	   falciparum	  generate	  high	  genetic	  diversity	  
by	  allowing	  selection-­‐targeted	  sites	  to	  evolve	  freely	  especially	  in	  regions	  containing	  the	  large	  
multi-­‐gene	  families,	  implicated	  in	  cell	  surface	  interactions	  (Bowman	  et	  al.	  1999;	  Gardner	  et	  
al.	   2002),	   that	   are	   under	   strong	   immune-­‐mediated	   diversifying	   selection	   (Volkman	   et	   al.	  
2002).	   Apart	   from	   sub-­‐telomeres,	   copy	   number	   polymorphisms	   occur	   throughout	   the	   P.	  
falciparum	   genome	   (Kidgell	   et	   al.	   2006),	   including	   in	   drug	   resistance	   and	   invasion	   genes,	  
suggesting	  that	  duplications	  and	  deletions	  are	  important	  determinants	  for	  parasite	  survival	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and	   malaria	   pathogenesis	   (Sidhu	   et	   al.	   2006;	   Van	   Tyne	   et	   al.	   2011;	   Triglia	   et	   al.	   2005).	  
Correlations	   between	   CNV	   and	   repetitive	   sequences	   in	   human	   genomes	   have	   also	  
highlighted	  the	  role	  of	  non-­‐allelic	  homologous	  recombination	  (NAHR)	  in	  generating	  diversity	  
(Hastings	   and	   Lupski	   2009;	   Conrad	   and	   Hurles	   2007)	   such	   as	   amplified	   genomic	   regions	  
(amplicons)	  breakpoints	  in	  the	  P.	  falciparum	  MQ	  resistance	  locus	  (pfmdr1)	  on	  chromosome	  
5	   and	   the	   GTP	   cyclohydrolase	   (gch1)	   occurring	   within	  microsatellite	   regions	   or	   repetitive	  
monomeric	  A/T	  tracts	  (Nair	  et	  al.	  2007,	  2008).	  
Gene	  deletions	  usually	  have	   little	  phenotypic	  effects,	  owing	  to	  several	  mechanisms	  
of	  compensation,	  and	  are	  usually	  purged	  from	  the	  populations	  (Gu	  et	  al.	  2003;	  Conrad	  et	  al.	  
2006).	  The	  first	  is	  the	  existence	  of	  duplicated	  genes	  that	  ensures	  that	  loss	  of	  function	  in	  one	  
copy	  can	  be	  compensated	  by	  other	  copy	  or	  copies.	  Second,	  compensation	  could	  also	  result	  
from	  alternative	  metabolic	  pathways	  or	  regulatory	  networks	  (Gu	  et	  al.	  2003).	  	  
3.3 Types	  of	  structural	  variation	  
	  
The	  spectrum	  of	  genetic	  variation	   in	  P.	  falciparum	   ranges	  from	  the	  single	  base	  pair	  
(SNP)	   (Wootton	  et	  al.	  2002)	   to	   large	  chromosomal	  events	  such	  as	   INDELs	   (Anderson	  et	  al.	  
2005),	   large	   scale	   deletions	   (Biggs	   et	   al.	   1989),	   amplifications	   (Cowman	   et	   al.	   1994),	  
inversions	   (Pologe	   et	   al.	   1990)	   and	   translocations	   (Hinterberg	   et	   al.	   1994)	   (Figure	   3.1).	  
Discovering	  the	  full	  extent	  of	  structural	  variation,	  particularly	  in	  field	  isolates	  and	  to	  be	  able	  
to	   genotype	   it	   routinely	   in	   order	   to	   understand	   its	   effects	   on	   malaria	   pathogenesis	   and	  
evolution	  will	  be	  important.	  
The	  bulk	  of	   analysis	   of	   diversity	   in	  P.	   falciparum	   has	   concentrated	  on	  detection	  of	  
SNPs	   and	   INDELs	   using	   oligonucleotide	   hybridization	   microarrays,	   CGH	   and	   DNA	   re-­‐
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sequencing	  methods	  (Kidgell	  et	  al.	  2006;	  Jiang	  et	  al.	  2008b;	  Volkman	  et	  al.	  2007;	  Manske	  et	  
al.	   2012).	   These	   studies	   have	   provided	   a	   map	   of	   diversity	   (including	   of	   recombination	  
hotspots)	  in	  the	  entire	  genome	  that	  is	  vast	  in	  subtelomeric	  regions	  of	  the	  14	  chromosomes,	  
higher	   in	   genes	   encoding	   surface	   and	   drug	   proteins,	   whereas	   low	   in	   genes	   encoding	  
mitochondrial,	  metabolic	   and	   cell	   growth	   proteins	   (Mu	   et	   al.	   2005,	   2007;	   Volkman	   et	   al.	  
2007,	   2002;	   Gardner	   et	   al.	   2002;	   Mu	   et	   al.	   2010;	   Jiang	   et	   al.	   2011).	   SNPs	   and	   INDELs,	  
together	  with	  large	  gene	  deletions	  and	  amplifications	  have	  been	  shown	  to	  play	  a	  significant	  
role	   in	   the	   adaptive	   biology	   of	   the	   parasite.	  With	   the	   advent	   of	  MPS,	   and	   a	   drastic	   cost	  
reduction	  of	  DNA	  sequencing,	  there	  is	  unprecedented	  genomic	  resolution	  and	  large	  sample	  
size	  applications	  that	  have	  accelerated	  efforts	  to	  map	  and	  catalogue	  structural	  variation	  in	  
several	  genomes	  (Sepúlveda	  et	  al.	  2013).	  	  
	  
	  
(A)	   Duplications	  –	  increases	  the	  number	  of	  copies	  of	  a	  chromosomal	  region	  	  	  
Tandem	  duplication	  –	  duplicated	  copy	  reside	  
adjacent	  to	  duplicated	  region	  	  
Non-­‐tandem/interspersed	  duplication	  –duplicated	  
copy	  reside	  further	  apart	  from	  duplicated	  region	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Figure	  3.1:	  Types	  of	  structural	  variation.	  Adapted	  from	  http://www.kean.edu/~ftamari	  	  
	  
Deletion	  –	  removal	  of	  a	  section	  of	  DNA	  
Inversion	  –	  half	  circle	  rotation	  of	  a	  section	  of	  DNA	  after	  double-­‐stranded	  break	  
Paracentric	  	  -­‐	  does	  not	  include	  the	  centromere	  
Pericentric	  -­‐	  includes	  the	  centromere	  	  	  	  
(B) 
(C)	  
(D)	  Translocation–	  attachment	  of	  part	  of	  a	  chromosome	  to	  another	  
Non-­‐reciprocal	  –	  unequal	  exchanges	  between	  non-­‐
homologous	  chromosomes	  
	  
Reciprocal	  –	  two	  different	  parts	  of	  non-­‐homologous	  
chromosomes	  switch	  places	  
(E)	  Transposition	  –	  movement	  of	  part	  of	  a	  chromosome	  from	  one	  position	  to	  
another	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3.4 Importance	  of	  structural	  variation	  in	  P.	  falciparum	  
3.4.1 Cytoadherence	  
	  
Unlike	   other	   human	  malaria	   parasites,	  mature	   P.	   falciparum-­‐infected	   erythrocytes	  
(IE)	  are	  known	  to	  adhere	  and	  block	  human	  microvasculature,	  leading	  to	  the	  development	  of	  
severe	   malaria	   (SM).	   Ligands	   expressed	   on	   the	   surface	   of	   IE	   can	   bind	   to	   a	   number	   of	  
endothelial	   cell	   receptors,	   including	   CD36,	   intercellular	   adhesion	   molecule-­‐1,	  
thrombospondin,	   chondroitin-­‐4-­‐sulfate,	   vascular	   cell	   adhesion	  molecule-­‐1,	   E-­‐selectin,	   and	  
platelet	   endothelial	   cell	   adhesion	  molecule-­‐1	   (Craig	   et	   al.	   2012;	   Chakravorty	   et	   al.	   2008).	  
One	  molecule	  identified	  on	  the	  surface	  of	  IE,	  known	  as	  P.	  falciparum	  erythrocyte	  membrane	  
protein-­‐1	   (PfEMP-­‐1)	   encoded	   by	   var	   genes,	   has	   been	   correlated	   with	   this	   cytoadherence	  
(Scherf	   et	   al.	   2008).	  An	   important	   feature	  of	  P.	   falciparum	   intra-­‐erythrocytic	   stages	   is	   the	  
parasite’s	  ability	  to	  export	  specific	  proteins	  to	  the	  IE	  surface,	  thus	  modifying	  the	  surface	  of	  
IE	  to	  become	  rigid	  and	  inflexible.	  A	  reduced	  flexibility	  of	  IE	  makes	  their	  circulation	  through	  
the	  microvasculature	  difficult	  and	  favours	  their	  adhesion	  to	  endothelial	  cells	  (Dondorp	  et	  al.	  
2004).	  Higher	   levels	  of	   IE	  seen	   in	  cerebral	  vessels	  of	  patients	  dying	   from	  CM	  compared	  to	  
non-­‐CM	  cases	  demonstrated	  involvement	  of	  IE	  cytoadhesion	  in	  the	  brain	  to	  cerebral	  malaria	  
(MacPherson	  1985).	  The	  point	  of	  contact	  for	  this	  cytoadhesion	  was	  identified	  as	  a	  knob-­‐like	  
structure	   on	   the	   surface	   of	   IE	   caused	   by	   deposition	   of	   knob-­‐associated	   His-­‐rich	   protein	  
(KAHRP)	   under	   the	   red	   cell	   membrane,	   that	   contains	   several	   proteins	   including	   PfEMP1	  
(MacPherson	  1985;	  Howard	  et	  al.	  1990).	  A	  major	  contribution	  of	  KAHRP	   in	  cytoadherence	  
was	   illustrated	   in	   in	  vitro	   culture	  of	  P.	   falciparum	  where	  some	  parasites	   lost	   the	  ability	   to	  
produce	  knobs	  and	  subsequently	  cytoadherence	  ability.	  This	  loss	  of	  function	  was	  shown	  to	  
be	  a	  consequence	  of	  subtelomeric	  deletions	  of	  the	  region	  of	  chromosome	  2	  containing	  the	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kahrp	  gene	  (Biggs	  et	  al.	  1989).	  Subtelomeric	  deletions	  have	  also	  been	  shown	  to	  be	  involved	  
in	   a	   loss	   of	   IE	   cytoadherence	   through	   deletion	   of	   genes	   encoding	   adhesion	   molecules	  
(Trenholme	   et	   al.	   2000).	   In	   this	   study	   they	   showed	   that	   targeted	   gene	   disruption	   of	  
cytoadherence	  linked	  asexual	  gene	  on	  chromosome	  9	  (clag9)	  reduced	  cytoadherence	  to	  C32	  
human	   melanoma	   cells	   and	   CD36.	   Antibodies	   raised	   against	   clones	   with	   disrupted	   clag9	  
gene	  did	  not	  react	  to	  it.	  
3.4.2 Anti-­‐malarial	  drug	  resistance	  
	  	  
Amplifications	  on	  chromosome	  12	  of	  GTP	  cyclohydrolase	  1,	   the	  first	  enzyme	   in	  the	  
folate	  biosynthesis	  pathway	  is	  likely	  due	  to	  compensation	  for	  the	  decreased	  efficiency	  of	  the	  
folate	   pathway	   caused	   by	  mutations	   in	  pfdhps	   and	  pfdhfr	   (Kidgell	   et	   al.	   2006;	   Nair	   et	   al.	  
2008).	   The	   importance	   of	   the	  multidrug	   resistance	   (MDR)	   gene	   (pfmdr1)	   copy	   number	   in	  
determining	  the	  P.	  falciparum	  susceptibility	  to	  a	  variety	  of	  antimalarial	  drugs	  has	  been	  well	  
documented.	  This	  gene	  is	  a	  member	  of	  ABC	  transporter	  family,	  is	  located	  on	  chromosome	  5	  
and	  encodes	  a	  predicted	  12-­‐transmembrane-­‐domain	  protein	  (also	  known	  as	  “Pgh-­‐1”)	  (Foote	  
et	   al.	   1989),	   which	   localizes	   to	   the	   parasite	   digestive	   vacuole,	   a	   site	   of	   action	   of	   CQ	   and	  
other	  quinoline-­‐based	  antimalarial	  drugs,	  including	  quinine	  (QN)	  (Cowman	  et	  al.	  1991;	  Sidhu	  
et	   al.	   2006).	   Development	   of	   resistance	   has	   rendered	   several	   drugs	   including	   CQ	   and	   SP	  
ineffective,	  and	  of	  concern	  now,	  are	  reports	  of	  drug	  failure	  of	  currently	  used	  first	  line	  drug,	  
ACT.	  	  
CQ	   resistance	   in	   P.	   falciparum	   provided	   a	   classic	   example	   of	   how	   this	   parasite	  
evolved	   to	   overcome	  drug	   pressure	   and	  has	   been	   replicated	   in	   latter	   studies	   that	   sort	   to	  
elucidate	   resistance	   to	   other	   drugs.	   A	   decrease	   in	   CQ	   concentration	   in	   resistant	   parasites	  
more	  than	  in	  sensitive	  ones	  was	  linked	  to	  CQ	  resistance	  phenotype	  (Krogstad	  et	  al.	  1987).	  A	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complex	  mechanism	  was	  observed	  between	  P.	  falciparum	  response	  to	  CQ	  and	  other	  drugs,	  
where	  MQ-­‐selected	   parasite	   lines	   showed	   increased	   expression	   of	   the	   pfmdr1	   gene,	  MQ	  
resistance,	   decreased	   CQ	   resistance	   and	   cross-­‐resistance	   to	   HF	   and	   QN	   (Cowman	   et	   al.	  
1994).	   A	   decreasing	  pfmdr1	   copy	   number	  was	   reported	   to	   heighten	   susceptibility	   to	   ACT	  
regimens	  including	  LF	  and	  ART	  drugs	  (Sidhu	  et	  al.	  2006)	  
More	   recently,	   a	   member	   of	   MSP3	   multigene	   family,	   merozoite	   surface	   protein	  
encoded	   by	   msp3.8	   gene	   was	   associated	   with	   antimalarial	   drug	   resistance.	   Through	  
functional	   testing	   using	   genome-­‐wide	   association	   approach,	   this	   study	  demonstrated	   that	  
msp3.8	   overexpression	   in	  P.	   falciparum	  decreased	   sensitivity	   to	  HF,	  MQ,	   and	   LF	   and	   that	  
increased	   gene	   copy	   number	   mediated	   resistance	   (Van	   Tyne	   et	   al.	   2011).	   Interestingly,	  
positive	  selection	  was	  also	  detected	  at	  this	  locus	  in	  this	  analysis.	  
3.5 Detecting	  structural	  variation	  in	  P.	  falciparum	  
	  
Originally	   developed	   to	   profile	   RNA,	   microarrays	   have	   now	   been	   used	   to	   detect	  
SNPs,	  gene	  duplications	  and	  loss.	  Microarray	  methods	  are	  based	  on	  hybridization	  of	  target	  
DNA	   to	   immobilized	   cDNA	   oligonucleotide	   probes	   in	   glass	   slides.	   Commonly	   used	  
microarrays	   for	   detecting	   CNV	   are	   array-­‐CGH	   and	   SNP	   microarrays	   with	   Affymetrix	   and	  
Illumina	  being	   the	   leading	  brands.	  However,	   sequencing-­‐based	  methods	   for	   the	  detecting	  
CNV	  are	  becoming	  more	  cost-­‐effective	  and	  popular,	  and	  several	  tools	  have	  been	  developed	  
to	  detect	  CNV	  e.g.,	  Delly	  (Rausch	  et	  al.	  2012),	  FREEC	  (Boeva	  et	  al.	  2011),	  CNVnator	  (Abyzov	  
et	  al.	  2011).	  
3.5.1 Hybridization-­‐based	  SNP	  micro-­‐array	  methods	  
	  	  
SNP	  microarrays	  have	  been	  used	  to	  determine	  genomic	  copy	  number.	  In	  this	  method	  
	   	  89	  
20	  matched	  and	  mismatched	  probe	  pairs	  that	  are	  25	  bases	  long	  are	  designed	  to	  each	  SNP	  
allele.	   Only	   the	   test	   sample	   is	   hybridized,	   with	   no	   competitively	   hybridizing	   reference	  
sample	  (co-­‐hybridization	  of	  two	  DNA)	  as	  in	  array-­‐CGH.	  To	  improve	  the	  signal-­‐to-­‐noise	  ratio,	  
the	   DNA	   is	   digested	  with	   a	   restriction	   enzyme	   and	   ligated	  with	   fluorescent	   adapters	   and	  
then	   the	   smaller	   fragments	  amplified	  using	  universal	  primers	   to	   reduce	   the	   complexity	  of	  
the	  hybridization.	  The	   intensity	  of	   the	  fluorescence	  upon	  binding	   is	  used	  as	  a	  measure	  for	  
the	  matching	  sequences	  in	  the	  sample.	  For	  the	  detection	  of	  CNV,	  the	  signal	  intensities	  of	  the	  
match	   and	   mismatch	   probes	   are	   clustered	   and	   compared	   with	   values	   from	   another	  
individual	   (or	   group	   of	   individuals)	   and	   relative	   copy	   number	   per	   locus	   is	   determined	  
(Winchester	  et	  al.	  2009;	  Carter	  2007).	  
This	   method	   has	   a	   number	   of	   advantages	   such	   as	   its	   ability	   to	   be	   used	   in	   SNP	  
genotyping	   and	   targeted	   copy	   number	   analysis.	   It	   also	   requires	   less	   sample	   volume	   per	  
experiment	  (as	  compared	  to	  CGH)	  and	  is	  cost	  effective	  allowing	  more	  sample	  analysis	  on	  a	  
limited	  budget.	  Disadvantages	   include	  being	  biased	   towards	  detecting	  mostly	   known	  CNV	  
(as	  SNP	  chip	  coverage	  are	  biased	  towards	  known	  SNPs)	  and	  because	  CNV	  are	  most	  common	  
in	  regions	  containing	  high	  levels	  of	  segmental	  duplication	  (such	  as	  sub-­‐telomeres)	  with	  low	  
SNP	   coverage,	   SNP	   arrays	   may	   decrease	   the	   number	   of	   CNV	   or	   polymorphisms	   typed	  
(Winchester	  et	  al.	  2009).	  Cheeseman	  et	  al	   (Cheeseman	  et	  al.	  2009),	   successfully	  used	   this	  
method,	   a	   custom	   designed	   Affymetrix	   PFSANGER	   GeneChip	   array	   to	   describe	   CNV	  
throughout	   the	   P.	   falciparum	   genome	   and	   reported	   that	   they	   form	   a	   major	   source	   of	  
genetic	  variation	  in	  P.	  falciparum.	  He	  observed	  that	  CNV	  allow	  adaptive	  expansion	  of	  diverse	  
gene	   families	   whilst	   copy	   numbers	   of	   core	   “housekeeping”	   genes	   are	   maintained	   by	  
negative	  selection.	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3.5.2 Array-­‐CGH	  
	  
Array-­‐CGH	   is	   widely	   used	   in	   detecting	   CNV	   by	   competitively	   hybridizing	   two	  
fluorescently	   labelled	   samples	   to	   the	   target	   DNA	   (cohydridization	   technique).	   Briefly,	   the	  
experimental	   and	   reference	   DNA	   are	   fragmented	   in	   size	   and	   differentially	   fluorescently	  
labelled	   and	   hybridized	   in	   duplicate	   together	   to	   the	   array.	   The	   resulting	   fluorescence	  
ratio/signal	   intensity	   is	  measured	  and	  quantified.	  Previously,	  DNA	  sequences	  were	  used	  to	  
construct	  arrays	   included	   larger-­‐insert	  clones	   (40–200-­‐kb	   in	  size),	   small	   insert	  clones	   (1.5–
4.5-­‐kb),	   cDNA	   clones	   (0.5–2-­‐kb),	   and	   genomic	   PCR	   products	   (100-­‐bp–1.5-­‐kb)	   and	   this	  
resulted	   to	  CNV	  detection	  at	   low	  resolution.	  However,	  many	  developments	  made	   in	  array	  
technology	   over	   the	   past	   years	   have	   led	   to	   an	   increase	   in	   resolution	   at	   which	   CNV	   are	  
detected	  by	  increasing	  number	  of	  features	  (“spots”)	  and	  using	  shorter	  DNA	  sequences	  e.g.,	  
oligonucleotides	   (at	   25-­‐80bp).	   However,	  much	   of	   resolution	   of	   an	   array	   across	   the	  whole	  
genome	   still	   depends	   on	   the	   number,	   distribution	   and	   lengths	   of	   probes.	   The	   ability	   to	  
detect	  CNV	  also	  largely	  depends	  on	  signal-­‐to-­‐noise	  ratio	  and	  probe	  response	  characteristics.	  
Normalization	  is	  also	  often	  needed	  to	  correct	  for	  experimental	  biases	  for	  GC/AT	  content	  in	  
the	   DNA.	   The	   main	   advantage	   of	   the	   array-­‐CGH	   to	   others	   is	   the	   co-­‐hybridization	   of	   the	  
experimental	  and	  reference	  DNAs	  where	  the	  reported	  fluorescent	  ratios	  are	  influenced	  less	  
by	   spotted	   probe	   concentration	   (signal	   intensity)	   and	   variations	   in	   slide	   production	   and	  
processing	  (Carter	  2007;	  Ylstra	  et	  al.	  2006).	  	  
3.5.3 Sequencing	  based	  computational	  approaches	  (SBC)	  
	  
Next	   generation	   sequencing	   techniques	   (NGS)	   have	   revolutionized	   SNP	   genotyping	  
and	  structural	  variation	  discovery,	  and	  are	  slowly	  replacing	  microarrays.	  Unlike	  array-­‐based	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methods	  that	  can	  only	  detect	  gains	  and	  losses	  in	  respect	  to	  the	  reference	  used	  to	  design	  the	  
probes,	   sequencing	   based	   methods	   can	   detect	   previously	   unknown	   polymorphisms	   and	  
variants	  such	  as	  inversions,	  translocations	  (Figure	  3.2)	  and	  thus	  the	  higher	  cost	  is	  justified.	  In	  
SBC,	   smaller	   variants	   and	   the	   exact	   location	   of	   a	   variation	   breakpoint	   are	   also	   easily	  
detected	  at	  high	  resolution.	  Although	  more	  expensive	  than	  array-­‐based	  methods,	  SBC	  can	  
be	   robustly	   used	   in	   high	   throughput	   large-­‐scale	   studies	   as	   shown	   with	   human	   genome	  
projects	   such	   as	   the	   1000	   Genomes	   project.	   However,	   analysis	   of	   sequence-­‐based	   data	  
requires	  more	  computational	  work,	  but	   is	  superior	  to	  array	  based	  computational	  methods	  
which	   are	   limited	   by	   the	   size	   and	   breakpoint	   resolution	   of	   prediction	   which	   is	   directly	  
correlated	  to	  the	  density	  of	  the	  probes	  on	  the	  array,	  which	  in	  turn	   is	   limited	  by	  either	  the	  
density	   of	   the	   array	   itself	   (for	   array-­‐CGH)	   or	   by	   the	   density	   of	   known	   SNP	   loci	   (for	   SNP	  
arrays)	  (Carter	  2007;	  Alkan	  et	  al.	  2011;	  Medvedev	  et	  al.	  2009).	  
There	  are	  four	  general	  strategies	  for	  SV	  discovery	  in	  SBC	  and	  largely	  rely	  on	  mapping	  
sequencing	   reads	   to	   the	   reference	   genome,	   Pf3D7	   (with	   very	   few	   involving	   de	   novo	  
assembly),	  in	  the	  case	  of	  P.	  falciparum	  and	  subsequently	  identifying	  genomic	  differences.	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Figure	  3.2:	  Structural	  variation	  sequence	  discovery	  methods	  using	  (A)	  read	  pair,	  (B)	  read	  
depth,	  (C)	  split	  read	  and	  (D)	  sequence	  assembly	  methods.	  A	  basic	  deletion	  event	  occurs	  
when	  a	  mate	  pair	  maps	  to	  the	  corresponding	  regions	  of	  the	  reference,	  but	  the	  insert	  size	  
is	  less	  than	  the	  mapped	  distance.	  Conversely,	  an	  event	  is	  an	  insertion,	  if	  the	  insert	  size	  is	  
greater	  than	  the	  mapped	  distance.	  Insertion	  may	  involve	  a	  novel	  sequence	  or	  a	  mobile-­‐
element.	   A	   mobile	   element	   insertion	   can	   result	   from	   translocations	   or	   duplications.	  
Duplications	  can	  occur	  as	  tandem	  duplications,	  where	  the	  duplicated	  segment	  remains	  
adjacent	  to	  the	  source	  DNA,	  or	  interspersed,	  where	  the	  duplicated	  DNA	  is	  incorporated	  
elsewhere	   in	  the	  genome.	  These	  events	  may	  occur	  within	  a	  single	  chromosome	  (intra-­‐
chromosomally)	   or	   inter-­‐chromosomally	   (between	   different	   chromosomes).	   A	   basic	  
inversion	  signature	  occurs	  when	  the	  order	  of	  the	  two	  mates	  mapping	  to	  the	  reference	  is	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3.5.3.1 Read	  pair	  methods	  
	  
Current	   sequencing	   technologies	   are	   capable	   of	   generating	   paired-­‐end	   or	   mate-­‐
paired	   reads.	   In	   read	   pair	   sequencing	   (producing	   paired-­‐end	   reads),	   genomic	   DNA	   is	  
fragmented	   into	   short	   segments/libraries	   (approximately	   300-­‐500-­‐bp),	   followed	   by	  
sequencing	  of	  both	  ends	  of	  the	  segment.	  In	  mate-­‐pair	  sequencing,	  a	  circularized	  fragment	  is	  
used.	   Genomic	   DNA	   is	   fragmented	   and	   size-­‐selected	   inserts	   (usually,	   1.5-­‐20-­‐kb)	   are	  
circularized	   and	   linked	   by	   means	   of	   an	   internal	   adaptor,	   to	   create	   mate-­‐pairs.	   The	  
circularized	   fragment	   is	   then	   randomly	   sheared,	   and	   segments	   containing	   the	   adaptor	  
purified	   and	   sequenced	   to	   generate	  mate	   pairs.	  Mate	   pair	   libraries,	   compared	   to	   paired-­‐
end,	   are	   more	   DNA	   intensive	   owing	   to	   the	   low	   yield	   of	   circularization	   of	   large	   DNA	  
molecules.	  In	  this	  method,	  variation	  in	  insert	  sizes	  plays	  an	  important	  role	  in	  SV	  detection,	  
for	  example	  the	  large	  insert	  for	  mate-­‐pair	   libraries	  allows	  for	  detection	  of	   larger	  structural	  
events	   than	  do	  paired-­‐end	   libraries.	  However,	  paired-­‐end	   reads	  provide	   tighter	   insert-­‐size	  
distributions	  and	  because	  both	  ends	  of	   library	   fragments	  are	   sequenced,	   it	   is	   valuable	   for	  
highly	   repetitive	   genomes;	   aligning	   at	   least	   one	   end	   read	   of	   a	   pair	   uniquely	   onto	   the	  
reference	  sequence	  provides	  sufficient	  certainty	  that	  the	  read	  pair	  is	  uniquely	  mapped	  to	  its	  
locus	  of	  origin.	  Equally	  disadvantageous	  is	  aligning	  short,	  single	  end	  or	   ‘fragment’	  reads	  to	  
the	  genome	  which	  results	   in	  a	  higher	  proportion	  of	  non-­‐unique	  reads	  that	  cannot	  be	  used	  
for	  variant	  discovery	  (Mardis	  2011;	  Alkan	  et	  al.	  2011;	  Medvedev	  et	  al.	  2009).	  	  
Read	   pairs	   are	   mapped	   back	   to	   the	   reference	   genome	   to	   detect	   SV.	   Mapping	  
span/distance	   and	   orientation	   of	   the	   reads	   to	   the	   reference	   genome	   are	   assessed	   and	   a	  
discordant	  distance	  or	  orientation	  of	   the	   read	  pair	   indicates	   the	  occurrence	  of	   a	   genomic	  
rearrangement	  (Figure	  3.2A).	  Read	  pairs	  aligning	  too	  far	  apart	  than	  the	  expected	  mapping	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distance	   suggests	   a	  deletion	   in	   sample/insertion	   in	   reference	   (where	   insert	   size	   is	   smaller	  
than	  mapping	   distance),	  whereas	   read	   pairs	  mapping	   closer	   together	   are	   indicative	   of	   an	  
insertion.	   A	   novel	   insertion	   is	   produced	   when	   only	   one	   end	   of	   a	   read	   pair	   maps	   to	   the	  
reference	   while	   the	   others	   do	   not.	   Orientation	   inconsistencies	   predict	   inversion	  
breakpoints.	   Interspersed	   duplications	   or	   translocations	   are	   detected	   by	   more	   complex	  
patterns	   where	   in	   several	   pairs	   one	   of	   the	   reads	   maps	   to	   a	   different	   location	   or	  
chromosome.	  Finally,	  tandem	  duplications	  can	  be	  detected	  by	  read	  pairs	  that	  have	  a	  correct	  
orientation,	  but	  are	  reversed	  in	  their	  order	  and	  have	  differences	  in	  their	  span	  (Alkan	  et	  al.	  
2011;	  Medvedev	  et	  al.	  2009).	  Several	  tools	  such	  as	  Delly	  (Rausch	  et	  al.	  2012)	  are	  based	  on	  
read	  pair	  technology.	  
3.5.3.2 Read	  depth	  methods	  
	  
Also	  known	  as	  depth	  of	  coverage	  (DOC),	  it	  is	  probably	  the	  best	  method	  for	  predicting	  
copy	  numbers	  (Alkan	  et	  al.	  2009).	  DOC	  assumes	  a	  random	  Poisson	  distribution	  in	  mapping	  
depth	  and	  any	  deviation	  from	  this	  distribution	  is	  assumed	  to	  be	  due	  to	  copy	  number	  in	  the	  
sequenced	  genome	  (Bailey	  et	  al.	  2002).	  The	  basic	  concept	   is	   that	  a	  duplicated/gain	  region	  
will	  show	  higher	  read	  depth	  while	  deleted/loss	  region	  will	  show	  reduced	  read	  depth	  (Figure	  
3.2B).	  The	  main	  disadvantage	  of	  this	  method	  is	  that	  only	  CNV	  can	  be	  detected.	  Because	  it	  is	  
largely	  related	  to	  sequence	  coverage,	  sequence	  biases	  will	  affect	  SV	  detection,	  for	  example,	  
in	  P.	  falciparum	  with	  AT	  rich	  and	  repeat	  regions,	  are	  sequenced	  less	  reliably	  with	  low	  read	  
depth,	   while	   GC-­‐rich	   will	   have	   higher	   read	   depth.	  Mis-­‐mapped	   reads	   will	   also	   negatively	  
influence	   SV	   detection.	   Larger	   variants	   are	   more	   reliably	   detected	   than	   smaller	   ones	   as	  
statistical	  power	  increases	  with	  the	  size	  (Harismendy	  et	  al.	  2009).	  Methods	  that	  have	  used	  
this	  approach	  include	  CNVnator	  (Abyzov	  et	  al.	  2011)	  and	  FREEC	  (Boeva	  et	  al.	  2011).	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3.5.3.3 Split-­‐read	  methods	  
	  
In	  split	  read	  method	  un-­‐mappable	  or	  partially	  mappable	  reads	  are	  used	  to	  detect	  SV	  
(Figure	   3.2C).	   A	   broken	   read	   alignment	   to	   the	   reference	   genome	   defines	   SV	   breakpoint	  
(‘split’	   sequence	  read	  signature).	  Split	   reads	  mapping	  to	   the	  reference	  genome	   in	  parts	  or	  
showing	   a	   continuous	   stretch	   of	   alignment	   gaps	   indicates	   a	   deletion	   in	   the	   sample	   or	   an	  
insertion	   in	   the	   reference.	   Reads	   spanning	   tandem	   duplications	   will	   have	   the	   split	   read	  
mapping	   in	   reverse	   order.	   Interspersed	   duplications	   or	   inter-­‐chromosomal	   translocations	  
are	   defined	   by	   reads	   mapping	   partly	   to	   the	   duplicated	   region	   or	   another	   chromosome.	  
Clustering	  of	   reads	   is	  used	   to	   increase	   the	   reliability	  of	   SV	  detection	   in	   read	  pair	  method.	  
This	  method	   is	   powerful	   in	   detecting	   SV	   as	   small	   as	   a	   single	   base	   pair,	   but	   the	   power	   is	  
greatly	  reduced	  by	  shorter	  read	  lengths	  as	  the	  length	  of	  a	  split	  read	  generated	  from	  shorter	  
reads	  is	  rarely	  uniquely	  mapped	  to	  the	  reference	  genome.	  Therefore,	  this	  method	  is	  greatly	  
affected	   by	   the	   use	   of	   current	   NGS	   platforms	   that	   produce	   short	   reads.	   However,	   NGS	  
technologies	  generating	  longer	  reads	  will	  make	  this	  approach	  more	  powerful.	  	  
3.5.3.4 Sequence	  assembly	  	  
	  
A	   complete	   genome	   sequencing	   approach	   using	   technologies	   that	   produce	   long	  
sequence	  reads,	  would	  allow	  an	  accurate	  whole	  genome	  assembly	  and	  thereby	  identifying	  
all	   SV	   (accurately	   identifying	   breakpoints)	   by	   comparing	   it	   to	   a	   high	   quality	   reference	  
genome	   (Miller	   et	   al.	   2010)	   (Figure	   3.2D).	   This	   approach	   is	   possible	   using	   the	   ‘split’	   read	  
method	   to	   detect	   SV,	   but	   its	   application	   is	   difficult	   due	   to	   short	   reads	   lengths	   that	   are	  
produced	   by	   current	   NGS	   methods	   that	   require	   a	   combination	   of	   de	   novo	   and	   local	  
assembly	   algorithms	   to	   produce	   contigs	   that	   can	   be	   compared	   to	   a	   reference	   genome	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(Miller	   et	   al.	   2010).	   De	   novo	   assembly	   is	   more	   accurate	   when	   dealing	   with	   highly	  
characterisable	   or	   unique	   genomic	   regions,	   but	   its	   application	   is	   more	   limited	   when	  
identifying	  SV	  in	  repetitive	  regions	  or	  highly	  polymorphic	  regions	  such	  as	  sub-­‐telomeres	  in	  P.	  
falciparum.	  
To	   provide	   a	   comprehensive	   analysis	   of	   copy	   number	   variation	   (mainly	   gains	   and	  
losses)	   in	   a	   Malawian	   P.	   falciparum	   population,	   two	   complimentary	   methods	   using	   read	  
depth	   coverage	   principle	   were	   used,	   FREEC	   (Boeva	   et	   al.	   2011)	   and	   Poisson	   hierarchical	  
modelling	  approach	  (PG,	  developed	  by	  Sepúlveda	  et	  al.	  2013).	  In	  theory	  these	  two	  tests	  rely	  
on	   assumptions	   that	   deletions	   show	   regions	   with	   extremely	   low	   coverage	   whereas	  
amplifications	   are	   found	   in	   regions	  with	   exceptionally	   high	   coverage.	   Particularly,	   the	  PG	  
method	  was	   used	   because	   of	   two	   reasons:	   that	   it	   uses	   read	   depth	   of	   coverage	   approach	  
(one	   of	   the	   best	   in	   detecting	   amplification	   and	   deletions)	   and	   it	   is	   flexible	   and	   robust	   in	  
handling	  different	  patterns	  of	  data,	  for	  example	  those	  generated	  by	  NGS	  where	  coverage	  is	  
never	  uniform	  across	  all	   samples	  and	   individual	   isolates	  appear	  unique.	   In	   this	   scenario,	  a	  
test	  that	   is	  performed	  across	  all	  samples	  with	  default	  settings	   is	   less	  sensitive	  as	   it	   fails	  to	  
deal	  with	  underlying	  uniqueness	  of	  each	  sample	  data.	  The	  PG	  method	  had	  also	  been	  tested	  
in	  P.	   falciparum	   lab	  and	  clinical	   isolates	  and	  was	   found	   to	  be	  very	  effective	  and	  sensitive,	  
accurately	   measuring	   CNV	   including	   previously	   identified	   ones,	   and	   outperforming	   other	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Table	  3.1:	  List	  of	  important	  P.	  falciparum	  CNV	  previously	  detected.	  	  
Gene	   Name	   CNV	   Method	  
PF3D7_0523000	   Multidrug	  resistance	  protein	  	   Amp	   PG/PCR	  
PF3D7_0302200	   Cytoadherence	  linked	  asexual	  protein	  3.2	   Del	   PG/PCR	  
PF3D7_0424400	   SURFINs	   Dup	   PCR	  
PF3D7_0202000	   Knob-­‐associated	  histidine-­‐rich	  protein	   Del	   PFGE	  
PF3D7_0935800	   Cytoadherence	  linked	  asexual	  protein	  9	   Del	   PCR/SNP	  array	  
PF3D7_0402300	   Reticulocyte	  binding	  protein	  homologue	  1	   Amp	   PCR/gene	  disruption/CGH	  
PF3D7_1224000	   GTP	  cyclohydrolase	  I	   Amp	   PG/FREEC/CGH	  
PF3D7_0930300	   Merozoite	  surface	  protein	  1	   Del	   PG	  
PF3D7_1148700	   Plasmodium	  exported	  protein	  (PHISTc)	  	   Amp	   PG	  
PF3D7_1253000	   Gametocyte	  erythrocyte	  cytosolic	  protein	   Del	   PG	  
PF3D7_0522400	   Conserved	  Plasmodium	  protein	   Amp	   PG	  
PF3D7_0713400	  	   Serpentine	  receptor,	  putative	   Del	   PG	  
PF3D7_0935900	   Ring-­‐exported	  protein	  1	  	   Del	   Affymetrix	  array	  	  
PF3D7_0935600	   Gametocytogenesis-­‐implicated	  protein	   Del	   Affymetrix	  array	  	  
PF3D7_0501300	  	   Skeleton-­‐binding	  protein	  1	  	   Del	   Affymetrix	  array	  	  
PF3D7_0501400	   Interspersed	  repeat	  antigen	   Del	   Affymetrix	  array	  	  
PF3D7_1401000	   Glycophorin	  binding	  protein	   Del	  
	  PF3D7_0414300	   Rab5-­‐interacting	  protein,	  putative	   Amp	   PG	  
PF3D7_1223400	   Phospholipid-­‐transporting	  ATPase,	  putative	   Amp	   PG	  
PF3D7_1301200	   Glycophorin	  binding	  protein	   Del	   Affymetrix	  array	  	  
PF3D7_1038400	   Gametocyte-­‐specific	  protein	  	   Amp	   Affymetrix	  array	  	  
PF3D7_1228300	   NIMA	  related	  kinase	  1	  	   Amp	   Affymetrix	  array	  	  
PF3D7_0102200	   Ring-­‐infected	  erythrocyte	  surface	  antigen	   Amp	   Affymetrix	  array/CGH	  
PF3D7_1035700	   Duffy	  binding-­‐like	  merozoite	  surface	  protein	   Del	   Affymetrix	  array	  	  
PF3D7_0935400	   Gametocyte	  development	  protein	  1	   Del	   Affymetrix	  array	  	  
PF3D7_0522900	   Zinc	  finger	  protein,	  putative	   Amp	   CGH	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3.6 Methodology	  
3.6.1 Sequence	  data	  	  
	  
All	  the	  Malawi	  samples	  (n=93)	  described	  above	  were	  used	  in	  this	  analysis.	  BAM	  files	  
for	  all	  the	  93	  samples	  generated	  from	  the	  previous	  section	  (Chapter	  2)	  were	  used	  to	  detect	  
CNV.	  	  
3.6.2 Detecting	  Copy	  Number	  Variation	  using	  FREEC	  and	  PG	  
3.6.2.1 Pre-­‐analysis	  steps	  in	  FREEC	  
	  
The	   FREEC	   (version	   6.2)	   algorithm	   was	   run	   on	   the	   Malawi	   samples.	   Briefly,	  
chromosome	   length	   file	   (chrLen)	   containing	   details	   of	   the	   14	   chromosome	   lengths	   was	  
generated	   using	   a	   perl	   script	   provided	   with	   the	   FREEC	   software.	   A	   configuration	   file	  
containing	  locations	  of	  the	  chrLen	  file,	  fasta	  files	  (for	  individual	  P.	  falciparum	  chromosomes)	  
and	   BAM	   files	   (for	   the	   93	   samples)	  were	   generated,	   as	   required	   by	   the	  FREEC	   algorithm.	  
Important	  parameters	   included	   in	  the	  configuration	  file	  were	  the	  minimum	  and	  maximum	  
expected	  GC	  contents	  that	  were	  set	  at	  0	  and	  0.6	  respectively,	  with	  a	  stepwise	  window	  size	  
(500-­‐bp,	  stepwise	  at	  250-­‐bp)	  for	  calculation	  of	  raw	  copy	  number	  profile.	  
3.6.2.2 Estimating	  coverage	  profiles	  and	  CNV	  detection	  using	  FREEC	  	  
	  
Running	  FREEC	   followed	   several	   steps.	   In	   brief,	   for	   each	  of	   the	   96	   samples,	  FREEC	  
calculates	  raw	  copy	  number	  (coverage)	  profile	  by	  counting	  the	  number	  of	  mapped	  reads	  in	  
equal-­‐size	   windows	   of	   500-­‐bp,	   and	   a	   stepwise	   increment	   of	   250-­‐bp	   (personal	  
communication	   from	  Valentina	  Boeva	  –	  FREEC	   software	  developer).	  Within	   each	  window,	  
the	  numbers	  of	  mapped	  reads	  are	  counted	  using	  their	  starting	  mapping	  positions	  to	  provide	  
coverage	  depth.	  P.	  falciparum	   is	  AT	  rich,	  leading	  to	  coding	  regions	  with	  higher	  GC	  content.	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In	  general,	  sequence	  coverage	  is	  influenced	  by	  GC-­‐content	  (where	  a	  non-­‐linear	  relationship	  
between	  read	  depth	  and	  GC-­‐content	  has	  been	  observed,	  Yoon	  et	  al.	  2009).	  FREEC	  assumes	  a	  
GC-­‐content	  bias	  and	  after	  calculating	  this	  GC-­‐content,	  it	  does	  a	  polynomial	  regression	  to	  find	  
the	  dependency	  function	  i.e.,	  read	  count	  (RC)	  per	  window	  ~	  GC-­‐content.	  It	  then	  normalizes	  
the	   RC	   by	   fitting	   the	   observed	   read	   count	   by	   the	   GC	   profile	   (i.e.,	   divides	   the	   RC	   by	   the	  
corresponding	   value	   of	   function)	   to	   produce	   smooth	   normalised	   ratio	   profiles	   that	   are	  
segmented	  and	  analysed	  for	  genomic	  gains	  and	  losses.	  During	  normalization,	  values	  close	  to	  
1	   show	   there	   is	   no	   copy	   number	   alteration	   (CNA),	   values	   significantly	   lower	   than	   1	   (but	  
higher	  than	  0)	  show	  loss	  and	  gains	  have	  values	  significantly	  higher	  than	  1.	  Because	  of	  high	  
levels	   of	   noise	   due	   to	   mapping	   differences,	   FREEC	   does	   not	   annotate	   each	   window	  
separately,	   instead	   it	   segments	   normalised	   ratio	   profiles,	   and	   calculates	  median	   values	  of	  
these	  normalized	  RC	  of	  each	  segment.	  Median	  value	  falling	  closer	  to	  1,	  show	  no	  CNA;	  closer	  
to	  0,	  show	  loss	  and	  gains	  are	  median	  values	  closer	  to	  1.5.	  
3.6.2.3 Detecting	  copy	  number	  variation	  using	  PG	  
	  
To	   detect	   copy	   number	   variation	   (CNV)	   in	   each	   P.	   falciparum	   sample,	   we	   used	  
sequence	  coverage	  data	  and	  a	  Poisson	  hierarchical	  modelling	  approach	   for	   the	   respective	  
data	   analysis.	   This	   CNV	   discovery	   strategy	   is	   briefly	   outlined.	   First,	   using	   FREEC,	   the	   3D7	  
reference	   genome	   was	   divided	   into	   non-­‐overlapping	   windows	   of	   100-­‐bp	   each	   and	   the	  
coverage	  of	  each	  window	  calculated	  using	  FREEC	  by	  counting	  the	  number	  of	  reads	  mapped	  
onto	  it	  and	  using	  the	  starting	  position	  of	  the	  reads.	  This	  window	  size	  was	  used	  as	  previously	  
reported	  as	   it	  provided	  a	  good	   resolution	   for	  estimating	   copy	  number	  profile	   (Yoon	  et	   al.	  
2009),	   within	   which	   observed	   read	   count	   distribution	   approached	   standard	   normal	  
distribution.	   Larger	   window	   size	   (e.g.,	   ≥	   1000-­‐bp)	   resulted	   in	   less	   precision/resolution	   in	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defining	   CNV	   breakpoints	   with	   smaller	   CNV	   (that	   span	   one	   or	   two	   windows)	   being	  
particularly	  difficult	   to	  detect	   (Sepúlveda	  et	  al.	  2013;	  Yoon	  et	  al.	  2009;	  Boeva	  et	  al.	  2011).	  
Second,	  quality	  control	  included	  removing	  windows:	  within	  100-­‐kb	  of	  subtelomeric	  regions,	  
containing	   reads	  with	  poor	  mapping	   score,	   those	  associated	  with	  high	  polymorphic	  multi-­‐
gene	   families	   (e.g.,	   vars,	   stevors,	   and	   rifins)	   and	   those	   in	   non-­‐coding	   regions.	  PG	   analysis	  
therefore	   focused	   only	   on	   the	   P.	   falciparum	   exome,	   which	   on	   average	   contained	   2-­‐fold	  
coverage.	  This	  filtering	  process	  resulted	  into	  120,309	  100-­‐bp	  windows	  accounting	  for	  nearly	  
53%	   of	   the	   3D7	   reference	   genome.	   Third,	   since	   the	   underlying	   GC	   content	   can	   affect	  
coverage,	  we	  divided	  windows	  according	  to	  this	  genomic	  variable	  using	  the	  10%-­‐centiles	  of	  
its	   distribution	   across	   the	   whole	   genome	   to	   account	   for	   the	   non-­‐uniform	   GC-­‐content	  
distribution	  in	  the	  3D7	  reference	  genome	  (Gardner	  et	  al.	  2002),	  to	  ensure	  similar	  statistical	  
power	   across	   the	   different	   set	   of	  windows.	   Fourth,	   each	   set	   of	  windows	  with	   similar	  GC-­‐
content	   is	   analysed	   separately	   by	   fitting	   two	   flexible	   probability	   distributions,	   Poisson-­‐
Gamma	  and	  Poisson-­‐Lognormal,	  to	  the	  respective	  coverage	  data.	  Fifth,	  the	  best	  model	  for	  
each	  individual	  data	  set	  is	  determined	  and	  used	  to	  define	  lower	  and	  upper	  bounds	  at	  99%	  
credible	  level	  for	  the	  expected	  coverage	  under	  the	  hypothesis	  of	  no	  copy	  number	  variation.	  
Sixth,	   windows	   were	   classified	   individually	   into	   no	   copy	   variation,	   deletions,	   or	  
amplifications,	   if	   the	   respective	   coverage	   values	   were	   between	   those	   expected	   bounds,	  
lesser	  than	  the	  lower	  bound,	  or	  greater	  than	  upper	  bound,	  respectively.	  At	  this	  stage	  of	  the	  
analysis	  we	  considered	  false	  positive	  deletions	  if	  the	  coverage	  per	  nucleotide	  position	  of	  the	  
corresponding	  windows	  was	  greater	  than	  zero.	  	  The	  final	  step	  is	  to	  pool	  together	  windows	  
with	   the	   same	   classification	   in	  order	   to	   identify	   larger	   regions	   containing	  putative	  CNV.	  A	  
more	  detailed	  description	  and	  discussion	  of	  this	  analysis	  approach	  can	  be	  found	  elsewhere	  
(Sepúlveda	  et	  al.	  2013).	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3.7 Results	  D	  
3.7.1 Distribution	  of	  CNV	  across	  chromosomes	  and	  P.	  falciparum	  genomes	  
	  
Analysis	   of	   CNV	   focused	   on	   the	   P.	   falciparum	   exome.	   The	   sub-­‐telomeres,	   internal	  
regions	  associated	  with	  highly	  polymorphic	  gene	  families	  (including	  vars,	  stevors,	  and	  rifins)	  
were	  discarded.	  Non-­‐coding	  regions	  and	  isolates	  with	  low	  genome	  coverage	  (<10-­‐fold)	  were	  
also	  removed	  from	  analysis.	  	  
PG	  model	   (γ	   =	  99%,	  where	  >	   γ	   increases	   the	   “credibility”	  of	   those	   SV	   identified	  or	  
lowers	  the	  chances	  of	  a	  false	  positive)	  identified	  2,374	  CNV	  genes	  in	  49	  isolates	  and	  at	  γ	  =	  
99.9%,	   1,335	   genes	   in	   48	   isolates	   were	   identified	   (Table	   3.2).	   The	   median	   size	   of	   CNV	  
detected	  by	  PG	  model	  was	  100-­‐bp	  (range=100-­‐1,700-­‐bp	  and	  100-­‐8,600-­‐bp	  for	  amplifications	  
and	  deletions	  respectively).	  Cdc2-­‐related	  protein	  kinase	  1	  and	  gametocyte	  specific	  protein	  
contained	   the	   largest	  amplification	   (1,700-­‐bp),	  while	   the	   largest	  deletion	   (8,600-­‐bp)	   spans	  
two	  conserved	  Plasmodium	  proteins	  of	  unknown	  function	  on	  chromosome	  14.	  	  
FREEC	  identified	  a	  total	  of	  429	  CNV	  genes	  across	  72	  isolates	  (Table	  3.2).	  The	  median	  
size	   of	   CNV	   is	   2,749	   (range=499-­‐177,409-­‐bp)	   and	   20,249	   (range=499-­‐194,906-­‐bp)	   for	  
amplifications	  and	  deletions	  respectively.	  The	  largest	  deletion	  (194,906-­‐bp)	  on	  chromosome	  
10	   spans	   33	   genes	   while	   the	   largest	   amplification	   (285,749-­‐bp)	   spans	   52	   genes	   on	  
chromosome	  10.	  
The	  PG	  method	  was	  more	  sensitive	  in	  detecting	  CNV	  and	  detected	  a	  larger	  number	  
of	   previously	   identified	   CNV	   (compared	   to	   FREEC).	   FREEC,	   however,	   identified	   larger	   CNV	  
than	  the	  PG	  method	  (Table	  3.2).	  CNV	  were	  detected	  in	  all	  chromosomes	  and	  isolates	  (Table	  
3.3-­‐3.4	  and	  Figure	  3.3).	   There	  was	  an	  excess	  of	  CNV	   in	   larger	   chromosomes.	   There	  was	  a	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slight	  bias	  of	  CNV,	  with	  amplifications	  being	  more	  frequent	  than	  deletions	  and	  maybe	  as	  a	  
result	  of	  positive	  selection	  acting	  on	  duplications	  to	  favour	  the	  retention	  of	  paralogs	  (Table	  
3.2).	  	  
CNV	   size	   distribution	   differed	   between	   isolates,	   but	   in	   general	   smaller	   size	   CNV	   occur	   at	  
higher	   frequencies	   than	   larger	  ones	   (Figure	  3.3).	   It	  has	  been	  proposed	  that	  CNV	  evolution	  
(particularly	   deletions)	   is	   largely	   shaped	   by	   purifying	   selection	   and	   would	   act	   more	  
effectively	   in	   larger	   populations,	   such	   as	   African	   P.	   falciparum	   populations	   (Dopman	   and	  
Hartl	  2007).	  Several	  theories	  have	  been	  proposed	  as	  to	  why	  smaller	  CNV	  could	  be	  selected	  
for,	   such	   as,	   high	   multi-­‐clonal	   infections	   creating	   a	   greater	   inter-­‐clonal	   competition	   with	  
parasites,	  with	  smaller	  CNV	  outcompeting	   those	  with	   larger	  ones	  and	  high	  outbreeding	   in	  
African	  populations	  that	  could	  lead	  to	  the	  breakdown	  of	  CNV	  size	  as	  well	  (Dopman	  and	  Hartl	  
2007).	  Final	  CNV	  analysis	  was	  focussed	  to	  those	  polymorphisms	  spanning	  only	  a	  single	  gene.	  
Table	  3.2:	  Summary	  of	   identified	  CNV.	  Hits2	  and	  Genes2	  correspond	  to	  total	  hits	  and	  CNV	  






	   	   	   	   	  
Size	  (bp)	   	   	   	  
	   	  
CNV	  type	   Hits	   No.	  of	  genes	   Range	   Mean	   Median	   	  Hits2	   Genes2	  
No.	  of	  
isolates	  
PG	   γ	  =99.9%	   Amplifications	   11,907	   1,771	   100-­‐1,800	   140	   100	   15,871	   2,374	   49	  
	   	  
Deletions	   3,964	   1,049	   100-­‐8,600	   148	   100	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	  
	  
γ	  =99%	   Amplifications	   4,266	   912	   100-­‐1,700	   140	   100	   6,889	   1,335	   48	  
	   	  
Deletions	   3,341	   611	   100-­‐8,600	   153	   100	   	   	   	  
	   	   	   	   	   	   	   	   	   	   	  FREEC	  
	  
Amplifications	   2,480	   396	   499-­‐177,409	   8,645	   2,749	   2,689	   429	   72	  
	   	  
Deletions	   209	   51	   499-­‐194,906	   32,520	   20,249	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Table	  3.3:	  Chromosomal	  distribution	  of	  CNV	  detected	  by	  FREEC	  and	  PG.	  CNV	  were	  
detected	  across	  all	  P.	  falciparum	  chromosomes.	  
	  
≥	  500-­‐bp	   ≥	  100-­‐bp	  
Chromosome	   FREEC	   γ=99%	   γ=99.9%	   γ=99%	   γ=99.9%	  
1	   81	   37	   28	   557	   296	  
2	   195	   6	   2	   664	   275	  
3	   219	   48	   18	   1209	   587	  
4	   113	   29	   12	   942	   401	  
5	   177	   10	   0	   1017	   407	  
6	   68	   18	   3	   726	   353	  
7	   258	   14	   4	   1168	   504	  
8	   152	   9	   4	   789	   243	  
9	   141	   46	   12	   903	   349	  
10	   212	   63	   36	   1623	   819	  
11	   284	   38	   25	   1481	   649	  
12	   173	   20	   3	   1273	   549	  
13	   272	   72	   30	   1773	   801	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Table	  3.4:	  Distribution	  of	  CNV	  in	  isolates	  detected	  by	  FREEC	  (≥	  500-­‐bp)and	  PG	  (≥	  500	  and	  
100-­‐bp)	  methods. 
 
≥ 500-bp ≥ 100-bp 
 Isolate FREEC γ=99% γ=99.9% γ=99% γ=99.9% 
 1 110 0 0 0 0 
 2 73 35 13 560 189 
 3 48 15 6 578 165 
 4 79 23 9 561 247 
 5 108 54 15 763 255 
 6 73 34 8 517 183 
 7 103 0 0 0 0 
 8 54 0 0 0 0 
 9 94 42 17 680 281 
 10 73 29 14 586 244 
 11 68 1 0 19 1 
 12 66 26 6 554 183 
 13 69 39 6 742 216 
 14 61 10 5 362 109 
 15 27 9 3 468 241 
 16 68 0 0 0 0 
 17 61 8 3 479 206 
 18 59 10 3 492 209 
 19 22 8 4 358 168 
 20 32 5 2 279 89 
 21 32 0 0 0 0 
 22 31 9 6 369 173 
 23 25 7 6 266 154 
 24 21 0 0 0 0 
 25 41 2 1 185 100 
 26 33 1 1 279 112 
 27 28 5 4 244 179 
 28 39 0 0 0 0 
 29 30 1 1 275 105 
 30 41 0 0 0 0 
 31 20 0 0 0 0 
 32 22 0 0 0 0 
 33 9 0 0 0 0 
 34 12 34 34 144 106 
 35 11 5 4 169 119 
 36 45 0 0 0 0 
 37 42 2 0 540 191 
 38 10 0 0 0 0 
 	  
 
≥ 500-bp ≥ 100-bp 
Isolate FREEC γ=99% γ=99.9% γ=99% γ=99.9% 
39 29 1 1 412 141 
40 40 0 0 0 0 
41 19 2 1 309 145 
42 29 0 0 0 0 
43 44 0 0 0 0 
44 28 4 3 238 125 
45 34 0 0 0 0 
46 44 0 0 173 92 
47 4 4 5 170 99 
48 29 7 6 383 213 
49 13 0 0 0 0 
50 29 3 3 195 123 
51 21 4 3 371 223 
52 11 6 6 353 158 
53 16 0 0 0 0 
54 10 1 0 67 50 
55 20 1 0 251 135 
56 26 3 2 269 127 
57 15 0 0 109 42 
58 44 0 0 186 123 
59 13 0 0 0 0 
60 23 4 1 211 106 
61 36 0 0 201 93 
62 29 0 0 0 0 
63 29 0 0 0 0 
64 6 2 2 124 62 
65 24 0 0 0 0 
66 8 5 4 280 67 
67 16 2 2 170 54 
68 13 5 3 261 131 
69 46 7 6 272 180 
70 18 0 0 162 60 
71 41 0 0 234 115 
72 42 0 0 0 0 
 




Figure	  3.3:	  CNV	  size	  distribution	  using	  FREEC	  and	  PG.	  Smaller	  size	  CNV	  (less	  than	  500-­‐bp)	  
dominate	  in	  the	  population.	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Figure	   3.4:	   Frequency	   of	   polymorphic	   and	   monomorphic	   CNV.	   	   Polymorphic	   CNV	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3.7.2 Detection	  of	  previously	  identified	  CNV	  
	  
These	   two	  methods	   identified	   important	  CNV	   that	   have	  previously	   been	   identified	  
(Table	   3.3).	   Well-­‐documented	   deletions	   with	   roles	   in	   cytoadherence,	   invasion	   and	  
pathogenesis	   were	   detected.	   These	   include	   cytoadherence	   linked	   asexual	   genes	   on	  
chromosome	  3	   (clag	  3.1	   and	   clag	  3.2,	  PF3D7_0302500	  and	  PF3D7_0302200	   respectively),	  
reticulocyte	  binding	  protein	  2	  homologue	  b	  (pfRh2b,	  PF3D7_1335300)	  on	  chromosome	  13,	  
gametocyte-­‐specific	   protein	   (pf11-­‐1,	  PF3D7_1038400)	  on	   chromosome	  10,	   and	  a	   locus	  on	  
chromosome	   2	   containing	   the	   knob-­‐associated	   histidine-­‐rich	   protein	   (kahrp,	  
PF3D7_0202000)	  also	  associated	  with	  loss	  of	  cytoadherence.	  Deletions	  were	  also	  detected	  
in	   two	   multigene	   families	   associated	   with	   the	   merozoite	   surface,	   a	   Duffy	   binding-­‐like	  
merozoite	   surface	   protein	   (dbl-­‐msp,	   PF3D7_1035700)	   with	   a	   possible	   role	   in	   binding	   of	  
merozoites	  with	  erythrocytes	  during	  invasion	  (Wickramarachchi	  et	  al.	  2009)	  and	  merozoite	  
surface	   protein	   (msp3.8,	   PF3D7_1036300).	   Another	   deletion	  was	   detected	   in	   antigen	   332	  
(Pf332,	   PF3D7_1149000).	   Parasites	   lacking	   this	   gene	   have	   been	   found	   to	   be	   rigid,	   less	  
adhesive	   to	   “Cluster	   of	   Differentiation	   36”	   (CD36),	   and	  with	   decreased	   expression	   of	   the	  
major	  cytoadherence	  ligand,	  PfEMP1,	  on	  the	  IE	  surface	  and	  thus	  could	  have	  a	  role	  in	  malaria	  
pathogenesis	   (Glenister	   et	   al.	   2009).	   Amplifications	  were	  detected	   in	   8	   genes	   including	   in	  
msp3.8,	   that	   had	   previously	   been	   associated	   with	   parasite	   drug	   resistance,	   ring-­‐infected	  
erythrocyte	   surface	   antigen	   (RESA,	   PF3D7_0102200),	   ring-­‐exported	   protein	   1	   (rex1,	  
PF3D7_0935900)	  and	  pf11-­‐1.	  Residing	  in	  Maurer’s	  cleft	  (a	  transporter	  of	  parasite	  proteins	  to	  
IE	  surface),	  the	  rex1	  gene	  makes	  a	  group	  of	  four	  homologous	  genes	  (rex1,	  rex2,	  rex3,	  rex4)	  
found	  on	   chromosome	  9	   that	   encode	   ring-­‐stage	  proteins	   exported	   into	   the	   IE	   (Spielmann	  
and	  Hawthorne	  2006;	  Hawthorne	  et	  al.	  2004;	  Bhattacharjee	  et	  al.	  2008).	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Table	  3.5:	  List	  of	  previously	  identified	  CNV	  detected	  in	  this	  study.	  CNVp	  represents	  CNV	  
type	  in	  previous	  studies	  and	  CNVn	  represents	  CNV	  type	  in	  this	  study.	  
Gene	   Product	  description	   CNVp	   CNVn	   Method	  
PF3D7_0102200	   Ring-­‐infected	  erythrocyte	  surface	  antigen	   Amp	   Amp	   PG	  
PF3D7_0202000	   Knob-­‐associated	  histidine-­‐rich	  protein	   Del	   Del	   FREEC	  
PF3D7_0302200	   Cytoadherence	  linked	  asexual	  protein	  3.2	   Del	   Del	   FREEC/PG	  
PF3D7_0302500	   Cytoadherence	  linked	  asexual	  protein	  3.1	   Del	   Del	   PG	  
PF3D7_0321600	   ATP-­‐dependent	  RNA	  helicase,	  putative	   Amp	   Amp	   PG	  
PF3D7_0522900	   Zinc	  finger	  protein,	  putative	   Amp	   Amp	   PG	  
PF3D7_0722400	   GTP	  binding	  protein,	  putative	   Amp	   Amp	   PG	  
PF3D7_0935900	   Ring-­‐exported	  protein	  1	  	   Del	   Amp	   PG	  
PF3D7_1035700	   Duffy	  binding-­‐like	  merozoite	  surface	  protein	   Del	   Del	   PG	  
PF3D7_1036300	   Merozoite	  surface	  protein	   Amp/Del	   Del	   PG	  
PF3D7_1038400	   Gametocyte-­‐specific	  protein	  	   Amp/Del	   Amp/Del	   FREEC/PG	  
PF3D7_1149000	   Antigen	  332,	  DBL-­‐like	  protein	   Del	   Del	   PG	  
PF3D7_1228300	   NIMA	  related	  kinase	  1	  	   Amp	   Amp	   FREEC	  
PF3D7_1335300	   Reticulocyte	  binding	  protein	  2	  homologue	  b	  	   Del	   Del	   PG	  
Del=Deletion.	  Amp=Amplification.	  
	  
3.7.3 Identification	  of	  deletions	  (loss)	  spanning	  only	  a	  single	  gene	  
	  
Apart	   from	   deletions	   listed	   in	   Table	   3.5	   that	   were	   previously	   identified,	   several	  
others	   were	   detected	   (Table	   3.6-­‐3.8),	   and	   these	   include:	   a	   deletion	   on	   chromosome	   10	  
containing	  a	  liver	  stage	  antigen	  1	  (lsa1,	  PF3D7_1036400),	  with	  an	  important	  role	  in	  parasite	  
transition	   from	   liver	   to	  blood	   (Mikolajczak	  et	   al.	   2011).	  A	  deletion	  on	   chromosome	  7	   in	   a	  
well	   characterized	   invasion	   gene,	   erythrocyte	   binding	   antigen	   (eba-­‐175,	   PF3D7_0731500)	  
(Sakura	   et	   al.	   2013).	   Deletion	   in	   sporozoite-­‐specific	   transmembrane	   protein	   S6	   (trep,	  
PF3D7_1442600)	   that	   aids	   in	   parasites	   gliding	   mortility	   (Combe	   et	   al.	   2009)	   and	   in	   a	  
circumsporozoite-­‐	  and	  TRAP-­‐related	  protein	  (ctrp,	  PF3D7_0315200),	  an	  essential	  protein	  in	  
ookinite	   infectivity	   and	   mosquito	   transmission	   of	   malaria	   	   (Dessens	   et	   al.	   1999).	   Other	  
deletions	  were	   found	   in	   two	   structural	   RNAs	   (18S	   and	   28S	   ribosomal	   RNA)	  with	   possible	  
roles	   in	   ribosomal	   gene	   expression	   (Chakrabarti	   et	   al.	   2007),	   and	   in	   a	   cysteine	   repeat	  
modular	   protein	   4	   (pfcrmp4)	   on	   chromosome	   14	   that	   mediates	   host-­‐parasite	   interaction	  
throughout	  P.	   falciparum	   life	  cycle	  and	  specifically	   transmission	   from	  the	  mosquito	   to	   the	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host	  (Douradinha	  et	  al.	  2011).	  The	  largest	  deletion	  spanning	  a	  single	  chromosome	  appeared	  
on	  pf11-­‐1	  (5,249-­‐bp,	  FREEC)	  and	  conserved	  Plasmodium	  protein,	  PF3D7_1474400	  (3,900-­‐bp,	  
PG).	   Several	   genes	   appeared	   at	   very	   high	   frequencies	   by	   PG	   method	   -­‐	   a	   DBL	   containing	  
protein,	   PF3D7_0113800	   (75%),	   clag3.2	   (70%),	   clag3.1	   (50%)	   and	   pf11-­‐1	   (57%)	   and	   by	  
FREEC,	  clag3.2	  occurred	  in	  24%	  of	  all	  isolates	  
Table	  3.6:	  List	  of	  deletions	  (≥	  500-­‐bp)	  identified	  by	  FREEC.	  	  
Chromosome	   Gene	   Size	   Product	  description	  
Pf3D7_10_v3	   PF3D7_1038400	   5249	   gametocyte-­‐specific	  protein	  
Pf3D7_03_v3	   PF3D7_0302200	   3749	   cytoadherence	  linked	  asexual	  protein	  3.2	  
Pf3D7_07_v3	   PF3D7_0726000	   1999	   28S	  ribosomal	  RNA	  
Pf3D7_02_v3	   PF3D7_0202000	   1249	   knob-­‐associated	  histidine-­‐rich	  protein	  
Pf3D7_14_v3	   PF3D7_1442600	   999	   sporozoite-­‐specific	  transmembrane	  protein	  S6	  
Pf3D7_10_v3	   PF3D7_1036400	   999	   liver	  stage	  antigen	  1	  
Pf3D7_03_v3	   PF3D7_0315200	   749	   circumsporozoite-­‐	  and	  TRAP-­‐related	  protein	  
Pf3D7_13_v3	   PF3D7_1371000	   749	   18S	  ribosomal	  RNA	  
Pf3D7_14_v3	   PF3D7_1473700	   749	   nucleoporin	  NUP116/NSP116,	  putative	  
	  
Table	  3.7:	  List	  if	  deletions	  ≥	  500-­‐bp	  identified	  by	  PG	  (γ	  =	  99%).	  
Chromosome	   Gene	   Size	   Product	  description	  
Pf3D7_14_v3	   PF3D7_1474400	   3900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1473700	   2700	   nucleoporin	  NUP116/NSP116,	  putative	  
Pf3D7_03_v3	   PF3D7_0302200	   1200	   cytoadherence	  linked	  asexual	  protein	  3.2	  	  
Pf3D7_10_v3	   PF3D7_1038400	   1100	   gametocyte-­‐specific	  protein	  	  
Pf3D7_03_v3	   PF3D7_0302500	   900	   cytoadherence	  linked	  asexual	  protein	  3.1	  
Pf3D7_01_v3	   PF3D7_0113800	   800	   DBL	  containing	  protein,	  unknown	  function	  
Pf3D7_10_v3	   PF3D7_1036300	   600	   merozoite	  surface	  protein	  
Pf3D7_10_v3	   PF3D7_1036400	   600	   liver	  stage	  antigen	  1	  
Pf3D7_13_v3	   PF3D7_1335300	   600	   reticulocyte	  binding	  protein	  2	  homologue	  b	  
Pf3D7_14_v3	   PF3D7_1442600	   600	   sporozoite-­‐specific	  transmembrane	  protein	  S6	  
Pf3D7_07_v3	   PF3D7_0731500	   500	   erythrocyte	  binding	  antigen-­‐175	  
Pf3D7_10_v3	   PF3D7_1035700	   500	   duffy	  binding-­‐like	  merozoite	  surface	  protein	  
Pf3D7_11_v3	   PF3D7_1149000	   500	   antigen	  332,	  DBL-­‐like	  protein	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Table	  3.8:	  List	  deletions	  ≥	  500-­‐bp,	  identified	  by	  PG	  (γ	  =	  99.9%).	  	  
Chromosome	   Gene	   Size	   Product	  description	  
Pf3D7_14_v3	   PF3D7_1474400	   3900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1475400	   3800	   cysteine	  repeat	  modular	  protein	  4	  
Pf3D7_14_v3	   PF3D7_1473700	   2700	   nucleoporin	  NUP116/NSP116,	  putative	  
Pf3D7_14_v3	   PF3D7_1476300	   1300	   Plasmodium	  exported	  protein	  (PHISTb),	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0302200	   1100	   cytoadherence	  linked	  asexual	  protein	  3.2	  
Pf3D7_10_v3	   PF3D7_1038400	   1100	   gametocyte-­‐specific	  protein	  	  
Pf3D7_03_v3	   PF3D7_0302500	   800	   cytoadherence	  linked	  asexual	  protein	  3.1	  	  
Pf3D7_01_v3	   PF3D7_0113800	   600	   DBL	  containing	  protein,	  unknown	  function	  	  
Pf3D7_10_v3	   PF3D7_1036300	   600	   merozoite	  surface	  protein	  
Pf3D7_10_v3	   PF3D7_1036400	   600	   liver	  stage	  antigen	  1	  
Pf3D7_13_v3	   PF3D7_1335300	   600	   reticulocyte	  binding	  protein	  2	  homologue	  b	  
Pf3D7_10_v3	   PF3D7_1035700	   500	   duffy	  binding-­‐like	  merozoite	  surface	  protein	  
Pf3D7_11_v3	   PF3D7_1149000	   500	   antigen	  332,	  DBL-­‐like	  protein	  
Pf3D7_13_v3	   PF3D7_1318300	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1417900	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1442600	   500	   sporozoite-­‐specific	  transmembrane	  protein	  S6	  
	  
	  
3.7.4 Identification	  of	  amplifications	  (gains)	  spanning	  a	  single	  gene	  
	  
All	   amplifications	   detected	   by	   FREEC	   and	   PG	  methods	   are	   listed	   in	   Table	   3.9-­‐4.1.	  
There	  were	  more	  amplifications	  than	  deletions	  both	  by	  FREEC	  and	  PG	  method	  (Tables	  3.2).	  
Several	  genes	  contained	  both	  deletions	  and	  amplifications	  e.g.,	  pf11-­‐1,	  ctrp,	   lsa1,	  28S	  and	  
18S	   ribosomal	   RNAs.	  Of	   interest	   is	   a	   previously	   unidentified	   amplification	   on	   kahrp	   gene,	  
noting	   that	   deletions	   on	   this	   gene	   have	   been	   associated	   with	   loss	   of	   cytoadherence.	  
Amplification	   was	   also	   detected	   in	   a	   well-­‐characterized	   malaria	   vaccine	   candidate,	  
circumsporozoite	   protein	   (csp,	   PF3D7_0304600)	   (Plassmeyer	   et	   al.	   2009)	   a	  major	   surface	  
component	  of	  P.	   falciparum	   sporozoites	   and	  essential	   for	  host	   cell	   invasion.	  Using	  FREEC,	  
the	   highest	   copy	   number	   gains	   (223	   and	   63)	   were	   observed	   in	   two	   putative	   genes;	   a	  
nucleoporin	   NUP116/NSP116	   (PfNup116,	   PF3D7_1473700)	   and	   a	   eukaryotic	   translation	  
initiation	   factor	   3	   subunit	   10	   (PF3D7_1212700)	   respectively.	   In	   addition,	   23	   gains	   in	   6-­‐
cysteine	  protein	  (p230,	  PF3D7_0209000),	  18	  gains	  in	  pf11-­‐1,	  16	  gains	  in	  kahrp,	  and	  15	  gains	  
in	  csp	  were	  observed.	  In	  terms	  of	  frequency,	  lsa1	  occurred	  at	  62%	  by	  FREEC	  and	  68%	  by	  PG	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(γ	  =	  99%),	  79%	  of	  isolates	  (PG,	  γ	  =	  99%)	  contained	  ABC	  transporter,	  (mrp2,	  PF3D7_1229100),	  
rex1	  (72%;	  PG,	  γ	  =	  99%).	  On	  average	  64%	  of	  isolates	  contained	  pf11-­‐1	  gene	  by	  PG	  method.	  
Largest	  amplifications	  were	  observed	  in	  a	  Plasmodium	  conserved	  protein	  spanning	  5,249-­‐bp	  
(PF3D7_0213600;	  FREEC)	  and	  pf11-­‐1	  (1,700-­‐bp,	  PG).	  
Table	  3.9:	  List	  of	  amplifications	  (≥	  500-­‐bp)	  identified	  by	  FREEC.	  
Chromosome	   Gene	   Gain	   Size	   Product	  description	  
Pf3D7_02_v3	   PF3D7_0213600	   3	   5249	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_10_v3	   PF3D7_1038400	   18	   4999	   gametocyte-­‐specific	  protein	  	  
Pf3D7_07_v3	   PF3D7_0726000	   2	   2999	   28S	  ribosomal	  RNA	  
Pf3D7_10_v3	   PF3D7_1014600	   3	   2249	   transcriptional	  coactivator	  ADA2	  
Pf3D7_10_v3	   PF3D7_1036400	   3	   2249	   liver	  stage	  antigen	  1	  
Pf3D7_11_v3	   PF3D7_1148600	   2	   1999	   18S	  ribosomal	  RNA	  
Pf3D7_09_v3	   PF3D7_0905100	   2	   1749	   nucleoporin	  NUP100/NSP100,	  putative	  
Pf3D7_11_v3	   PF3D7_1116000	   5	   1499	   rhoptry	  neck	  protein	  4	  
Pf3D7_02_v3	   PF3D7_0220000	   2	   1249	   liver	  stage	  antigen	  3	  
Pf3D7_09_v3	   PF3D7_0909500	   2	   1249	   subpellicular	  microtubule	  protein	  1,	  putative	  	  
Pf3D7_02_v3	   PF3D7_0202000	   16	   999	   knob-­‐associated	  histidine-­‐rich	  protein	  
Pf3D7_05_v3	   PF3D7_0527000	   2	   999	   DNA	  replication	  licensing	  factor	  MCM3,	  putative	  	  
Pf3D7_08_v3	   PF3D7_0803400	   2	   999	   DNA	  repair	  protein	  RAD54,	  putative	  
Pf3D7_01_v3	   PF3D7_0112700	   7	   749	   28S	  ribosomal	  RNA	  
Pf3D7_02_v3	   PF3D7_0209000	   24	   749	   6-­‐cysteine	  protein	  
Pf3D7_03_v3	   PF3D7_0304600	   15	   749	   circumsporozoite	  (CS)	  protein	  
Pf3D7_03_v3	   PF3D7_0315200	   9	   749	   circumsporozoite-­‐	  and	  TRAP-­‐related	  protein	  
Pf3D7_05_v3	   PF3D7_0508900	   3	   749	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_05_v3	   PF3D7_0525200	   2	   749	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_08_v3	   PF3D7_0807100	   3	   749	   RNA	  helicase,	  putative	  
Pf3D7_11_v3	   PF3D7_1110400	   2	   749	   asparagine-­‐rich	  antigen	  
Pf3D7_11_v3	   PF3D7_1147800	   3	   749	   merozoite	  adhesive	  erythrocytic	  binding	  protein	  	  
Pf3D7_12_v3	   PF3D7_1212700	   63	   749	   eukaryotic	  translation	  initiation	  factor	  3	  subunit	  10,	  putative	  	  
Pf3D7_12_v3	   PF3D7_1228300	   6	   749	   NIMA	  related	  kinase	  1	  
Pf3D7_13_v3	   PF3D7_1311900	   2	   749	   vacuolar	  ATP	  synthase	  subunit	  a	  
Pf3D7_13_v3	   PF3D7_1367800	   9	   749	   secreted	  ookinete	  protein,	  putative	  
Pf3D7_14_v3	   PF3D7_1462800	   9	   749	   glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	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Table	  4.0:	  List	  of	  amplifications	  ≥	  500-­‐bp,	  identified	  using	  PG	  (γ	  =	  99%).	  	  
Chromosome	   Gene	   Size	   Product	  description	  
Pf3D7_10_v3	   PF3D7_1038400	   1700	   gametocyte-­‐specific	  protein	  
Pf3D7_04_v3	   PF3D7_0417800	   1700	   cdc2-­‐related	  protein	  kinase	  2	  
Pf3D7_03_v3	   PF3D7_0311300	   1700	   phosphatidylinositol	  3-­‐	  and	  4-­‐kinase,	  putative	  	  
Pf3D7_11_v3	   PF3D7_1104600	   1700	   radial	  spoke	  head	  protein,	  putative	  
Pf3D7_03_v3	   PF3D7_0310200	   1600	   phd	  finger	  protein,	  putative	  
Pf3D7_03_v3	   PF3D7_0318200	   1600	   DNA-­‐directed	  RNA	  polymerase	  II,	  putative	  
Pf3D7_10_v3	   PF3D7_1033000	   1600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_07_v3	   PF3D7_0716100	   1500	   large	  ribosomal	  subunit	  assembling	  factor,	  putative	  
Pf3D7_12_v3	   PF3D7_1251200	   1500	   coronin	  
Pf3D7_13_v3	   PF3D7_1309400	   1400	   HORMA	  domain	  protein,	  putative	  
Pf3D7_01_v3	   PF3D7_0102200	   1300	   ring-­‐infected	  erythrocyte	  surface	  antigen	  
Pf3D7_04_v3	   PF3D7_0404600	   1300	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1128300	   1300	   6-­‐phosphofructokinase	  
Pf3D7_09_v3	   PF3D7_0924500	   1200	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  
Pf3D7_04_v3	   PF3D7_0408700	   1100	   sporozoite	  micronemal	  protein	  essential	  for	  cell	  traversal	  	  
Pf3D7_06_v3	   PF3D7_0607300	   1100	   uroporphyrinogen	  III	  decarboxylase	  
Pf3D7_09_v3	   PF3D7_0934100	   1100	   DNA	  excision-­‐repair	  helicase,	  putative	  
Pf3D7_13_v3	   PF3D7_1323800	   1100	   vacuolar	  protein	  sorting-­‐associated	  protein	  52,	  putative	  
Pf3D7_14_v3	   PF3D7_1423400	   1100	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0321600	   1000	   ATP-­‐dependent	  RNA	  helicase,	  putative	  
Pf3D7_07_v3	   PF3D7_0716200	   1000	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_08_v3	   PF3D7_0828800	   1000	   GPI-­‐anchored	  micronemal	  antigen	  
Pf3D7_10_v3	   PF3D7_1004600	   1000	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  
Pf3D7_10_v3	   PF3D7_1033100	   1000	   S-­‐adenosylmethionine	  decarboxylase/ornithine	  decarboxylase	  
Pf3D7_11_v3	   PF3D7_1104500	   1000	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1125100	   1000	   vacuolar	  membrane	  protein-­‐related,	  putative	  
Pf3D7_13_v3	   PF3D7_1350400	   1000	   ubiquitin-­‐activating	  enzyme	  E1,	  putative	  
Pf3D7_13_v3	   PF3D7_1365700	   1000	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0316500	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0318200	   900	   DNA-­‐directed	  RNA	  polymerase	  II,	  putative	  	  
Pf3D7_04_v3	   PF3D7_0404600	   900	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  	  
Pf3D7_08_v3	   PF3D7_0803400	   900	   DNA	  repair	  protein	  RAD54,	  putative	  
Pf3D7_10_v3	   PF3D7_1031300	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1143500	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_12_v3	   PF3D7_1249800	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1365700	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1323900	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1350900	   900	   transcription	  factor	  with	  AP2	  domain(s)	  
Pf3D7_14_v3	   PF3D7_1421600	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1432200	   900	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0303500	   800	   spindle	  pole	  body	  protein,	  putative	  
Pf3D7_03_v3	   PF3D7_0318300	   800	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0310200	   800	   phd	  finger	  protein,	  putative	  
Pf3D7_04_v3	   PF3D7_0407300	   800	   transcription	  factor,	  putative	  
Pf3D7_04_v3	   PF3D7_0406700	   800	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_07_v3	   PF3D7_0716200	   800	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_08_v3	   PF3D7_0818500	   800	   zinc	  finger	  protein,	  putative	  
Pf3D7_10_v3	   PF3D7_1031200	   800	   MORN	  repeat-­‐containing	  protein	  1	  
Pf3D7_10_v3	   PF3D7_1036400	   800	   liver	  stage	  antigen	  1	  
Pf3D7_12_v3	   PF3D7_1233200	   800	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1350700	   800	   N6-­‐adenine-­‐specific	  methylase,	  putative	  
Pf3D7_14_v3	   PF3D7_1421800	   800	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0311300	   700	   phosphatidylinositol	  3-­‐	  and	  4-­‐kinase,	  putative	  
Pf3D7_05_v3	   PF3D7_0504800	   700	   conserved	  Plasmodium	  protein,	  unknown	  function	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Pf3D7_10_v3	   PF3D7_1004600	   700	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1128300	   700	   6-­‐phosphofructokinase	  
Pf3D7_13_v3	   PF3D7_1348500	   700	   TBC	  domain	  protein,	  putative	  
Pf3D7_13_v3	   PF3D7_1323800	   700	   vacuolar	  protein	  sorting-­‐associated	  protein	  52,	  putative	  
Pf3D7_14_v3	   PF3D7_1440500	   700	   allantoicase,	  putative	  
Pf3D7_14_v3	   PF3D7_1423400	   700	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  	  
Pf3D7_01_v3	   PF3D7_0110800	   600	   transcription	  initiation	  factor	  TFIIB,	  putative	  	  
Pf3D7_02_v3	   PF3D7_0212700	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0316600	   600	   formate-­‐nitrite	  transporter,	  putative	  
Pf3D7_03_v3	   PF3D7_0313600	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_04_v3	   PF3D7_0407100	   600	   methyltransferase,	  putative	  
Pf3D7_04_v3	   PF3D7_0417700	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_04_v3	   PF3D7_0417900	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_05_v3	   PF3D7_0525500	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_05_v3	   PF3D7_0508900	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_06_v3	   PF3D7_0615300	   600	   GPI-­‐anchored	  wall	  transfer	  protein	  1,	  putative	  
Pf3D7_07_v3	   PF3D7_0704100	   600	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  	  
Pf3D7_09_v3	   PF3D7_0925100	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1128500	   600	   conserved	  protein,	  unknown	  function	  
Pf3D7_12_v3	   PF3D7_1233700	   600	   homocysteine	  S-­‐methyltransferase,	  putative	  
Pf3D7_12_v3	   PF3D7_1237200	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_12_v3	   PF3D7_1229100	   600	   ABC	  transporter,	  (CT	  family)	  
Pf3D7_13_v3	   PF3D7_1330200	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1322900	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1340300	   600	   nucleolar	  complex	  protein	  2,	  putative	  
Pf3D7_13_v3	   PF3D7_1304600	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1309400	   600	   HORMA	  domain	  protein,	  putative	  
Pf3D7_13_v3	   PF3D7_1322400	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_01_v3	   PF3D7_0111000	   500	   kinesin-­‐8,	  putative	  
Pf3D7_03_v3	   PF3D7_0312200	   500	   TPR	  domain	  containing	  protein	  
Pf3D7_04_v3	   PF3D7_0419900	   500	   phosphatidylinositol	  4-­‐kinase,	  putative	  
Pf3D7_04_v3	   PF3D7_0418000	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_05_v3	   PF3D7_0506500	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_05_v3	   PF3D7_0530600	   500	   XAP-­‐5	  DNA	  binding	  protein,	  putative	  	  
Pf3D7_07_v3	   PF3D7_0722400	   500	   GTP	  binding	  protein,	  putative	  
Pf3D7_09_v3	   PF3D7_0928200	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_09_v3	   PF3D7_0932600	   500	   apicoplast	  ribosomal	  protein	  S6,	  putative	  
Pf3D7_09_v3	   PF3D7_0934700	   500	   UBX	  domain,	  putative	  
Pf3D7_09_v3	   PF3D7_0908200	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_09_v3	   PF3D7_0924500	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_09_v3	   PF3D7_0935900	   500	   ring-­‐exported	  protein	  1	  
Pf3D7_10_v3	   PF3D7_1018200	   500	   serine/threonine	  protein	  phosphatase,	  putative	  
Pf3D7_10_v3	   PF3D7_1025000	   500	   formin	  2,	  putative	  
Pf3D7_10_v3	   PF3D7_1020500	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1117000	   500	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  	  
Pf3D7_11_v3	   PF3D7_1106800	   500	   protein	  kinase,	  putative	  
Pf3D7_12_v3	   PF3D7_1245600	   500	   kinesin,	  putative	  
Pf3D7_12_v3	   PF3D7_1249900	   500	   apicoplast	  dimethyladenosine	  synthase,	  putative	  
Pf3D7_13_v3	   PF3D7_1307300	   500	   DEAD	  box	  helicase,	  putative	  	  
Pf3D7_13_v3	   PF3D7_1350400	   500	   ubiquitin-­‐activating	  enzyme	  E1,	  putative	  
Pf3D7_14_v3	   PF3D7_1455300	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1422100	   500	   mitochondrial	  ribosomal	  protein	  L21	  precursor,	  putative	  	  
Pf3D7_14_v3	   PF3D7_1435700	   500	   ataxin-­‐2	  like	  protein,	  putative	  
Pf3D7_14_v3	   PF3D7_1435600	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	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Table	  4.1:	  List	  of	  amplifications	  ≥	  500-­‐bp,	  identified	  using	  PG	  (γ	  =	  99.9%).	  	  
Chromosome	   Gene	   Size	   Product	  description	  
Pf3D7_10_v3	   PF3D7_1038400	   1700	   gametocyte-­‐specific	  protein	  	  
Pf3D7_04_v3	   PF3D7_0417800	   1700	   cdc2-­‐related	  protein	  kinase	  1	  
Pf3D7_11_v3	   PF3D7_1104600	   1700	   radial	  spoke	  head	  protein,	  putative	  
Pf3D7_10_v3	   PF3D7_1033000	   1600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_11_v3	   PF3D7_1104500	   1200	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_03_v3	   PF3D7_0311300	   1100	   phosphatidylinositol	  3-­‐	  and	  4-­‐kinase,	  putative	  
Pf3D7_12_v3	   PF3D7_1251200	   1100	   coronin	  
Pf3D7_09_v3	   PF3D7_0932100	   1000	   protein	  MAM3,	  putative	  
Pf3D7_03_v3	   PF3D7_0318200	   900	   DNA-­‐directed	  RNA	  polymerase	  II,	  putative	  	  
Pf3D7_06_v3	   PF3D7_0607300	   900	   uroporphyrinogen	  III	  decarboxylase	  
Pf3D7_11_v3	   PF3D7_1125100	   900	   vacuolar	  membrane	  protein-­‐related,	  putative	  
Pf3D7_13_v3	   PF3D7_1350900	   900	   transcription	  factor	  with	  AP2	  domain(s)	  
Pf3D7_08_v3	   PF3D7_0818500	   800	   zinc	  finger	  protein,	  putative	  
Pf3D7_08_v3	   PF3D7_0828800	   700	   GPI-­‐anchored	  micronemal	  antigen	  
Pf3D7_10_v3	   PF3D7_1031200	   700	   MORN	  repeat-­‐containing	  protein	  1	  
Pf3D7_10_v3	   PF3D7_1033100	   700	   S-­‐adenosylmethionine	  decarboxylase/ornithine	  decarboxylase	  	  
Pf3D7_11_v3	   PF3D7_1108500	   700	   succinyl-­‐CoA	  synthetase	  alpha	  subunit,	  putative	  
Pf3D7_03_v3	   PF3D7_0310200	   600	   phd	  finger	  protein,	  putative	  
Pf3D7_04_v3	   PF3D7_0406700	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1330200	   600	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1330300	   600	   DnaJ	  protein,	  putative	  
Pf3D7_13_v3	   PF3D7_1348500	   600	   TBC	  domain	  protein,	  putative	  
Pf3D7_01_v3	   PF3D7_0102200	   500	   ring-­‐infected	  erythrocyte	  surface	  antigen	  
Pf3D7_01_v3	   PF3D7_0110800	   500	   transcription	  initiation	  factor	  TFIIB,	  putative	  	  
Pf3D7_04_v3	   PF3D7_0404600	   500	   conserved	  Plasmodium	  membrane	  protein,	  unknown	  function	  	  
Pf3D7_04_v3	   PF3D7_0417900	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_06_v3	   PF3D7_0615300	   500	   GPI-­‐anchored	  wall	  transfer	  protein	  1,	  putative	  
Pf3D7_10_v3	   PF3D7_1031300	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_13_v3	   PF3D7_1323900	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	  
Pf3D7_14_v3	   PF3D7_1422100	   500	   mitochondrial	  ribosomal	  protein	  L21	  precursor,	  putative	  
Pf3D7_14_v3	   PF3D7_1422200	   500	   conserved	  Plasmodium	  protein,	  unknown	  function	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Figure	  3.5:	  Overlap	  of	  CNV	  detected	  by	  the	  three	  methods.	  A:	  3.5%	  overlap	  of	  deletions.	  
B:	  6.9%	  overlap	  of	  duplications.	  More	  than	  70%	  overlap	  of	  CNV	  detected	  by	  PG,	  γ	  =	  99%	  
and	  PG,	  γ	  =	  99.9%	  was	  observed,	  as	  the	  stringency	  of	  the	  two	  methods	  is	  controlled	  by	  γ,	  
where	  as	  you	  increase	  γ	  from	  99	  to	  99.9%,	  the	  number	  of	  false	  positives	  is	  lowered.	  The	  
low	   proportion	   of	   shared	   CNV	   between	   the	   three	   methods	   is	   mainly	   due	   to	   the	  
sensitivity	   of	   the	   methods;	   PG	   method	   detects	   hits,	   most	   of	   which	   occur	   in	   loci	   not	  
targeted	  by	  FREEC.	  Less	  overlap	  between	  the	  three	  methods	  could	  also	  result	  from	  the	  
reduced	  number	  of	  CNV	  detected	  by	  FREEC	  owing	  to	  the	  default	  settings	  that	  could	  only	  
identify	  CNV	  ≥	  500-­‐bp,	  while	  PG	  identified	  CNV	  ≥	  100-­‐bp.	  
	  
3.7.5 Using	  copy	  number	  variation	  to	  define	  population	  structure	  in	  
Malawian	  P.	  falciparum	  isolates	  
	  
CNV	  were	   used	   to	   define	   population	   structure	   of	  Malawian	  P.	   falciparum	   parasite	  
populations	   using	   a	   principal	   component	   analysis	   (PCA)	   (Figure	   3.8).	   As	   in	   PCA	   using	   SNP	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Figure	   3.6:	   Population	   structure	   inferred	   from	   principal	   component	   analysis	   of	   CNV	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Figure	   3.7:	   Visual	   representation	   of	   copy	   number	   variation	  with	   FREEC	   software	   (A-­‐B)	  
and	  Lookseq	  browser	  (C-­‐D).	   (A-­‐B)	  GC-­‐	  content	  normalized	  copy	  number	  profiles	  for	  (A)	  
chromosome	  3	  and	  (B)	  chromosome	  10.	  Automatically	  predicted	  copy	  number	  gains	  are	  
shown	  in	  red	  and	  predicted	  losses	  in	  blue.	  Because	  of	  low	  ‘mappability’	  in	  subtelomeric	  
regions,	  there	  are	  predicted	  losses	  close	  to	  the	  chromosome	  ends.	  (A)	  Isolates	  PT0042,	  
PT0044	   and	   PT0056	   show	   loss	   between	   0-­‐1(y-­‐axis,	   normalized	   copy	   number)	   and	  
amplification	   between	   1.5-­‐3.0	   for	   PT0042.	   This	   region	   contains	   clag3.1	   and	   clag3.2	  
genes.	   (B)	   Amplification	   is	   detected	   between	   1-­‐3.0	   in	   PT0099	   and	   PT0100	   containing	  
pf11-­‐1	  gene.	   In	   isolates	  PT0105,	  PT0108	  and	  PT0109	  very	   low	  or	  no	   read	  counts	  were	  
observed.	  (C-­‐D)	  Visual	  representation	  in	  Lookseq	  browser	  for	  deletion	  and	  amplification	  
in	  a	  region	  containing	  clag3.1	  and	  clag3.2	   (C),	  and	  amplification	  of	  a	  region	  containing	  
pf11-­‐1	   gene	   (D).	   Very	   low	   or	   no	   read	   counts	  were	   observed	   in	   some	   isolates	   such	   as	  




Several	  studies	  (mostly	  in	  the	  human	  genome)	  have	  demonstrated	  that	  copy	  number	  
variants	  contribute	  significantly	  to	  genetic	  variation	  in	  natural	  populations	  of	  both	  humans	  
and	   pathogens,	   playing	   a	   major	   role	   in	   genome	   evolution,	   adaptive	   changes	   and	  
pathogenesis	   of	   disease.	   In	   the	   human	   genomes,	   CNV	   are	   more	   prevalent	   than	   point	  
mutations	  or	  SNPs	  with	  an	  estimated	  rate	  of	  10,000	  to	  1,000,000	  per	  generation	  (compared	  
to	  mice	  at	  100	  –	  1,000	  per	  generation	  (Korbel	  et	  al.	  2008)),	  and	  have	  been	  associated	  with	  
important	   human	   clinical	   phenotypes.	   In	   P.	   falciparum,	   an	   organism	   with	   extensive	   and	  
rapid	   rates	  of	   genome	  variation	   (especially	   in	  Africa)	   and	  evolution,	   rates	  of	  CNV	  are	  also	  
likely	   to	  be	  high.	  However,	   studies	  of	  CNV	   in	  P.	   falciparum	  have	  often	  been	   ignored	   (with	  
larger	  efforts	   geared	   towards	   studying	   SNPs)	  but	  have	  only	   lately	  been	  well	   documented.	  
Even	  with	  relatively	  few	  studies	  existing	  in	  P.	  falciparum,	  important	  phenotypic	  associations	  
to	  CNV	  have	  been	   confirmed,	   notably	   in	   drug	   resistance.	   In	   addition,	   repeats	   in	   csp	  gene	  
evolve	   (contract	   and	   expand)	   by	   internal	   duplications	   and	   deletions	   and	   could	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influence/modulate	  host	  immune	  responses	  against	  this	  gene	  (Zeeshan	  et	  al.	  2012)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
To	  date,	  perhaps	  the	  most	  important	  and	  well-­‐documented	  CNV	  is	  an	  amplification	  
of	  the	  P.	  falciparum	  multidrug	  resistance	  1	  gene	  (pfmdr1)	  on	  chromosome	  5	  that	  influences	  
parasite	   susceptibility	   to	   a	   variety	   of	   antimalarial	   drugs	   including	   MQ,	   LF,	   QN,	   and	   ART	  
(Sidhu	  et	  al.	  2006).	  Amplification	  of	  GTP	  cyclohydrolase	  1	  (on	  chromosome	  12)	  of	  the	  folate	  
biosynthesis	  is	  also	  associated	  with	  anti-­‐folate	  drug	  resistance	  (Kidgell	  et	  al.	  2006;	  Nair	  et	  al.	  
2008),	  and	  another	  amplification,	  msp3.8	  has	  recently	  been	  documented	  to	  be	  involved	  in	  
decreasing	  sensitivity	  to	  HF,	  MF,	  and	  LF	  (Van	  Tyne	  et	  al.	  2011).	  In	  this	  present	  study,	  none	  of	  
these	   amplifications	   were	   detected	   in	   Malawi	   population.	   In	   fact,	   a	   deletion	   instead	   of	  
amplification	  was	  contained	  in	  msp3.8.	  Undetected	  pfmdr1	  copy	  changes	  are	  not	  surprising,	  
as	   this	   has	   been	   documented	   before,	   where	   100%	   of	   isolates	   analyzed	   lacked	   this	  
amplification	  in	  Malawi	  (Nkhoma	  et	  al.	  2009).	  This	  observation	  may	  be	  explained	  by	  the	  low	  
drug	  pressure	  (such	  as	  QN	  which	  has	  only	  been	  used	  in	  treating	  severe	  malaria)	  associated	  
with	  amplifications	  in	  this	  gene	  in	  Malawi.	  ART	  and	  LF	  were	  recently	  introduced	  and	  thus	  if	  
there	  were	  any	  selected	  copies	  of	  pfmdr1	  they	  would	  be	  limited/undetectable	  compared	  to	  
the	   effective	   parasite	   population	   size.	   In	   contrast,	   for	   example,	   Thailand	   P.	   falciparum	  
populations	  has	  been	  under	   intense	  pressure	   from	  almost	   all	  pfmdr1	   selective	  drugs,	   and	  
thus	   show	  pfmdr1	   amplicon	   frequency	  at	  >30%	   (Nair	  et	  al.	  2007;	  Price	  et	  al.	  1999,	  2006).	  
Other	   well-­‐characterized	   CNV	   include	   deletions	   on	   kahrp	   gene	   (associated	   with	   loss	   of	  
cytoadherence)	   (Biggs	   et	   al.	   1989),	   clag9	   gene	   (involved	   in	   gametocytogenesis	   and	  
associated	  with	  loss	  of	  cytoadherence	  of	  in	  vitro	  parasite	  cultures)	  (Trenholme	  et	  al.	  2000).	  
Amplifications	   of	   pfRh1	   gene	   is	   prevalent	   in	   lab	   lines	   only,	   and	   has	   been	   correlated	   to	  
overexpression	   that	   influenced	   higher	   growth	   rates	   of	   P.	   falciparum	   through	   facilitating	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erythrocytes	  invasion	  (Triglia	  et	  al.	  2005;	  Nair	  et	  al.	  2011;	  Jiang	  et	  al.	  2008a).	  This	  study	  did	  
not	   detect	   any	   amplification	   or	   deletion	   on	   pfRh1	   and	   clag9	   genes	   respectively,	   but	   a	  
deletion	   on	   reticulocyte	   binding	   protein	   2-­‐homologue	   b	   (pfRh2b)	   was	   observed.	   PfRH	  
proteins	  are	   involved	   in	  a	   sialic	   acid-­‐dependent	  merozoite	   invasion	  of	  erythrocytes,	   and	  a	  
0.58-­‐kb	  deletion	  on	  pfRh2b	  was	  primarily	  found	  in	  Africa,	  first	  observed	  at	  high	  frequencies	  
in	  parasites	  from	  Senegal	  (Jennings	  et	  al.	  2007)	  and	  later	  in	  Tanzania,	  Malawi,	  Gambia	  and	  
Malaysia	  (Ahouidi	  et	  al.	  2010).	  This	  study	  also	  observed	  that	  the	  C-­‐terminal	  region	  of	  PfRh2b	  
harbouring	   the	   PfRh2b	   deletion	   does	   elicit	   immune	   responses	   that	  may	   exert	   directional	  
selection	  on	  the	  polymorphism,	  but	  may	  not	  necessarily	  be	  under	  balancing	  selection.	  	  
A	   deletion	   and	   amplification	  was	   detected	   in	   kahrp	   gene.	   Deletion	   in	   this	   gene	   is	  
consistent	  with	  previous	  reports	  (Biggs	  et	  al.	  1989),	  while	  an	  amplification	  (16	  gains	  in	  copy	  
number,	  making	   it	   one	  of	   the	  highest	   in	   this	   population)	   is	   previously	   unreported.	  Whilst	  
deletion	   on	   this	   gene	   is	   associated	  with	   loss	   of	   cytoadherence,	   amplification	  may	   lead	   to	  
over-­‐expression	   of	   this	   gene	   resulting	   in	   increased	   cytoadherence	   ability	   of	   parasites	  
bearing	  the	  amplification.	  	  
Deletions	  were	  also	  detected	  on	  chromosome	  3	  containing	  two	  highly	  polymorphic	  
and	   paralogous	   genes	   with	   96.7%	   nucleotide	   similarity,	   clag3.1	   and	   clag3.2	   (Iriko	   et	   al.,	  
2009).	  Deletions	  in	  these	  two	  genes	  were	  present	  at	  high	  frequencies	  in	  Malawi	  population	  
and	   have	   also	   been	   previously	   reported	   elsewhere	   (Iriko	   et	   al.,	   2009;	   Jiang	   et	   al.,	   2008a;	  
Sepúlveda	  et	  al.,	  2013),	  particularly	  in	  Ghanaian	  samples	  (Sepúlveda	  et	  al.	  2013).	  Members	  
of	   this	  gene	   family	  are	   thought	   to	  play	  an	  essential	   role	   in	   IE	   cytoadherence	  and	   invasion	  
and	   have	   been	   studied	   as	   vaccine	   targets	   (Iriko	   et	   al.,	   2009;	   Kaneko	   et	   al.,	   2005).	  
Polymorphisms	  in	  this	  multigene	  family,	  including	  copy	  number	  polymorphisms,	  are	  thought	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to	   confer	   advantage	   to	   the	   parasite	   e.g.,	   through	   redundancy	   of	   erythrocyte	   invasion	   or	  
antigenic	   variation	   and	   could	   have	   undergone	   positive	   diversifying	   selection	   during	   P.	  
falciparum	  evolution	  (Iriko	  et	  al.,	  2009).	  
Also	   detected	   was	   a	   deletion	   and	   amplification	   on	   a	   gametocyte-­‐specific	   protein	  
(encoded	  by	  pf11-­‐1	  gene)	  on	  chromosome	  10,	  which	  plays	  a	   role	   in	  gametocytogenesis	   in	  
the	   rupture	   of	   the	   host	   erythrocyte	   and	   emergence	   of	   gametes	   (Scherf	   et	   al.	   1992).	   This	  
gene	  possessed	  several	  characteristics	  in	  this	  study:	  it	  contained	  the	  largest	  deletion	  and	  a	  
large	  amplification;	  both	  deletion	  and	  amplification	  appeared	  at	  high	  frequencies	  in	  Malawi	  
population	   (57	   and	   64%	   respectively)	   and	   contained	   a	   high	   number	   of	   copy	   gains	   (18	  
copies).	  Initial	  reports	  had	  suggested	  that	  deletion	  on	  this	  gene	  only	  occurred	  in	  laboratory	  
lines	  possibly	  in	  response	  to	  stress	  of	  in	  vitro	  culture	  and	  its	  function	  in	  gametocytogenesis	  
(Scherf	   et	   al.	   1992).	   These	   CNV	   have	   now	   been	   reported	   in	   both	   lab	   and	   field	   isolates	  
(Dharia	  et	  al.	  2010;	  Jiang	  et	  al.	  2008a;	  Mackinnon	  et	  al.	  2009;	  Kidgell	  et	  al.	  2006).	  
	  Other	   notable	   CNV	   observed	   at	   high	   frequencies	   in	   this	   population	   include	  
amplifications	  in	  lsa1	  gene	  (average	  frequency	  by	  FREEC	  and	  PG,	  65%),	  rex1	  gene	  (72%,	  PG),	  
ABC	  transporter,	  pfmrp2	  (79%,	  PG)	  and	  deletion	  in	  a	  DBL	  containing	  protein,	  with	  unknown	  
function	  (75%,	  PG).	  The	  pfmrp2	  encodes	  a	  member	  of	  the	  ABC	  transport	  family	  localized	  to	  
the	  plasma	  membrane	  in	  all	  asexual	  stages	  of	  the	  parasite	  (Kavishe	  et	  al.	  2009).	  Membrane	  
transport	  proteins	  have	  been	  shown	  to	  mediate	  translocation	  of	  molecules	  and	  ions	  across	  
biological	  membranes,	  including	  the	  uptake	  of	  nutrients	  into	  cells,	  the	  removal	  of	  unwanted	  
metabolic	  waste	  products	   such	  as	  drugs.	   In	   reference	   to	  drug	   resistance,	  by	  pumping	  out	  
drugs,	   intracellular	   drug	   accumulation	   is	   decreased.	   Two	   transport	   proteins	   multidrug	  
resistance	  proteins	  (MDR/MRP)	  have	  largely	  been	  shown	  to	  be	  responsible	  for	  this	  type	  of	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resistance.	  It	  might	  be	  reasonable	  to	  think	  that	  pfmrp2	  amplification	  and	  its	  high	  frequency	  
should	   be	   further	   studied	   for	   possible	   roles	   in	   drug	   resistance	   or	   facilitating	   growth	   and	  
replication	  of	  the	  parasite	  (Kavishe	  et	  al.	  2009;	  Martin	  et	  al.	  2005).	  	  
The	   functional	   categories	  of	  genes	   involved	   in	  CNV	  were	  examined	   for	  enrichment	  
using	  gene	  ontology	  (GO)	  analysis	  in	  MADIBA	  with	  significance	  of	  the	  annotation	  evaluated	  
using	   a	   hypergeometric	   P-­‐value	   with	   a	   false	   discovery	   rate	   (FDR)	   correction	   (Law	   et	   al.	  
2008).	  Functional	   categories	   that	  are	   significantly	  enriched	   (FDR	   corrected	  P-­‐values	  <0.05)	  
are	  associated	  with	  genes	  involved	  in	  biological	  processes	  such	  as	  cytokinesis,	  transcription,	  
metabolism,	  biosynthesis,	   transport	  of	  molecules	  and	   ions	   (including	  multidrug	   transport),	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Chapter	  4	  




P.	   falciparum	   malaria	   is	   an	   important	   clinical	   disease	   widespread	   in	   sub-­‐Saharan	  
Africa	   and	   causing	   the	   highest	   morbidity	   and	  mortality	   in	   children	   under	   the	   age	   of	   five	  
years	   and	   pregnant	   mothers	   (WHO.	   World	   Malaria	   Report	   2012).	   	   Because	   of	   increased	  
deployment	  of	   several	  malaria	   control	   interventions	   in	  malaria	  endemic	   regions	   there	  has	  
been	  a	   considerable	  decrease	   in	   the	  number	  of	  malaria	   cases	   in	   some	  areas	   (Trape	  et	   al.	  
2011).	   But	   despite	   these	   efforts	   the	   overall	   number	   of	   deaths	   attributable	   to	   malaria	  
remains	  unchanged	  (WHO.	  World	  Malaria	  Report	  2012).	  There	  are	  four	  main	  malaria	  control	  
tools	   that	  are	  used	   in	  malaria	  endemic	   regions	   including	  Malawi,	  namely:	   ITNs,	   IRS,	   IPTpd	  
and	  ACTs.	   In	  Malawi,	   even	  as	   these	   interventions	   are	   increasingly	  used,	   there	  has	  been	  a	  
lack	   of	   decline	   in	   childhood	   malaria	   between	   2001-­‐2010	   (Roca-­‐Feltrer	   2012).	   To	   reduce	  
malaria	  effectively,	  it	  is	  predicted	  that	  countries	  should	  reach	  coverage	  of	  70%	  of	  the	  above-­‐
mentioned	  interventions	  (Rowe	  and	  Steketee	  2007)	  	  
P.	   falciparum	   faces	   strong	   natural	   selection	   its	   two	   hosts.	   The	   human	   immune	  
response	  and	  mosquito	  vector	  provide	  the	  strongest	  natural	  selective	  force.	  Drug	  treatment	  
and	   changes	   in	   transmission	   intensity	   owing	   to	   specific	   intervention	   drive	   environmental	  
pressure	   (Mackinnon	   and	  Marsh	   2010).	   Data	   available	   suggest	   that	   this	   parasite	   escapes	  
selective	  pressure	  through	  evolution	  thereby	  leaving	  distinct	  evolutionary	  paths	  that	  can	  be	  
scanned	  by	  genetic	  and	  genomic	  tools	  to	  identify	  and	  understand	  key	  aspects	  of	  its	  biology	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and	  transmission	  amidst	  these	  pressures.	  Key	  to	  this	  is	  to	  identify	  targets	  that	  are	  vulnerable	  
to	   these	   interventions	   and	   whether	   these	   targets	   provide	   further	   knowledge	   of	   the	  
parasite’s	   survival	   strategies.	   	   Indeed,	   several	  approaches	  have	  applied	  population-­‐biology	  
based	  investigations	  to	  either	  validate	  or	  identify	  genetic	  loci	  responding	  to	  these	  pressures	  
including	   drug	   targets	   (e.g.,	   pfcrt,	   pfdhps,	   pfdhfr,	   pfmdr1)	   and	   vaccine	   candidates	   (e.g.,	  
pfama1,	  msp3.8,	  eba175)	   (Amambua-­‐Ngwa	  et	  al.	  2012a,	  2012b;	  Mu	  et	  al.	  2007;	  Miotto	  et	  
al.	   2013).	   In	   addition,	   most	   recent,	   use	   of	   genome-­‐wide	   or	   whole	   genome	   sequencing	  
strategies	  have	  taken	  a	  center	  stage	  owing	  to	  the	  increasingly	  lower	  costs	  of	  producing	  large	  
amounts	  of	  sequence	  data	  (e.g.,	  use	  of	  Illumina	  sequencing	  technology).	  This	  combined	  with	  
the	   rising	   amount	   of	   computational	   tools	   to	   analyse	   genome	   data	   has	   allowed	   the	  
production	  of	   rich/extensive	  genetic	  diversity	  data	  and	  population	   structure	  of	  worldwide	  
populations	   of	   P.	   falciparum	   to	   identify	   loci	   under	   selection	   or	   associated	   with	   clinical	  
phenotypes	   (Miotto	   et	   al.	   2013;	   Cheeseman	   et	   al.	   2012).	   Using	   similar	   approaches	   to	  
identifying	   tools	   for	   monitoring	   and	   evaluating	   malaria	   interventions	   will	   be	   immensely	  
informative.	  
In	   this	  present	  study,	   I	  have	  used	  massive	  parallel	   sequencing	   (MPS,	   Illumina	  short	  
read)	   technology	   and	   identified	   >100,000	   SNPs	   in	   69	   clinical	  P.	   falciparum	   isolates	  which	  
were	  obtained	  directly	  from	  children	  in	  an	  on-­‐going	  3-­‐year	  longitudinal	  study	  of	  a	  Malawian	  
P.	   falciparum	   rural	  population	   in	  the	  Chikwawa	  district.	  Using	  the	  sequence	  data	  available	  
for	   the	  93	   isolates,	  and	   two	  software	  packages	   for	  detecting	  copy	  number	  variation	  using	  
read	  depth	   coverage,	   I	   provide	   a	   comprehensive	   documentation	  of	   deletions	   (losses)	   and	  
amplifications	  (gains)	  in	  this	  population.	  Specifically,	  the	  objectives	  of	  this	  thesis	  were	  to	  use	  
second-­‐generation	  sequencing	  techniques:	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1. To	   sequence	   uncultured	   P.	   falciparum	   paediatric	   isolates	   obtained	   from	   a	   3-­‐year	  
longitudinal	   study	   of	   a	   Malawian	   population	   after	   a	   selective	   sweep	   with	   SP	   and	  
continuous	  selective	  pressure	  from	  intensive	  use	  of	  LA,	  ITNs	  and	  IRS;	  
2. To	   identify	   genetic	   variants	   including	   SNPs,	   and	   large	   structural	   variants	   (e.g.	  CNV,	  
INDELs)	  and	  provide	  a	  map	  of	  genomic	  variation;	  
3. To	  use	  the	  SNP	  variation,	  to	  identify	  regions	  under	  selection	  pressure	  specific	  to	  this	  
P.	  falciparum	  population;	  
4. To	  compare	  Malawi	  genetic	  variation	  to	  other	  populations	  of	  disperse	  origins	  (Kenya,	  
Burkina	  Faso,	  Mali,	  Thailand	  and	  Cambodia);	  
Important	  findings	  resulting	  from	  this	  thesis	  are	  briefly	  described	  below.	  	  
4.2 Whole	  genome	  sequencing	  of	  P.	  falciparum	  isolates	  and	  SNP	  identification	  
	  
Five	  hundred	  uncultured	  clinical	  P.	  falciparum	  isolates	  have	  been	  sampled,	  depleted	  
of	  human	  white	  blood	  cells	  and	  genomic	  DNA	  extracted.	  Parasite	  to	  human	  DNA	  has	  been	  
quantified	   using	   qPCR	   in	   329	   samples.	   93	   samples	   were	   successfully	   sequenced	   using	  
massive	  parallel	   sequencing.	  The	  process	  of	  depleting	  white	  blood	  cells	   (using	  CF11)	   from	  
whole	  blood	  sample	  was	  largely	  successful	  in	  the	  329	  samples	  with	  >90%	  of	  samples	  having	  
less	   than	   30%	   human	  DNA	   contamination.	  Median	   human	  DNA	   concentration	  was	   0.78%	  
(range,	  0-­‐100%)	  
This	   analysis	   identified	   a	   rich	   SNP	   diversity	   in	   Malawi	   P.	   falciparum.	   115,965	   raw	  
SNPs	   across	   the	   69	   isolates	   and	   giving	   a	   SNP	   density	   of	   approximately	   1/198-­‐bp.	   Further	  
quality	  filtering	  produced	  88,655	  high	  quality	  SNPs	  (SNP	  density	  of	  1/259-­‐bp,	  compared	  to	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1/266-­‐bp	  in	  Manke	  et	  al.	  2012).	  The	  principal	  component	  analysis	  using	  this	  SNP	  catalogue	  
indeed	  showed	  an	  extensive	  genetic	  variation	  within	  the	  sampling	  region.	  
4.3 Local	  selection	  in	  Malawi	  P.	  falciparum	  genomes	  
	  
Using	   this	   SNP	   variation	   two	   statistical	   metrics	   (haplotype	   and	   allele	   based)	   were	  
calculated	   to	   identify	   genome	   regions	   under	   strong	   positive	   and	   balancing	   selection	  
respectively.	  
4.3.1 Signatures	  of	  balancing	  selection	  	  
	  
Using	   Tajima’s	   D	   metric,	   genomic	   regions	   under	   positive	   diversifying	   selection,	  
consistent	  with	  actions	  of	  balancing	  selection	  that	  maintains	  allelic	  variation	  in	  population,	  
were	   identified.	   Large	   negative	   Tajima’s	  D	   values	  were	   observed	   (>80%	  alleles),	   depicting	  
singletons	  and	  excess	  of	  rare	  derived	  alleles	  at	  high	  frequencies,	  showing	  a	  genome	  mostly	  
under	   purifying	   selection	   (eliminating	   deleterious	   mutations)	   or	   population	   expansion	  
possibly	  after	  a	  bottleneck	  (Aris-­‐Brosou	  and	  Excoffier	  1996;	  Swanson	  2003;	  Alexandre	  et	  al.	  
2011;	   Li	   2011).	  Candidate	   signatures	  of	  balancing	   selection	   identified	   included	  merozoites	  
invasion	   ligands	   contributing	   to	   31.5%	   of	   all	   genes	  with	   significant	   Tajima’s	  D	   (i.e.,	   ≥1.0),	  
showing	   that	   considerable	   number	   merozoite	   proteins	   possess	   rare	   alleles	   that	   are	  
maintained	   at	   intermediate	   frequencies	   and	   are	   candidate	   targets	   of	   immune	   responses.	  
Some	  of	  these	  genes	  are	  also	  replicated	  in	  other	  independent	  studies	  of	  different	  endemic	  
populations,	   suggesting	   their	   roles	  as	  potential	   vaccine	  candidates,	   and	  possible	  based	  on	  
multi-­‐allelic	  antigen	  formulation	  (Tetteh	  et	  al.	  2009;	  Ochola	  et	  al.	  2010;	  Amambua-­‐Ngwa	  et	  
al.	   2012b;	   Weedall	   and	   Conway	   2010;	   Alexandre	   et	   al.	   2011;	   Kaewthamasorn	   2012;	  
Xangsayarath	  et	  al.	  2012).	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4.3.2 Positive	  directional	  selection	  	  
	  
Positive	  directional	   selection	   enables	   species	   to	   adapt	   to	   their	   living	   environments	  
and	   usually	   leave	   footprints	   in	   the	   genomes	   of	   living	   organisms	   that	   can	   be	   detected.	   In	  
particular,	  it	  allows	  an	  allele	  that	  is	  beneficial	  to	  either	  reproduction	  or	  survival	  to	  increase	  
in	   frequency	   (toward	   fixation)	   as	   a	   result	   of	   the	   individual	   carrying	   the	   allele	   having	   an	  
increased	  fitness.	  To	  infer	  directional	  selection	  in	  this	  population,	  haplotype	  based	  iHS	  was	  
used	   to	   detect	   strong	   selection	   in	   areas	   surrounding	   SP	   drug	   resistance	   loci	   pfdhps	   and	  
pfgch1.	  Weak	   selection	   signals	   at	   the	   pfcrt	   gene	   is	   likely	   due	   to	   the	   replacement	   of	   CQ-­‐
resistant	   parasites	   with	   CQ-­‐sensitive	   parasites	   following	   CQ	   withdrawal	   from	   Malawi	   20	  
years	  ago.	  	  
4.4 Inferring	  directional	  selection	  in	  Malawi	  P.	  falciparum	  population	  by	  comparing	  
to	  geographically	  dispersed	  others	  
	  
This	  analysis	  identified	  294,187	  SNPs	  across	  6	  populations	  –	  Malawi,	  Kenya,	  Burkina	  
Faso,	   Mali,	   Cambodia	   and	   Thailand.	   An	   analysis	   of	   SNP	   density	   showed	   that	   the	   African	  
populations	  were	  more	  polymorphic	  than	  the	  Southeast	  Asian.	  
4.4.1 Positioning	  Malawi	  parasites	  in	  the	  global	  population	  structure	  of	  P.	  
falciparum	  
	   	  
A	   principal	   component	   analysis	   of	   all	   populations	   showed	   distinct	   population	  
differences	  between	  African	  and	  southeast	  Asian	  parasites	  with	  little	  genetic	  differentiation	  
observed	   in	  Africa	  compared	   to	  Asia.	  Within	  Africa	  moderate	  population	  differences	  were	  
detected	  between	  those	  parasites	  from	  the	  east	  (Malawi	  and	  Kenya)	  and	  west	  (Burkina	  Faso	  
and	  Mali).	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4.4.2 Inferring	  directional	  selection	  in	  Malawi	  P.	  falciparum	  population	  
using	  XP-­‐EHH	  
	  
A	   search	   for	   selective	   sweeps	   by	   comparing	   Malawi	   to	   the	   six	   geographically	  
dispersed	  population	  detected	   long-­‐range	  haplotypes	   in	   loci	  surrounding	  pfdhps,	  pfcrt	  and	  
gch1.	  This	  meant	  that	  strong	  drug	  selection	  by	  SP	  and	  CQ	  is	  largely	  responsible	  for	  reduction	  
in	  haplotype	  diversity	  at	  drug	   targets	  and	  thus	  varying	  selection	  signals	  between	  different	  
populations.	  	  
4.4.3 Inferring	  positive	  selection	  in	  Malawi	  P.	  falciparum	  population	  using	  
FST	  
Using	  FST	  metric,	  genomic	  regions	  that	  have	  significantly	  differentiated	  between	  the	  
six	   populations	   were	   identified.	   Two	   major	   observations	   were	   made:	   1)	   that	   this	  
differentiation	  increased	  with	  geographic	  distance	  from	  Malawi,	  Kenya,	  Burkina	  Faso,	  Mali,	  
Cambodia	   and	   Thailand;	   2)	   drug	   resistant	   alleles	   at	   known	   drug	   targets	   (pfcrt,	   pfdhps,	  
pfmdr1)	   were	   highly	   differentiated	   and	   reflect	   parasite	   adaptation	   to	   historical	   drug	  
pressure	   in	   these	   regions.	   There	  was	  a	  high	   level	  of	  differentiation	   in	  clag3.1	  and	   clag3.2	  
genes	   (genes	   implicated	   in	   the	  process	  of	  parasite	   invasion)	  between	  Malawi	  and	  the	  two	  
Asian	   populations,	   probably	   depicting	   a	   major	   underlying	   survival/adaptive	   strategy	  
between	  these	  populations.	  	  	  
4.5 Copy	  number	  variation	  in	  Malawi	  P.	  falciparum	  genomes	  
This	   thesis	   has	   examined	   copy	   number	   variation	   in	   field	   isolates	   of	   P.	   falciparum.	  
Studies	  of	   this	   kind	  have	   involved	  both	   in	   vitro	   adapted	  and	   in	   vivo	   parasites	  with	   results	  
showing	  adaptive	  differences	  caused	  by	  CNV.	  Whilst	  in	  vitro	  environment	  is	  largely	  buffered	  
in	  a	  supplemented	  medium	  and	  allows	  rapid	  propagation	  of	  asexual	  stage	  parasites,	  evasion	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of	  drugs,	  host	  immune	  defence	  and	  transmission	  to	  the	  mosquito	  vector	  via	  sexual	  stages	  is	  
critical	  in	  host	  environment	  highlighting	  the	  need	  to	  examine	  and	  characterize	  the	  extent	  of	  
CNV	  in	  vivo.	  CNV	  size,	  gene	  content,	  population	  frequency	  is	  examined,	  as	  well	  as	  the	  role	  of	  
genetic	   drift	   and	   selection	   in	   shaping	   CNV	   distributions.	   Polymorphic	   CNV	   (unique	   to	  
individual	  isolate)	  are	  as	  common	  as	  monomorphic	  ones	  (occurring	  in	  multiple	  isolates).	  This	  
analysis	   identifies	   both	   previously	   known	   CNV	   and	   unknown	   ones	   in	   both	   lab	   and	   field	  
isolates.	  Polymorphisms	  associated	  with	  important	  P.	  falciparum	  biological	  functions	  such	  as	  
cytoadherence,	  gametocytogenesis	  and	  merozoite	   invasion	  were	  observed.	  For	  example	  a	  
deletion	  on	  reticulocyte	  binding	  protein	  2	  homologue	  b	  (a	  homolog	  of	  a	  reticulocyte	  binding	  
protein	   gene	   well	   known	   to	   facilitate	   erythrocyte	   invasion)	   could	   modulate	   elicitation	   of	  
immune	   responses.	  Amplification	   in	  kahrp	  gene	  may	   lead	   to	   over-­‐expression	  of	   this	   gene	  
leading	   to	   increased	   cytoadherence	   capability.	   Deletions	   were	   present	   on	   clag3.1	   and	  
clag3.2,	  genes	  with	  essential	  roles	  in	  cytoadherence	  and	  invasion.	  	  
4.6 Implications	  and	  future	  directions	  
	  
The	  genetic	  variation	  detected	  in	  Malawi	  and	  five	  other	  dispersed	  populations	  may	  
enable	  us	   to	  monitor	  P.	   falciparum	   transmission	  dynamics	  as	   the	  epidemiology	  of	  malaria	  
changes	   over	   time	   in	   response	   to	   interventions.	   For	   example,	   by	   using	   XP-­‐EHH	   and	   FST	  
selection	  metrics	  we	  have	  shown	  that	  loci	  containing	  selective	  sweeps	  and	  allelic	  divergence	  
reflect	  the	  history	  of	  antimalarial	  drug	  use	  and	  selection	  at	  any	  given	  time,	  whereas	  during	  
intense	   drug	   selection,	   wild-­‐type	   alleles	   are	   increasingly	   replaced	   by	   mutant	   alleles.	   The	  
ability	   to	   use	   this	   strategy	   to	   monitor	   local	   adaptation	   to	   drug	   pressure,	   monitoring	  
transmission,	  and	  informing	  the	  type	  and	  timing	  of	  interventions	  is	  appealing.	  Future	  work	  
will	  aim	  to	  use	  this	  knowledge	  in	  Malawi	  to	  monitor	  the	  impact	  of	  ACTs,	  ITNs	  and	  IRS	  on	  the	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local	   parasite	   population	   of	   Chikwawa	   district	   over	   the	   three	   malaria	   seasons.	   We	  
hypothesise	  a	  change	  in	  population	  structure	  e.g.,	  bottlenecks,	  to	  occur	  in	  this	  population	  as	  
successful	  interventions	  are	  used.	  Further	  potentially	  exciting	  work	  would	  involve	  looking	  at	  
some	  of	  the	  genes	  detected	  under	  positive	  directional	  selection.	  For	  example,	   it	  would	  be	  
interesting	   to	   look	   at	   expression	  of	   transcription	   factors	   in	   drug	   resistant	   versus	   sensitive	  
parasites	   or	   in	   different	   clinical	   presentations	   of	  malaria	   such	   as	   severe	  malaria/cerebral	  
malaria	  versus	  uncomplicated	  malaria.	  	  
The	  roles	  of	  CNV	  in	  influencing	  important	  clinical	  phenotypes	  have	  been	  highlighted	  
before.	  Of	   importance	  will	   be	   to	   functionally	   validate	   these	  CNV	  and	   correlate	   them	  with	  
phenotypes	  in	  this	  population.	  Since	  clinical	  data	  from	  the	  500	  samples	  are	  available	  to	  us,	  
this	   will	   prove	   to	   be	   an	   exciting	   prospect.	   A	   possibility	   of	   complex	   phenotypes	   such	   as	  
virulence	  influenced	  by	  a	  collection	  of	  highly	  mutable	  CNV	  changes	  as	  seen	  in	  some	  complex	  
diseases	  in	  humans,	  could	  be	  explored	  (Sebat	  2007).	  In	  addition,	  genetics	  aspects	  of	  CNV	  in	  
P.	   falciparum	   field	   isolates	  maybe	   investigated,	   for	   example	   the	   rate	   and	  mechanisms	   of	  
mutation	  and	  complexity	  of	  CNV	  evolution	  (Anderson	  et	  al.	  2009).	  To	  provide	  a	  full	  map	  of	  
CNV	   in	   this	   population,	   future	  work	  will	   also	   involve	   using	   other	   available	   CNV	   detection	  
software	  to	  detect	  inversions	  and	  translocations.	  
There	   are	   few	   caveats	   to	   the	   analysis,	  which	   could	   turn	   into	   future	   opportunities.	  
First,	  there	  are	  multiple	  infections	  (mean	  MOI	  ≈	  2.7,	  Assefa	  et	  al.	  2014)	  in	  the	  samples,	  and	  
in	   general	   this	   can	   confound	   genotyping,	   diversity	   and	   population	   analysis	   by	   generating	  
false	  haplotype	  calls.	  The	  calculation	  of	  heterozygosity	  and	  detection	  of	  signatures	  of	  recent	  
positive	  selection	  assume	  clonal	  samples,	  and	  de	  novo	  assembly	  of	  genomes	  in	  the	  presence	  
of	  MOI	  can	  lead	  to	  potentially	  cryptic	  gene	  characterisations.	  To	  overcome	  the	  problem	  of	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multiplicity,	  we	  generated	  a	  ‘majority	  genotype’	  file	  where	  genotypes	  at	  SNP	  positions	  were	  
called	  using	  ratios	  of	  coverage	  and	  heterozygous	  calls	  converted	  to	  the	  majority	  genotype	  
on	  an	  80:20	  coverage	  ratio	  or	  greater.	  Over	  the	  entire	  preliminary	  dataset,	  29%	  mixed	  calls	  
were	   observed.	   	   Like	   others	   (e.g.,	   Manske	   et	   al.	   2012),	   we	   have	   restricted	   ourselves	   to	  
polymorphisms	  where	  the	  frequency	  is	  low	  (83%	  SNPs	  with	  two	  mixed	  calls	  or	  less),	  and	  not	  
biased	   our	   population	   genetic	   metrics.	   With	   longer	   read	   lengths	   it	   may	   be	   possible	   to	  
reconstruct	   the	   individual	   parasite	   genomes	   from	   the	   data.	   Second,	   some	   regions	   of	   the	  
genome	  were	  excluded,	  namely	  highly	  variable	   regions	   including	  var	  genes.	  The	  complete	  
reconstruction	  de	  novo	  of	  a	  P.	  falciparum	  genome	  to	  high	  quality	  will	  be	  possible	  in	  the	  near	  
future	  with	   longer	   read	   lengths.	   This	  de	  novo	   assembly	  approach	  will	   enable	   full	   genomic	  
variation	   identification,	   without	   the	   need	   for	   a	   reference	   genome.	   Future	   work	   could	  
consider	  the	  population	  genetics	  of	  these	  highly	  variable	  regions	  constructed	  using	  de	  novo	  
assembly,	   especially	   as	   these	   regions	   are	   important	   in	   P.	   falciparum	   pathogenesis,	   for	  
example,	   cytoadherence	   enables	   the	   parasite	   to	   evade	   splenic	   clearance	   and	   has	   been	  
associated	  with	  severe	  malaria.	  
Future	   work	   will	   also	   include	   examining	   P.	   falciparum	   genetic	   diversity	   and	  
population	   structure	   between	   the	   two	   geographically	   separated	   sampling	   sites	   i.e.,	  
Chikwawa	  and	  Zomba	  districts.	  Variables	  that	  that	  may	  affect	  parasite	  diversity	  such	  as	  age,	  
seasonality	  (dry	  and	  wet	  seasons)	  and	  drug	  pressure	  will	  also	  be	  examined.	  Because	  of	  the	  
nature	   of	   the	   study,	   it	  was	   possible	   to	   collect	   longitudinal	   samples	   from	   the	   same	   kid	   at	  
different	   time	   points	   and	   thus	   allowing	   within	   patient	   longitudinal	   analysis	   of	   parasite	  
genetic	  variation.	  Because	  CMX	  prophylaxis	  provides	  effective	  protection	  against	  malaria,	  it	  
may	  modulate	   the	  development	  of	  malaria-­‐specific	   immunity	  and	  potentially	   increase	   the	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risk	  of	  malaria	  after	  it	  is	  stopped	  (rebound	  effect).	  Future	  work	  will	  investigate	  whether	  CMX	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4.7 Appendices	  	  
Table	  A1:	  Genomic	  regions	  under	  balancing	  selection	  detected	  using	  Tajima’s	  D	  by	  
window	  approach.	  Bold	  refer	  to	  genes	  with	  D≥2.0.	  
Start	   Finish	   Tajima's	  D	   Genes	  
	   	  
414001	   418000	   2.69	   PF3D7_0709300	   	   	  1430001	   1434000	   2.64	   -­‐	   PF3D7_1036300	   	  1432001	   1436000	   2.55	   -­‐	   PF3D7_1036300	   	  846001	   850000	   2.24	   PF3D7_0220900	   -­‐	   PF3D7_0221000	  
330001	   334000	   2.08	   -­‐	   PF3D7_0806100	   PF3D7_0806200	  
880001	   884000	   2.07	   PF3D7_0720300	   PF3D7_0720400	   	  1286001	   1290000	   2.03	   PF3D7_0630700	   -­‐	   PF3D7_0630800	  
824001	   828000	   2.02	   PF3D7_0619500	   -­‐	   PF3D7_0619600	  
784001	   788000	   2.02	   -­‐	   PF3D7_1219600	   	  1324001	   1326231	   2.01	   -­‐	   PF3D7_0532800	   	  1144001	   1148000	   1.96	   PF3D7_0425400	   -­‐	   	  
408001	   412000	   1.81	   PF3D7_1110200	   -­‐	   PF3D7_1110300	  
1100001	   1104000	   1.79	   PF3D7_0424400	  
	   	  910001	   914000	   1.79	   -­‐	   PF3D7_0420200	   	  
514001	   518000	   1.77	   PF3D7_0113600	   	   	  1322001	   1326000	   1.77	   -­‐	   PF3D7_0532800	  
	  222001	   226000	   1.75	   PF3D7_1004800	   -­‐	   PF3D7_1004900	  
1098001	   1102000	   1.68	   -­‐	   PF3D7_0424400	   	  
220001	   224000	   1.63	   PF3D7_1004700	   -­‐	   PF3D7_1004800	  
1288001	   1292000	   1.61	   -­‐	   PF3D7_0630800	   PF3D7_0630900	  
2168001	   2172000	   1.60	   PF3D7_1253000	   -­‐	   PF3D7_1253100	  
848001	   852000	   1.59	   -­‐	   PF3D7_0221000	   PF3D7_0221100	  
1100001	   1104000	   1.59	   PF3D7_0825500	   -­‐	   PF3D7_0825700	  
122001	   126000	   1.56	   PF3D7_0302200	   	   	  
1986001	   1990000	   1.52	   PF3D7_1149400	   -­‐	   	  908001	   912000	   1.51	   PF3D7_0420100	   -­‐	   PF3D7_0420200	  
1036001	   1040000	   1.51	   PF3D7_0422500	   -­‐	   PF3D7_0422600	  
1390001	   1394000	   1.46	   -­‐	   PF3D7_1035100	   	  1292001	   1296000	   1.45	   -­‐	   PF3D7_1133400	  
	  1294001	   1298000	   1.45	   PF3D7_1133400	   PF3D7_1133500	   	  
840001	   844000	   1.43	   PF3D7_0220800	   	   	  328001	   332000	   1.43	   PF3D7_0806000	   -­‐	   PF3D7_0806100	  
1018001	   1022000	   1.43	   -­‐	   PF3D7_1126100	  
	  178001	   182000	   1.39	   PF3D7_0104100	   -­‐	   	  
1988001	   1992000	   1.38	   -­‐	   PF3D7_1149500	   	  822001	   826000	   1.37	   PF3D7_0619500	   -­‐	   PF3D7_0619600	  
796001	   800000	   1.36	   -­‐	   PF3D7_0619100	   PF3D7_0619200	  
844001	   848000	   1.36	   PF3D7_0220800	   -­‐	   PF3D7_0220900	  
180001	   184000	   1.35	   PF3D7_0104100	   -­‐	   PF3D7_0104200	  
522001	   526000	   1.34	   PF3D7_0113700	   -­‐	   	  
528001	   532000	   1.33	   PF3D7_0113800	   	   	  678001	   682000	   1.32	   -­‐	   PF3D7_0516300	   PF3D7_0516400	  
100001	   104000	   1.31	   -­‐	   PF3D7_1301800	   	  
2000001	   2004000	   1.29	   -­‐	   PF3D7_1149600	   	  422001	   426000	   1.25	   PF3D7_0808300	   -­‐	   PF3D7_0808400	  
1392001	   1396000	   1.23	   PF3D7_1035100	   -­‐	   	  
1198001	   1202000	   1.23	   -­‐	   PF3D7_0930300	   	  
1266001	   1270000	   1.21	   PF3D7_0630300	   -­‐	   	  106001	   110000	   1.20	   PF3D7_1301800	  
	   	  154001	   158000	   1.19	   -­‐	   PF3D7_1302900	   	  
104001	   108000	   1.16	   PF3D7_1301800	   	   	  1004001	   1008000	   1.14	   PF3D7_0422200	  
	   	  424001	   428000	   1.12	   PF3D7_0808400	   -­‐	   PF3D7_0808500	  
512001	   516000	   1.12	   PF3D7_0113600	   	   	  842001	   846000	   1.11	   PF3D7_0220800	   -­‐	   PF3D7_0220900	  
1142001	   1146000	   1.05	   PF3D7_0425300	   -­‐	   PF3D7_0425400	  
282001	   286000	   1.03	   PF3D7_0905600	   PF3D7_0905700	   	  534001	   538000	   1.02	   PF3D7_0113800	   -­‐	   PF3D7_0113900	  
102001	   106000	   1.02	   -­‐	   PF3D7_1301800	   	  
1388001	   1392000	   1.01	   PF3D7_1035000	   -­‐	   PF3D7_1035100	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